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INTRODUCTION
By Carolyn S. Leach, Ph. D.
The fourth Endocrine Program Conference, held at the NASA Lyndon B.
Johnson Space Center, was part of the continuing effort to fully understand
and to evaluate the endocrine changes observed during previous manned missions
and,; thereby, to further understand the physiological adaptation of man to the
space-flight environment. Investigators reported on work pertinent to the
overall program developed in support of the Apollo missions and the long-
duration Skylab flights. The goals of this program continue to be of utmost
importance and, indeed, the relevance of these goals has been augmented as man
further extends himself and his technology into space. For the purpose of
review, these goals are restated here.
1. The establishment (and continuation) of an operational laboratory for
immediate endocrinologic assays at the NASA Lyndon B. Johnson Space Center
2. The assembly of a group of endocrine experts who are qualified to ad-
vise on procedures and the interpretation of data
3. The advancement of the field of endocrinology by the application of
analytical procedures that are low in sample-volume requirements but that are
high in specificity
As in previous conferences, the attendees of the fourth annual NASA
Lyndon B. Johnson Space Center Endocrine Program Conference consisted of those
who were chosen to help conduct the program. Each participant presented a dis-
cussion of work in his area of specialization and related his contributions in
support of the program, either with respect to studies or to the development
of methodology. The tape-recorded transcripts of these presentations were sub-
mitted to the authors for editing and then were compiled into these proceedings.
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1. BIOCHEMICAL OBSERVATION DURING 28 DAYS OF SPACE FLIGHT
By Carolyn S. Leach, Ph. D., and Paul C. Rambaut, Sc. D.
With the completion of the 28-day flight of Skylab 2, the sum of biochem-	 w,
ical data on human reaction to the weightless environment was significantly
extended both quantitatively and qualitatively. The biochemical studies can
be divided into two broad categories. One group included the more routine
. _	 blood studies similar to those used in everyday medical practice. The second
r
	
	 category encompassed those analyses used to investigate more thoroughly the
endocrinological and fluid changes first seen in the crewmembers following
the Gemini, Apollo, and Soviet missions (refs. 1-1 and 1-2).
IN-FLIGHT CONDITIONS
x,
One of the principal objectives of the Skylab Program was to demonstrate
that man could live in a weightless environment for extended periods of time 	 J
and also accomplish useful scientific work. 	 To accomplish this objective,
a 100-ton laboratory was inserted into low Earth orbit on May 14, 1973, from
the NASA John F. Kennedy Space Center (KSC), Florida. 	 About 2 weeks later, on
May 25, three men in an Apollo command module were launched at 13:00 GMT from
KSC.	 Approximately 10 minutes after lift-off, the Apollo command and service
module was inserted into a 424— by 415-kilometer orbit and successfully ren-
dezvoused and docked with the orbiting workshop. 	 The first 24 hours of orbital
flight were spent in preparing the damaged workshop for repairs. 	 The second
day	 as occupied in entering the workshop and setting u	 experimental equip-Y	 P^	 g	 p	 g	 P	 P 	 	
went.	 With the exception of two extravehicular periods, the crew occupied
the workshop for the duration of the mission, orbiting the Earth every 90
minutes.	 The workshop maintained a gas pressure of 32.4 to 34.6 kN/m2 (4.70 to
5.02 psia), with a gas composition of approximately 70 percent oxygen, 30 per-
a	 cent nitrogen, and up to 2.5 percent carbon dioxide. 	 Relative humidity ranged
between 31 and 53 percent.
	
The lighting in the workshop was 108 im/m2 (10
{	 foot-candles). The conditioned work volume was 331 cubic meters (11 700 cubic
4	 -	 feet).	 Because part of the heat shield was lost during the launch phase,_
ambient temperatures reached 330 K (135° F) inside the workshop but later sub-
sided to 300 K (81° F) within 6 days following deployment of a sunshade.
j	 The command module was reactivated on June 20 and undocked from the work'-
i	 shop at 09:40 GMT on day 29. 	 It landed in the Pacific Ocean, 1300 kilometers
southwest of San Diego, California, at 13:50 GMT on June 22, 1973.
	
The total
flight timu of this first Skylab visit was 672 hours 49 minutes and 49 seconds.
The cretin underwent medical examinations onboard the recovery ship and returned
to Houston on June 25 at 02:47 GMT (ref. 1-3) .
d
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PROCEDURES
Biomedical observations began 31 days before the mission with controlled
dietary intake and complete urine and fecal collections. These procedures were
continued throughout the flight and for 17 days postflight. Preflight and
postflight urine collection was accomplished on a void-by-void basis. Following
each collection, the specimens were cooled to 277 K (4° C). Each morning, the
urine collected the previous day was received in its cooled state in the lab-
oratory and was analyzed. The in-flight collections were performed with an
automatic urine collection system designed to operate in a weightless environ-
ment. Urine was cooled during collection to approximately 277 K (4° C) and
remained at this temperature for no more than 24 hours, at which time a sample
of approximately 120 milliliters was frozen for return and postflight analysis.
Fasting blood samples were drawn five times during the 31-day preflight
phase, four times during the flight, and about 1, 24, and 72 hours, and 14 days
after recovery. For the analysis reported in this document, the blood volumes
preflight and postflight were 25 milliliters, whereas the in-flight plasma
volumes averaged 3 milliliters. Sodium ethylenediaminetetraacetic acid was
used as the anticoagulant both in flight and on the ground.
Radionuclides were used to estimate the size of body compartments. These
studies included the measurement of total body water, extracellular fluid, and
exchangeable potassium.
The mean dietary intake of nitrogen (N), sodium (Na), potassium (K), mag-
nesium (Mg), calcium (Ca), and phosphorus (P) was kept within approximately
±2 percent using repetitive 6-day menu cycles. Menus for the preflight and
postflight control phases were identical, except that a limited number of fresh
foods were substituted for some of the flight food items. Whenever a particular
food was not consumed, mineral supplements were provided to adjust the dietary
intake of every element within the prescribed-tolerance. In addition to ele-
mental intakes, caloric intake was also relatively constant. The actual mean
intakes (before, during, and after flight) for Na, K, calories, and water are
given in table 1-I. Daily water intake was not controlled but was recorded.
Since considerable variation in the response of individual crewmembers
has been observed in all space flights, each man served as his own control;
that is, his in-flight and postflight data were compared with his preflight
data. To facilitate interpretation, urine data have been grouped into periods
of equal duration that coincide with the 6-day dietary cycle of repeating menus:
A change in the level of a plasma constituent is considered to have oc-
curred when it differs by more than one standard deviation (SD) from the mean
of the five preflight values. The analyses performed on the plasma and serum
samples, with each substance and property quantitatively determined (an aster-
isk indicates determination was made during flight), are listed as follows.L
Sodium	 Uric _acid
Potassium
	
Creatinine
3z
s
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Calcium*	 Total protein
Magnesium	 Alkaline phosphatase
Chloride*	 Serum glutamic oxaloacetic transaminase
(SCOT) (aspartate aminotransferase)
Phosphorus* Creatine phosphokinase (CPK)
Osmolality* Lactic dehydrogenase (LDH)
Carbon dioxide Glucose*
li
Cholesterol Total bilirubin
Triglycerides Human growth hormone (HGH)
Adrenocorticotropic hormone Thyroxine
(ACTH)*
Cortisol* Thyroid-stimulating hormone (TSH)
Angiotensin I* Testosterone
r Aldosterone* Parathormone*
' Insulin's Calcitonin
Blood urea nitrogen (BUN) Vitamin D
The analyses performed on the 24-hour urine samples,-with each substance
' andro ertp	 p	 y quantitatively determined, are listed as follows.
Volume Antidiuretic hormone (ADH)
Sodium Aldosterone
Potassium Cortisol
Chloride Epinephrine
Osmolality Norepinephrine
Calcium Total 17-hydroxycorticosteroids (17-OHCS)
Phosphate Total 17-ketosteroids 5
Magnesium Uric acid
Creatinine
E.
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Urine was obtained from each crewmember each day of flight with the ex-
ception of the first day. In-flight measures of urine volumes by pressure plate
displacement assisted the crew physician in approximating the state of hydration
of the crewmembers. However, because of sufficient variation between the post-
flight lithium analysis and the volume determined in flight, the lithium-
dilution-derived answers were used for all biochemical analyses. A comparison
between the pressure plate volume readings and the lithium-determined volumes
for the three crewmembers over approximately 27 day.. in flight provided a cor-
relation coefficient of 0.87.
RESULTS
The serum and plasma biochemical determination results for those measure-
ments made on samples obtained in flight, as well as preflight and postflight,
are presented in tables 1-II and 1-III. These data indicate that an increase
in K, P, Ca, creatinine, insulin, cortisol, HGH, ACTH, aldosterone, and angio-
tensin I had occurred in flight. Decreases were observed in Na, chloride, and
glucose. When the postflight results are compared with the preflight data,
increases are observed in Ca, P, HGH, CPK, creatinine, glucose, insulin, aldos-
terone, osmolality, cholesterol, and total protein. Postflight decreases in
ACTH, LDH, angiotensin I, alkaline phosphatase, and uric acid were also shown.
The results of the urine analyses summarized in table 1-IV reflect signif-
icant increases in Na, K, Ca, P, Mg, ADH, osmolality, aldosterone, and cortisol
during the mission. In-flight decreases were observed in uric acid. Total 17-
OHCS were either decreased or not changed from preflight values for the science
pilot (SPT) and pilot (PLT). The commander (CDR) showed increases in three of
five in-flight periods. The component 17-OHCS changes are given in table 1 -V.
Total 17-ketosteroids were generally increased. The_17-ketosteroid fractions
responsible for this increase are indicated in table 1-VI, which gives pre-
flight, in-flight, and postflight data for pregnanediol (PD), androsterone
(AND), etiocholanolone (ETIO), dehydroepiandrosterone (DHEA), 11=0 AND, 11=0
ETIO, 11-OH AND, and 11-OH ETIO. Amino acids were measured in selected urine
samples; the results are summarized in tables 1-VII to l-IX.
DISCUSSION
With the advent of manned space flight and prolonged periods in null grav-
ity, physiological changes were expected. Some changes were observed in the
returning Mercury crewmembers, and further changes were observed in the Gemini
and Apollo crewmembers (refs. 1-4 and 1-5). Because of the difficulty in col-
lecting and preserving urine and blood samples in the weightless environment
and because of the return weight of the samples, very few such samples were
collected during the Geminiand Apollo missions. In the Skylab Program, how-
ever, a sufficient number of adequate samples were returned foran in-depth
study of human biochemical responses to extended stays in space. These samples
provided a basis for ascertaining the general biochemical response to flight
1-4
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and the particular response of fluid/electrolyte and muscul.oskeletal metabolism.
The regulation of these parameters together with the broader aspects of adapta-
tion and metabolic processes were also studied.	 ji
Of paramount interest were the crewmembers' responses during the initial
period of flight, particularly in fluid and electrolyte balance. The elevated
workshop temperature further augmented the initial reaction of the crew to
weightlessness. During the 28-day mission, • the CDR lost 1.9 kilograms, the
Gil lost 3 kilograms, and the PLT lost 3.7 kilograms. Caloric intake and body
compartment data have been interpreted to mean that, despite weight loss in all
three crewmembers, adequate calories were consumed in flight. Loss of muscle 	 a
mass and body fluids accounted for the weight loss (ref. 1-6).
A comparison between the preflight mean and the 6-day periods in flight
and postflight reveals that all three crewmembers initially had decreased urine
volumes that subsequently returned to or exceeded preflight values (fig. 1-1).
The postflight urine volume for the SPT decreased. Although no significant in-
flight diuresis was measured, it must be noted that collection of urine on the
first day in flight was not performed, and the entire first period occurred
during heat stress.
'r- _
	
..
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A pattern similar to the one observed for urine volume is also observed in
the urinary ADH results given in figure 1-2. 	 Significant increases in'ADH oc-
curred early-in all crewmembers, and the elevations persisted for the CDR and
PLT throughout the mission.	 The body fluid volumes shown in table 1-X indicate
a decrease of about 3 percent in total body water and 3 percent in extracel-
lular fluid; however, when the weight losses were taken into consideration,
a proportionate increase in fluid was expressed as a percentage of body weight.
These data indicate that the ADH mechanism was operative in water retention.
The crewmembers did not show evidence of dehydration despite the excessive heat
stress early in flight.
The urinary Na data (fig. 1-3) show slight losses early in flight for the
CDR and SPI'.	 All three crewmembers showed increased excretion during the re-
mainder of the mission with significant decreases immediately postflight. 	 This
increase in urinary Na occurred at the same time that Na intake actually de-
creased from a preflight mean of 203 meq/day to an in-flight mean of 193 meq/
day.	 Potassium intake remained constant (102 ± 2 meq/day preflight and 100 ±
2 meq/day in flight) during the control and flight phases.
	 Urinary excretion
of K (fig. 1-4) was increased throughout the mission for all three crewmembers
with evidence of retention immediately postflight.
	
This loss in K is confirmed
by the decrease of 6 to 8 percent in total body exchangeable K (table 1-XI)._
However, plasma K results (table 1-II) do not reflect changes.
	 A 20-percent
postflight decrease in total body K has been observed by measurement of the
total body K-40 after early Apollo flights. l	Total body exchangeable K was
measured on the Apollo 15 crewmembers and was found to be decreased about 13	 a
percent postflight.	 The crewmembers of the Gemini 7 mission demonstrated ,pos-
itive K balance pre- and postflight with a negative balance during the mission.
1
Personal communication, J. V. Bailey.
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The Gemini 7 results revealed increased urinary aldosterone excretion during
the flight (ref. 1-7). Aldosterone was increased in the 2 4+ hour urines of all
three of the Skylab 2 crewmembers for the duration of the mission and immedi-
ately postflight (fig. 1-5). The levels reached for this period of time could
certainly account for the urinary losses of K, but the data indicate the loss
:
	
	
of Na even though aldosterone was increased. Results from the in-flight meta-
bolic experiment on the 13-day Apollo 17 mission suggested similar responses
from that creTr (ref. 1-R). Several possibilities may account for these results.
The data are suggestive of other mechanisms operative in the renal tubule prox-
imal to the site of aldosterone action in the distal tubule. These mechanisms
could involve humoral (ref. 1-9) or physical factors (ref. 1-10). Plasma aldos-
terone and renin activity changes indicate that there was an actual increasa in
-_ production of aldosterone, probably by way of the renin-angiotensin mechanis,10.
This elevation could be produced by decreases in effective renal blood flow and
carotid-artery or right-atrial pressure changes. Increased aldosterone secre-
tion is the presumed cause cf the K loss.
The high temperatures in the spacecraft must be considered when the data
are evaluated because the effect of increased environmental temperature on the
control of fluid and electrolytes is well documented (ref. 1-11). Changes in
renal function could account for these changes. Postflight serum BUN did not
change, and urinary creatinine remained relatively constant throughout the
mission. However, plasma creatinine was slightly elevated during the mission
and in two crewmembers postflight, as shown in figure 1-6.
^-
	
	
Indicative of a significant stress response was the increase in urinary
cortisol (fig. 1.7) during the mission and continuing postflight. The metabolic
biochemical and exercise data must be viewed in light of the high cortisol
r
	
	
excretion because this steroid plays a key role -in thc regulation of cellular
metabolism. Plasma cortisol analysis (table 1-II) did not reflect a continuous
high production of this hormone during the flight, and the postflight values
were actually decreased in the CDR and PLT. These postflight results are com-
parable to the authors' earlier Apollo reports (ref. 1-12) and to the reports of
Dlusskaia (ref. 1-13), who found similar results after Soyuz 9.
The total 17-OHCS showed either a decrease or no change from preflight
values in two of the crewmembers. This occurred with changes shown in all four
fractions. Pregnantriol is generally elevated, even when the other fractions
are not changed or decreased.
The failure of the free cortisol increases to be reflected in total 17-OHCS
is presently not explainable. Results similar to these were observed during the
Gemini VII and the Apollo 16 and 17 flights. Metabolism of the adrenal steroids
is believed to be implicated (ref. 1-14)
Total and ketosteroid fractions help to indicate specific areas of in-
creases in the adrenal pathways of steroid production. Significant increases
in all fractions were noted; however, the large increases in DHEA were speci-
fically noteworthy. This compound is of adrenal origin, and increases in this
compound were also observed during Apollo 17. In a pilot study performed on
subjects deprived of adequate K intake, DHEA was significantly increased. These
r
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results led to speculation concerning a role for DHEA in plasma K regulation
(ref. 1-15).
The catecholamine excretion levels are variable, but both epinephrine
(fig. 1-8) and norepinephrine (fig. 1-9) were generally decreased in the CDR
during the mission. Postflight, both compounds were elevated significantly in
all three crewmembers. Norepinephrine remained elevated for the duration of
postflight testing. These compounds are secreted in response to physical and
ment°l stress. In particular, increases in norepinephrine are often seen in
response to challenges to the cardiovascular system. These data might be inter-
preted as part of the response of the cardiovascular system to a return to the
one-g environment. Increases in norepinephrine excretion after bed rest have
been reported and perhaps reflect an increase in vasomotor- tone following re-
t	
ambulation (ref. 1-16).
These data, are comparable to the results from the Gemini VII and Apollo
missions, and contrast with the lack of changes observed on the crewmembers
participating in the chamber simulation of Skylab (ref. 1-17). These findings
are not indicative of immediate medical problems but emphasize the need to main-
tain good dietary intake. There is no indication from these results for the
occurrence of a plateau in the biochemical responses to zero g within 28 days.
Both an immediate response and a more prolonged adaptive response appear to be
present.
The slight increases observed in plasma creatinine are indicative of de-
:,
	
	 creases in creatinine clearance because urinary creatinine lid not show parallel
changes. These findings provide evidence for minor alterations in renal func-
tion in flight, a supposition also advanced by Balakhovskii and Natochin (ref.
1-2).
Among the earliest concerns for the effects of weightless flight were
those involving losses of bone mineral. A complete metabolic study was con-
ducted on this flight. The results showed significant losses of Ca, P, Mg,
and N (ref. 1-18). The studies reported here extend the input/output balance
experiment by providing data concerning plasma levels of musculoskeletal con-
stituents. Plasma Ca and P increased during the flight in all three crew
members. Plasma parathormone and 25 hydroxycholecalciferol were not signifi-
cantly changed from preflight control values. Calcitonin was not detectable
with the sensitivity of the assay; however, slight physiologic changes cannot
be ruled out.
In humans, hypoalimentation stimulates HGH secretion. Hypoglycemia has a
particularly rapid effect on HGH secretion. Human growth hormone, an insulin
antagonist, raises blood glucose and plasma free fatty acids while lowering
plasma amino acids. Growth hormone measurements were made together with meas-
urements of insulin and glucose. Although plasma HGH levels were quite vari-
able, significant elevation occurred during the first day in flight and the
first days after recovery. Insulin and glucose were significantly decreased
during the flight and increased after recovery. There was an increase in plas-
ma cholesterol on recovery day. The constancy of the diets preflight, in-
flight, and postflight would tend to preclude diet as a significant factor in
1-7
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Athese changes immediately after flight, although losses in fat stores through-
out the long missions may account for the mobilization of triglycerides after
recovery.
The significant increases in thyroxine and the trend toward higher TSH
levels correlate well with the decreases in cholesterol for 2 weeks following
recovery. These data confirm earlier Apollo findings of an increased circula-
ting free thyroxine after space flight (ref. 1-19). Similar findings were re-
ported by the Soviets, who were able to correlate weight loss with cholesterol
decreases. The Soviet workers suggested, without supportive data, that the
thyroid gland might be implicated (ref. 1-2).
At recovery, blood glucose appears to be raised by the action of catechol-
amines, cortisol, and HGH, whereas the insulin is increased as a response to
the elevated blood sugar. The in-flight decreases observed in both glucose and
insulin have also been observed in bed rest. However, the decrease became sig-
nificant at 28 days in space but did not become significant until 56 days in
bed rest (ref. 1-20). The impaired tolerance to a glucose load that has been
reported for exposure to bed rest was not measured in this study (ref. 1-21).
Total plasma protein as well as albumin increased on recovery day. Albu-
min decreased on the 3rd and 14th days after recovery, but not as much as total
protein. This finding is inferential evidence that glycoproteins were increas-
ed immediately postflight. The cholesterol increase observed at recovery may
also indicate an elevation in lipoproteins, particularly in high-density lipo-
proteins. Plasma volume increases as a result of water and electrolyte reten-
tion caused by the effects of gravity were recorded during this period. Thus,
the decrease in albumin may have been dilutional rather than absolute. Unlike
the Apollo results, triglycerides were elevated after flight until the 14th day
postflight.
SUMMARY
i
The observations concerned with the biochemical reactions of the body to
	
a
the stress of space flight included both endocrinological and metabolic meas-
urements. This is the first comprehensive and integrated study of endocrinol-
ogy and metabolism during prolonged space flight. Significant biochemical
changes were observed that varied in magnitude and direction, but all disap-
peared shortly after return to Earth.
These changes are, for the most part, indicative of a successful adap-
tation by the body to the combined stresses of weightlessness. The transient
nature of'some of these changes, particularly in fluid and electrolyte metab-
olism, tends to support the conclusion that a new and stable condition of homeo-
stasis has been achieved. In other areas, particularly those concerned with
the metabolism of bone mineral, protein, and carbohydrates, unstable states
appear to persist. It is unclear at this time in which forts the ultimate
sequelae of these changes will manifest themselves after flight has continued
4
	 for much longer periods of time.
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Sodium, Potassium, Calories Water,
Menu meq meq ml
cycles
[7±SDSEMean ±SDa SEb Mean ±SD SE Mean ±SD I SE Mean
Preflight intake
1 173 28 16 76 17 10 2271 698 403 .2153 178 103
2 2o4 18 7 99 8 3 2808 93 38 2635 337 138
3 205 15 6 99 7 3 2726 148 60 2511 398 162
4 194 28 11 100 7 3 2907 204 83 2535 427 174
5 213 65 27 93 12 5 2881 181 74 2353 260 lo6
6 203 42 21 100 11 5 3076 287 144 2580 350 175
In-flight intake
1 189 17 7 97 12 5 2637 3o6 125 2842 580 237
2 196 8 3 102 6 3 2775 197 81 2374 222 91
3 200 11 4 103 6 2 2882 151 62 2412 148 60
4 202 8 3 103 6 2 2927 123 50 2379 154 63
5 193 23 12 104 1	 5 1.	 2 2988 1 175 1	 88 2413 1 231 1	 115
Postflight intake
1 211 29 12 107 12 5 3455 609 248 3047 830 339
2 211 16 6 98 7 3 3142 283 116 2533 286 117
3 215 20 9 102 8 4 3309 132 59 2716 961 430
a
a
TABLE 1-I.- DIETARY PARAMETERS
(a) Commander
Sodium, Potassium, Calories Water,
Menu meq meq ml
cycles
Mean ±SD=SE Mean
I 
±SDj SE] Mean ±SD D
I	
SE
Preflight intake
1 124 60 34 65 40 23 1858 767 443 1798 649 374
2 201 44 18 101 12 5 3222 301 123 2496 231 94
3 219 34 14 107 12 5 3244 157 64 2378 124 50
4 192 20 8 99 11 5 3092 228 93 2241 286 117
5 218 73 30 95 23 10 3334 505 206 2247 355 145
6 188 28 14 lol lo 5 3036 231 115 2395 532 266
In-flight intake
1 197 17 7 96 8 3 2761 251 103 2685 423 173
2 194 18 7 98 8 3 2920 163 66 2156 182 74
3 197 20 8 103 5 2 3114 187 76 2183 191 78
197 21 8 103 5 2 3079 133 54 2309 256 lo4
5 195 22 11 99 2 1	 1 1 2994, 191 96, 2194 253 127
Postflight intake
1 173 42 17 79 15 6 2619 398 163 2361 374 153
2 207 42 17 97 9 4 3089 1o8 44 2533 248 101
3 196 44 20 90 15 7 2976 227 101 2289 833 373
TABLE 1-I.- DIETARY PARAMETERS - Continued
(b) Science pilot
,r,^ J --^^^,r	 :,.._. „- r-,n-.,._._ .mot i`""_' ^..... .—.—,^,..—: . -•-.—,^,,,-,^.., :--.- -,.^.,- 	 f	 ^	 ,'•-
3
_	
f
F
4
TABLE 1-I.- DIETARY PARAMETERS - Concluded
(c) Pilot
Sodium, Potassium, Calories Water,
'Menu meq meq ml
cycles
Mean ±SD SE Mean ±SD SE Mean ±SD SE Mean ±SD SE
Preflight intake
1 101 82 48 48 34 20 1692 1o96 633 2443 994 574
2 200 6 2 95 12 5 3125 112 46 4254 424 173
3 196 8 3 96 11 5 3010 152 62 4496 592 242
4 199 6 2 95 12 5 3072 152 62 4210 484 198
5 225 39 16 95 16 7 3245 26o 106 3671 553 226
6 207 18 9 96 17 9 3112 171 86 3640 639 320
In-flight intake
1 184 37 15 89 21 8 2614 420 171 3541 1093 446
2 189 17 7 loo 14 6 2843 255 loo 4411 384 157
3 189 18 7 103 14 6 2871 176 72 3741 534 218
4 185 12 5 103 14 6 2877 131 53 4154 697 284
5 184 17 8 100 13 6 2874 209 loo 4190 1134 567
Postflight intake
1 198 3 1 105 15 6 3384 425 174 4332 595 243
2 196 7 3 92 11 4 3086 89 36 3897 5o8 207
3 194 7 3 92 15 _ 7 3156 202 90 4973 805 360
it
5
a
TABLE 1-II.- MMUM/PLASMA RESULTS
Semple schedule Sodium, Potassium, Chloride, Cr-einine, Glucose, Osmolslity,
(s) meq/liter meqter meq/11ter mg percent mg percent milliosmols/liter
Cesunder
F-21
-- -- -- __
-^ 293
F-14 137 4.25 96.8 1.o6 80.3 288
F-7 138 4.48 99.4 1.110 80..1 291
F-1 134 4.33 96.3 1.14 72.2 285
F-IA 140 4.13 97.5 1.19 81.9 289
Preflight mean ! SD 137 t 3 4.29 i	 .14 97.5 ' 1.4 1.13 i	 .05 78.6 t 4.4 289 i 3
MD4 138 4.49 98.1 1.18 80.6 286
MM 131. 4.24 100.8 1.18 82.3 286
MD13 14o 3.96 96.4 1.15 81.7 286
MD27 137 4.38 95.7 1.25 80.1 286
R+o 138 4.36 94.8 1.30 95.1 286
R+1 138 4.50 94.8 1.12 .89.3 .284
R+4 136 4.48 94.6 1.15 90.9 295
R+14• -- -- -- -- -- 297
R+67 __ _- -- -- -- 286
Science pilot
F-21 -_ -- _. __. __ 285
F-14 141 4.50 100.2 1.23 92.5 288
F-7 134 4.69. 100.9 1.18 90.7 290
F-1 143 4.28 99.0 1.20 89.1 286
F-IA 135 4.39 98.2 1.18 86.4 286
Preflight mean 4 SD 138 '- 4 4.46 '	 .17. 99.6 t 1.2 1.19 ! .02 90.2 t 1.8 287 t 2
MD4 140 4.28. 99.6 1.26 90.5 286
MD6 140 4.2T 99.6 1.23 88.4 288
MD13 138 4.62 97.2 1.26 87.5 285
MD27 137 4.46 96.o 1.38 83.2 284
R+o 134 4.19 96.8 1.18 91.4 287
R+1 136 3.90 96.8 1.43 101.9 286
R+4 135 4.22 96.8 1.25 92.5 289
R+14 -- -- -- -- -- 288
R+67
-- '- '- -' _- 290
Pilot
F-21 --. -- -- -- -- 287
F-14 143 3.96 98.3 1.31 88.9 288
F-7 143 4.52 99.6 1.31 92.7 289
F-1 141 4.22 98.6 1.36 88.0 284
F-lA 139 3.98 100.6 1.31 85.0 299
Preflight mean ! SD 142 s 2 4,17 3 .26 99.3'- 1.0 1.32 t .02 88,7 ± 3.2 289 a 6
MD4 139 4.32 96,9 1.33 89.1 .290
MD13 141 4.12 97.2 1.25. 90.9 289
MD27 135 4.48 97.0. 1.30 83.7 288
w 135 4.16 97.4 1.46. loo.4 292
R+1 137 4,44 96.6 1:33. 87..3 288
R+4 138 4.38 97,5 1.44 93.4 302
A+14 __ '_ _ __ - .287
R+6T
--
--
--
289
r
7
Calcium, Phosphate , Cortiaol, Mgiotens in I, Aldosterone, ACTH, Insulin, HGH, rmParathoone,.
mg percent mg percent WU100 al ng/ml/hr ug/3o0 al pg/ml /Ml ng/ml ng/ml
Com andmr
14.0 0.29 66 19.8 14 1.0 10.6
9.8 4.06 11.2 .55 390 24,4. 14 .4 1o.6
9.9 3.81 16.0 .34 106 24,0 12 1.5 13.8
9.6 4.o9 13.0: 1.13 480. 64.3 21 .8 10.9
10.0 4.15 16.2 1.65 480 26.7 18 .8 18.0
9.8 ! .2 4.02 !	 .1 1- 14.5 1 2.7 •79 !	 .58 3o4 • 203 31,8 t 18.3 16.0 • 4 .9	 •	 .4 13.0 1	 3.0
10.4 4.74 20.4 .83 530 -- 18 2.4 --.
10.3 4,27 20.6 1.17 62o 58.7 24 .4 1J.7
10.6 4.03 2o.6 .30 418 70.1 24 1.4 17.0
10.8 4.52 22.0. .40 500 -- 20 .4 10.5
10.1 4.58 6.o
.33 250 8.3 20 2.6 18.0
10.8 3.44 8.6 .76 290 9..5 24 5.8 18.0
10.6 3.62 19.8 .18 560. 18.9 10 2.6 18.0
-- -- 12.2 .29 100 47.3 12 1.3 10.0
-- -- 11.8 .44 1	 92 1 22.1 116 .8 11.5
Science pilot
-- -- 10.8 1.03 34 22.7 14 1.0 12.0
10.0 4,27. 8.8 1.94 210 35.1 14 1.0 11.8
9.8 4.24 16.4 1.39 96 34.7 19 1.1 10.2
10.0 4.65 11.4 2.42 255 70.6 18 .4 10.1
9.8 4.34 18.4 2.34 295 51.1 19 1.1 18.0
9.9 ! .1 4.37 ! .18 13.2 ! 4.1 1.82 t .60 178 • 110 42.8	 18.5 17 •	 3 .9	 •3 12.4 t 3.2
10.2 4.34 9.0 2.33 180 -- 24 1.8 10.8
9.8 4.89 14.8 3.47 350 61.7 22 1.8 16.6
10.5 4.8o 13.4 2.07 380 15.2 29 1.4 17.4
10.4. 4.40 8.2 .97 135 59.3 31 1.4 --
9.7 4.27 21.0 .46 64o 33.8 16 5.8 18.0
10.4 3;72 18.4 5.30 68o 26.3 22 8.0 18.0
10.0 3.93 15.4 .82 480 25.7 16 2.6 18.o
-- -- 11.0
.45 62 5T•5 16 2.0 12.0
-- -- 10.2 .22 14o 47.0 22	 1 .8 10.8
Pilot
-- 6.o 2.85 62.5 18.1 16 1_3 11.4
9.6 3.87 10.8 .22 170 34..9 15 1.3 11.3
9.9 3.75 22.0 .45 103 26.9 16 .4 12.3
10.0 3.53 14.4 .94 360 56.9 20 1.7 10.8
9.6 3.68 14.0 .14 225 29.4 12 1.1 18.0
9.8 ±..2 3.70 ! .14 13.4.! 5.8 .92 i 1.12 184.1 1 116 33.2 ! 14.5 16 3 3 1.2 ! ,5 12.8 1 3.0
10.3 4.83 11.8 1.43 370 34:0 26 1.0 19.0
10.4 4,40 13.8 .90 26o. 36.9. 22 1.0. 16.5-
10.5 4.68 17.0 ,90 44o 18.2 26 1.0 14.o
10.2	 .4.55 11.0 .63 530 .33 24 3.2 18..0
10.2 3.59 9.2 1.13 410 1.80 29 .8 18.0
10.3 3.99 13.6 .20 300 24.0 28 .8 18.0
-- -' 9.8 .10 36 49,2 30 .4 10.0
-- - 10.6 .07 115 34.2 13 .8 14.5.
i
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9	 .
Triiodothyronine,
Sample relative Thyroxine, Vitamin D, Calcitonin, TSH,
schedule percent 129/100 ml ng/ml ng/ml 11U/ml
uptake
Commander
F-21 34.2 5.0 56.7 0.3 2
F-14 33.8 6.1 38.0 .3 2
F-7 34.2 6.0 36.3 .3 2
F-1 36.2 7.5 45.3 .3 6
F-lA 35.0 6.6 27.0 .21 4
Preflight meant SD 34.7 ± 1.0 6.2 ± .9 40.7 ± 11.1 .28 ± .04 3 ± 2
R+0 33.5 7.2 20.5 .21 12
R+1 31.2 9.3 29. 5 .21 10
R'+4 32.7 7.7 49.o .21 4
R+14 33.8 4.5
--
.52
--
R+67 33.8 6.7 30.0
.7 --
Science pilot
F-21 34.6 6. 9 28.5 0.3 1
F-14 32.3 6.3 24.7 .3 4
F-7 30.8 11.5 37.0 :3 2
F-]_ 33.1 6.8 33.3 .3 2
F-lA 35.0 8.2 15.5 .21 7
Preflight mean t SD 33.2 ± 1.7 7.9 t 2.1 27.8 ± 8.3 .28 ±	 .04 3 ± 2
R+o 32.3 8.9 16.9 .21 25
R+1 31.5 12.8 35.0 .21 15
R+4 36.2 13.1 36.3 .21 6
R+14 33.1 6.3 58.0 .21 --
R+67 37.3 7.8 28.0 .7 --
Pilot
F-21 36.0 8.0 28.3 0.3 1
F-14 31.5 8.3 24.7
	 - .3 2
F-7 33.8 9.4 27.0 .3 0
F-1 35.0 8.o 25.7 .3 1
F-lA 35.4 9.3 -- .38 1
Preflight meant SD 34.3 t 1.8 8.6 ±	 .7 26.4 + 1.6 .32 ± .04 l t .7
_R+0 35.0 8.5 -- .4o 8
R+1 33.5 10.5 52.5 .47 6
R+4 35.0 8.8 32.7 Ao 6
R+14 33.1 5.7 38.5 .32 --
R+67 35.0 7.0 92.0 .7
--
TABLE 1-III.- SERUM/PLASMA RESULTS (PREFLIGHT-POSTFLIGHT COMPARISONS) - Concluded
(b) Sample schedule 2
Variable
(e)
Preflight
mean
In-flight period Postflight period
t SE 1 2 3 4 5 1 2 3
Sodium, meq/TV . . . . 151 ± 7 143 ± 18 165 ± 20 152 ± 11 165 ± 9 169 t 16 14o ± 12 177 t 17 133 ± 18
Potassium, meq/TV- . . . 72 ± 3 89 ± 7 73'± 6 91 ± 7 91 ± 4 84 ± 9 72 ± 5 80•± 8 76 ± 2
Chloride, meq/TV . . . . 147 ± 8 132 ± 18 153 ± 24 147 ± 12 154 ± 7 150 t 13 147 ± 11 163 ± 20 133 ± 8
Osmolality,
milliosmols	 . . 672 ± 43 918 ± 48 649 ± 81 678 ± 4o 66.1 ± ?5 776 ± 16 56o ± 41 559 '- 40 697 ± 22
Uric acid, mg/TV 936 ± 29 855 ± 77 849 ± 62 870 ± 32 807 ± 19 825 ± 73 967 ± 98 957 ± 100 827 ' 59
Creatinine, mg/TV	 . . . 1708 ± 46 1858 + 55 1855 ± u6 1663 ± 136 1765 ± 72 1750 ± 73 1935 ± 78 2016 ± 97 1650 ± 70
Calcium, meq/TV	 . .	 . . 11.7 ± 0.4 13.3 ± 0.8 18.9 ± 1 21.8 # 0.9 23.6 t 2 23.0 ± 1 20.8 ± 2 14.4 ± 2 12.2 ± 1
Phosphate, mg/TV	 . . 1001 ± 24 1457 ± 74 1211 ± 83 1365 ± 50 1371 ± 62 1387 ± 21 1229 ± 106 1127 ± 87 941 ± 116
Magnesium, meq/TV	 . 10.3 *_ 0.3 11.4 ± 0.9 11.8 # 1 11.4 ± o.6 11.0 ± 0.7 10.7 ± 0.5 10.3 t 0.8 11.1 t 1.4 9.4 ± 0.9
Hydrogen ion, ml
0.1 N NaOH/TV 	. . . . 253 ± 18 - - -- - -- 335 ± 60 232 ± 40 222 ± 17
Cortisol, jig/TV
	 •	 •	 •	 • 58.6 ± 4 55.1 ± 4 81.2 ± 9 80.5 ± 8 80.3 ± 6 89.1 ± 16 84.9 ± 14 78.6 t u 60.8 ± 4
Aldosterone, yg/TV . . . 17.7 ± 3 59.3 ± 5 54.9 ± 6 51.1 ± 6 36.5 ± 6 46.2 ± 8 25.8 t 10 13.8 ± 2 13.7 ± 3
ADH, mU/TV .
	 .	 . .	 . 75.6 ± 6 151.8 ± 9 109.2 ± 15 93.1 ± 3 82.4 ± 6 80.3 ± 14 78.o ± 14 85.9 ± 14 91.3 ± 24
Epinephrine, jig/TV . . . 43.0 ± 3 20.5 ± 7 29.4 ± 4 28.5 ± 4 27.1 + 3 33.1 ± 5 42.8 ± 8 44.2 ± 9 35.5	 8
Worepinephrine,
Ng/TV	 .	 .	 .	 .	 .	 .	 .	 . 51.4 ± 14 26.1 ± 1 39.6 ± 8 4o.9 ± 5 47.6 ± 4 55.3 ± 6 113.5 ± 16 96.6 ± to 81.4 ± 2
Total 17-OHCS,
mg/TV
	 .	 .	 .	 ...	 .	 . 5.19 ± 0.36 7.25 ± 1.11 7.19 ± 0.50 6.86 ± 0.15 5.62 ± 0.33 5.16 i 0.45 5.48 ± 0.67 4.91 ± 1.02 4.48 t 0.68
Total 17 keto-
steroids, mg/TV	 . . 5.43 + 0.44 5.83 ± o.44 6.49 + 0.02	 17.66 ± o.86	 18.63 ± 0.52	 17.09 * 0.61	 1 6.26 ± o.16 4.85 ± 0.65 5.11 ± 0.13
41V = ' total volume.
r
TABLE 1-IV.- TWENTY-FOUR-HOUR URINE RESULTS - Continued
(b) Science pilot
Variable
Preflight
mean
BE
In-flight period Postflight period
1 2 3 4 5 1 2 3
Sodium, meq/TV 149 ± 9 124 t 8 172 ± 16 145 ± 12 161 ± 7 176 ± 11 79 ± 22 169 ± 12 185 ± 7
Potassium, meq/TV 	 . . . 72 ± 4 83 ± 9 83 *- 3 84 ± 6 94 ± 6 115 ± 14 47 ± 4 63 ± 6 85 ± 10
Chloride, meq/TV
	
. . 132 ± 10 109 ± 10 147 ± 17 145 ± 12 150 ± 5 168 ± ll 69 ± 22 170 ± 18 191 ± 5
Osmolality,
milliosmols	 .	 . .	 .	 . 942 ± 34 1289 ± 4o 1090 ± 25 964 ± 46 799 ± 48 837 ± 84 775 ± 52 632 ± 68 831 t 85
Uric acid, mg/TV . . . . 871 ± 26 1208 ± 173 987 ± 66 869 ± 28 793 ± 41 973 ± 120 825 ± 44 824 ± 22 863 ! 50
Creatinine, mg/TV	 . 2056 ± 42 2001 ± 34 2009 ± 117 1966 ± 198 1900 ± 45 2282 ± 241 1943 ± 121 2002 ± 38 2139 ? 101
Calcium, meq/TV	 .. .	 .	 . 6.8 ± 0.3 8.1 # o.8 11.6 t o.8 11.8 ± 0.6 10.8 3 o.9 12.7 ± 0.9 9.3 ± 0.7 7.7 . 0.8 9.9 ± 1.1
Phosphate, mg/TV . . . 1083 ± 48 1476 ± 51 1357 ± 6o 1287 ± 62 1178 ± 86 1475 ± 100 1014 ± 54 1047 ± 56 1155 ! 28
Magnesium, meq/TV 8.9 *- 0.3 1.1.6 ± 0.3 12.0 ± 0.7 11.1 ± 0.3 10.2 ± 0.8 11.8 ± 0.5 7.7 ± 0.5 8.8 ± 0.5 10.2 ± 0.9
Hydrogen ion, ml
0.1 N NaOH/TV
	 .	 .	 . . 276 t 15 - - - - -- 293 ± 18 254 ± 25 305 ! 101
Cortisol, Vg/TV 43.0 f 4 57.1 ± 5 66.6 ± 3 62,2 ± 5 58.4 ± 5 70.8 ± 11 65.2 ± 17 59.5 ± 4 57.1 ± 5
Aldosterone, vg/TV 13.2 ± 2 47.5 ± 4 49.1 t 6 50.7 ± 4 25.1 ±. 3 62.2 ± 9 28.7 ± 11 9.7 -` 2 5.1 *_ 0.6
ADH, mU/TV .
	
. . 43.7 ± 5 65.9 ± 9 36.6 ± 4 34.9 ± 4 22.7 * 2 28.8 ± 8 54.3 ± 26 22.2 ± 3 26.7 ± 2
Epinephrine, ug/TV . 23.0 ± 2 12.5 ± 3- 27.6 ± 4 38.9 ± 6 24.0 ± 4 25.0 ± 5 34.9 ± 10 29.3 ± 4 25.4 ± 17
Norepinephrine,
ug/TV	 .	 •	 .	 .	 .	 .	 .	 . 51.6 ± 3 59.4 ± 6 61.5 ± 4 51.4 ± 10 57.9 ± 3 52.8 i 11 103.3 ± 6 96.5 t 14 89.8 ± 8
Total 17-OHCS,
mg/TV	 .	 .	 .	 . 6.09 ± 0.35 6.04 ± - 7.02 ± 0.24 4.68 ± 1.02 4.50 ± 0.37 5.10 ± 0.48 5.76 ± 0.72 5.72 ± 0.82 10.96 ± 5.36
Total 17-keto-
steroids, mg/TV 7.61 ± 0.24 6.55 '= - 8.62 ± 0.23 8.77 ± 0.23 9.29 ± 0.83 8.63 ± 1.05 6.94 ± 0.67 7.12 ± 0.74 8.14 ± 0.41
I
N1N
Variable
Preflight
mean
SE
In-flight period Postflight period
1 2 3 4 5 1 2 3
Sodium, meq/TV 154 t 8 139 ± 13 140 t 9 164 t 19 171 t 10 152 t 16 115 t 23 157 ± 10 148 +_ 16
Potassium, meq/TV	 . . . 72 t 3 76 ± 8 78 t 7 89 + 9 91 ± 5 92 ± 9 74 t 8 70 ± 6 72 t 5
Chloride, meq/TV . 	 . 148 t 11 114 ± 8 232 t 72 144 t 15 184 t 48 171 t 36 126 t 24 130 ± 8 130 t 13
Osmolality,
milliosmols	 . .	 . 331 t 12 706 ± log 417 t 62 414 t 48 371 t 26 417 t 72 328 ± 33 321 t 25 261 t 13
Uric acid, mg/TV . . . . 985-+ 15 811 ± 31 996 t 52 1034 t 92 897 ± 29 867 t 36 812 ± 72 940 ± 112 873 ± 48
Creatinine, mg/TV 	 . . 2227 t 37 2146 ± 78 2381 t 229 2100 t 201 2175 t 35 1885 t 324 2217 t 33 2189 t 37 2197 t 89
Calcium, meq/TV	 . . . . 7.2 t 0.4 12.5 ± 1.3 18.2 t 1.0 21.1 t 1.3 21.5 t 0.9 20.0 t 0.9 16.0 t 0.8 11.9 t 0.5 12.2 t 0.8
Phosphate, mg/TV . . . . 1157 ± 32 1475 ± 62 1385 t 106 1667 t 14o 1603 t 65 1504 ± 63 997 t 59 1144 t 51 1045 t 65
Magnesium, meq/TY ,. . . 9.6 ± CA 10.1 ± 0.5 12.4 t 0.5 12.3 t 1.0 12.4 t 0.5 12.4 t 0.4 9.6 t 0.6 10.6 t o.6 10.1 t 0.6
Hydrogen ion, ml
0.1 N NaOH/TV 221 ± 15 - - - - -- 213 t 82 227 t 20 227 t 31
Cortisol, vg/TV	 .	 . .	 . 59.0 ± 5 82.1 ± 13 121.2 t 16 109.6 ± 16 103.0 t 8 111.2 t 6 84.3 t 12 76.3 t 4 81.9 t 8
Aldosterone, pg/TV . 9.4 ± 0.7 42.8 t 2 45.7 t 10 25.0 ± 9 23.2 t 1 51.4 +_ 16 33.2 t 16 7.9 t 1 6.0 +->
ADH, mU/TV . . . . 23.0 t 2 54.5 ± ll 35.4 t 4 43.4 ± 5 42,9 t 2 36.9 t 2 47.6 t 20 30.7 t 2 30.6 t 1
Epinephrine, jig/TV ... 25.7 t 3 11.8 ± 4 21.9 t 4 27.8 t 3 26.7 t 6 32.9 t 7 27.3 ± 6 29.2 t 8 4.4 t 3
Norepinephrine,
ug/TV	 .	 .	 .	 .	 .	 .	 . 70.4 t 5' 63.7 t 7 80.3 t 9 67.5 ± 5 78.0 t 8 94.6 ± 19 117.6 ± 16 118.4 t 12 107.8 ± 12
Total 17-OHCS,
mg/TV	 .	 .	 .	 .	 .	 .	 .	 . 6.50 t 0.64 8.75 t 1.47 6.19 t 0.99 3.96 t 0.49 6.08 ± 0.28 6.99 ± 1.61 5.49 t 0.33 4.89 t 0.77 4.44 t 1.02
Total 17-keto-
steroids, mg/TV 10.41 t o.42 13.38+ 1.40 12.£-3 t 0.8, , 12.70 t 1.80 14.49 t 0.39 12.65 t 1.11 10.05 t 0.97 10.12 t 1.24 11.26 t 0.57
e
Fraction, mg/24 hr Tot al,
Schedule mg/24 hr
Pregnantriol Tetrahydroa T	 soletrahydrocorti Tetrahydrocortisone
Preflight data
Preflight 0.46 t 0.04 0.09	 0.02 1.20 ± 0.13 3.63 '- 0.24 5.19 ± o.36
man ± SE
Period:
1 .45 t	 .01 1.23 ±	 .21 3.41 ±	 .78 7.25 *- 1.11
2 .52 ±	 .01 - -- 3.67 *-	 .o6 7.19 ±	 •50
3 .32 ±	 .o6 - 1.39	 .38 4.07 ±	 .88 6.86 ±	 .15
4 .49 t	 -- -- .75 '-	 -- 3.27 '-	 -- 5 ^2 ±	 .33
5 - -- -- -- 5.16 t	 .45
In-flight data
Period:
1 0.80 ± 0.10 -- 1.76 ± 0.26 4.69 # 0.78 --
2 .88 !	 .10 1.89 *-	 .18 4.43 *-	 .27 --
3 1.07 ±	 .22 -- 1.82 ±	 .49 3.96 ±	 .45 --
4 .77 t	 .07 .03 .	 .01 1.34 t	 .o9 3.49 *-	 .21 --
5 .63 *-	 .o4 .11 ±	 -- 1.34 ±	 .20 3.15 *	 .24 --
Postflight data
Period:
1 0,69 ± 0.06 0.07 ± 0.01 1.49 ± 0.22 3.27 * 0.39 5.48 ± o.67
2 .72 ±	 .13 -- 1.14 ±	 .31 3.05 '-	 •62 4.91 t 1.02
3 .62 ±	 .09 -- 1.o6 ±	 .16 2.80 ±	 .66 4.48 ±	 .68
(b) Science pilot
Schedule
Fraction, mg/24 hr Total,
 mg/24 hr
Pregaantriol Tetrahydros Tetrahydrocortisol Tetrahydrocortisone
Preflight data
Preflight o.79 '- 0.06 0.03 *- 0.01 1.61 3 o.11 3.68 i 0.24 6.09 ± 0.35
man t BE
Period:
1 1.01 ±	 .15 .05 .	 .01 1.86 ±	 ,16 4.43 ±	 .56 6.o4 ±	 --
2 .70 ±	 .02 .02 ±	 -- 1.48 ±	 .08 3.6o ±	 .20 7.02 ±	 .24
3 .85 ±	 .06 .02 ±	 .00
- 1.95 '-	 .o6 3.91 ±	 .14 4.68 ± 1.02
4 .73 ±	 .o4 1.27 *-	 .20 3.34 ±	 .54 4.49 *-	 •37
5 •55 *-	 -- 1.38 ±	 - 2.57 '-	 -- 5.10 ±	 .48
In-flight data
Period:
1
2
3
4
5
o.68 ±	 --
1.10 ±	 .11
.93 ±	 .07
.83 *-	 .05
1.03 '-	 .12
--
__
--
-
-
1.58 ±	 --
1.69 ±	 .04
1,.20 t	 .28
.94 ±	 .o8
1.27 ±	 .11
3.79 *-	 --
4.24 t	 .41
3.22 ±	 .53
2.73 ±	 .24
2.80 t	 .29
--
--
----
--
--
Postflight data
Period:
1 0.85 *- 0.09 o.o6 ± 0.005 1.57 a 0.18 3.28 ± 0.50 5.76 t 0.72
2 1.11 ±	 .18 .03 ±	 -- 1.39 t	 .18 3.22 +_	 .46 5.72 ±	 .82
3 1.77 t	 .75 .16 r - 2.55 *- 1.24 6.58 3 3.42 10.96 ± 5.36
1
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TABLE 1-V.- TOTAL AND FRACTIONATED 17-SYDSOXYCORTICOSTEAOIDS
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fTABLE 1-V.- TOTAL AND FRACTIONATED 17-HYDROXYCORTICOOMOIDS - Concluded
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Fraction, mg/24 hr Total,
Schedule mg/24 hr
Pregnantriol Tetrahydrom Tetrahydrocortisol Tetrahydrocortisone
Preflight data
Preflight 0.72 i 0.06 -- 1.56 t 0.23 4.31 t 0.38 6.50 ± o.64
mean i SE
Period:
1 .84 i	 .10 -- 2.05 ±	 .16 4.57 t	 .38 8.75 ± 1.47
2 .74 i	 -- -- 1.55 '-	 -- 5.05 i	 -- 6.19 ±	 •99
3 .73 *-	 .00 - 1.38 ±	 .29 4.75 i	 .41 3.96 ±	 .49
4 .58 i	 .18 - 1.01 !	 .77 3.12 i 1.23 6.08 i	 .28
5 __ __ __ -- 6.99 '- 1.61
In-flight data
Period:
1 0.79 i 0.01 - 2.20 i 0..52 5.72 i 1.01 --
2 .78 i	 .10 •- 1.44 i	 .28 3.97 *-	 .68 --
3 .67 i	 .o6 - .67 i	 .15 2.62 i	 .29 --
4 .76 i	 .o4 - 1.42 t	 .09 3.90 i	 .16 --
5 .89 i	 .05 - 1.97 i	 .82 4.13 t	 .80 --
Postflight data
Period:
1 0.77 i 0.05 - 1.26 i 0.08 3.4T i 0.23 5.49 i 0.33
2 .76 i	 .07 - 1.06 *	 .24 3.07 *-	 .57 4.89 i	 •77
3 .91 i	 •06 - 1.11 i	 .25 2.92 i	 .68 4.44 i 1.02
7
RFraction, mg/24 hr
Schedule 1uta1,
mg/24 hrPD AND • ETIO. DHEA 11-0 AND 11-0 ETIO 11-OH AND 11-OH ETIO
Preflight data
Preflight 0.63 t 0.03 1.01 t 0.09 2.20 i 0.12 0.61 t 0.08 0.30 t 0.11 0.42 i o.o4 0.19 t o.04 0.41 i 0.05 5.43 t o.44
mean t BE
Period:
1 .55 t .o6 .69 t .18 1.48 t .12 .34 i .08 -- .30 t .05 .07 t .01 .31 t .06 5.83 t .44
2 •70 t .08 .96 t .22 2.22 t .22 .62 i .21 .30 i	 .25 .49 t .lo .27 t .14 .46 t .11 6.49 1 .02
3 .68 t .07 1.15 t .22 2.30 t .25 .80 i .20 .31 ±	 .01 .43 i .08 .23 t .08 .50 t .15 7.66 t ,86
4 .51 t .11 1.22 t .13 2.62 t .24 .55 t .4 -- .47 t .o6 -- .31 t .08 8.63 t .52
5 .66 t .03 1.o6 t .24 2.65 t. .11 .58 t .04 » .40 1 .14 -- .42 ± .13 7.09 t .61
In-flight . data
Period:
1 0.70 1 0.13 1.08 t o.o6 2.25 i 0.21 1.07 ± 0.05 0.03 t 0.02 0.37 t 0.06 0.12 1 -- 0.31 t 0.07
-
2 .67 t .o6 1.64 t .13 2.39 t .19 1.27 t .17 .05 t	 -- .35 t .05 ,22 t .02 .35 t .05
-
3 .67 -* .08 2.03 t .17 2.95 '- •27 1.26 t .33 -- .53 t .05 -- .30 t .07 -
4 .75 1 .06 1.94 t .15 3.88 t .25 1.40 t .21 .15
	 --
.49 t .07 .31 ± .15 .28 t .06 -
5 .74 t .oe 1.44 t .13 2.94 t .23 1.07 t .19 -- .46 t .08 .16 +_ .04 .43 t .13 --
Postflight data
Period: -
1 o.68 ± 0.05 1.27 t 0.05 2.58 t 0.06 0.82 t 0.09 -- 0.53 t 0.06 o.14 t 0.03 0.31 t 0.05 6.26 t o.i6
2 •57 ± .15 .98 t .18 2.27 t .30 .52 t .09 -- .54 t .16 .14 t .11 .21 1 - 4.85 1 .65
3 •59 *- .04 .93 i .06 2.00 t .13 .45 t .OT -- .78 t .03 .18 t -- .29 t .04 5.11 t .13.
is
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(b) Science pilot
Fraction, mg/24 hr
Schedule Total,.
mg/24 hrPD AND ETIO DHEA
	 1	 11-0 AND 11-0 ETIO I	 11-OH AHD 11-OH ETIO I
Preflight data
Preflight 0.34 ± 0.03 1.57 t 0.08 4.86 t 0.17 0.47 t. o.o6 0.04 t 0.02 0.17 ± 0.03 0.10 ± 0.01 0.25 t 0.05 7.61 ±0.24
mean *- BE
Period:
1 .37 t .OT 1.76 t .24 4.34 1 .18 .61 t .22 .12 t .04 .13 ±	 -- .16 t .03 6.55 t -
2 .30 i .02. 1.53 t .10 5.05 t .19 .44 i .05 .11 t .02 » .17 t .03 8.62 1 .23
3
.35 ! .02 1.67 t .22 5.79 *- .42 .46 t .02 .05 t	 -- .15 ! .02 .08 ±	 .O1 .25 1 .05 8.7T 1 .23
4 .24 1 .02 1.56 t .18 4.55 *- .46 .31 ± .14 .01 t	 -- .13 t
-- --
.16 t - 9.29 t .83
5 .25 t .00 1.52 t .29 5.00 t .15 .20 t .02 -- .15 t .04 -- .14 t .03 8.63 t 1.05
In-flight data
Period:
1 0.29 *- -- 1.19 t -- 3.89 3 -- 0.89t -- _-	 - 0.31.1 -_ 0.20 t
2 ..30 t .01 2.32 t .09 4.99 i .o6 .82 *- .02 -- .40 t -- -- - »
3 .30 '_ .03 2.25 t . .15 5.09 t ,24 .T2 t .09 .13 *-	 -- .35 t .06 -- .14 t -- --
4 .33 t .03 2.46 t .36 5.34 t .4o .93 i .14 .14 t	 .o4 .28 t .02 -- »
5 .31 t .02 2.15 t ,26 5.53 t .TT .63 t .03 -- -- --
Postflight data
Period:
1 0.30 t 0.05 1.27 t o.14 4.15 t 0.35 0.24 t o.o6 » 0.40 t 0.12 0.20 t	 -- 0.34 t o.11 6.94 t o.67
2 .20 i .o4 1.68 t .21 4.42 t .54 .48 t .08 -- .29 t .01 .26 t	 .o4 .22 t .02 7.12 t .74
3 .29 t .04 2.31. t .06 4.86 t .28 .53. t .05. » .10 t -- .26 t	 -- .10t » 8.14 t .41
TABLE 1-VI.- TOTAL POW FRACTIONATED 17-KETOSTEROIDS 	 -
(a) Commander
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Fraction, mg/24 hr
Schedule
Total,
vg/24 hr
PD AND ETIO DHEA
n.* No
11W ETIO 11-OH AND 11-ON ETIO
Preflight data
Preflight 0.39t 0.02 3.05 t 0.09 4.28 t 0.18 1.4T i 0.14 0.36 t 0.23 o.64 t o.o4 0.33 t 0.03 0.59 t o.o6 10.41 t o.42
seam i BE
Period:
1 .42 t .03 2.78 t .11 3.T5t .4i 1.35 t	 .31 .14 t	 .04 .58 t .03 .28 t .06 .55 t .10 13.38 t 1.41
2 .3T t .02 3.25 t- .14 4.53± .2T 1.36 t	 .21 - .73 t .05 .35 t •o6 .41 t .o3 12.23 t .83.
3 .36 t .02 3.43 t .17 4.46 "i 36 1.74 i	 .18 .80 t -- .66 i .13 .37 '- .05 •56 t .oB 12.70 ± 1.80
4 .33 i .06 3.09 '- •25 4.58 t .60 1.58 i	 .41 -- .62 t. .05 .38 t .05 •51 i .02 14.49 i .39
5 .28 t .04 2.50 t .02 4.23 3 .74 .49 t	 .11 - .38 t .o4 .15 t - - 12.65 2 1.11
In-flight data
Period:
1 0.41 t o.o4 3.37 t o.42 4.42 i 0.38 3.51 t 0.55 - 0.75 t 0.05 0.45 t 0.04 .0.73 ± 0.15
2 .40 t .07 3.62 t .22 4.50 i .28 2.91 t	 .24 - .54 t .15 .51 i .01 -
3 .37 ±. .02 3.93 t .37 5.17 i .88 2.43 t	 .42 - .72 t .09 .37 *- - - -
4 .40 ± .02 3.66 i .11 6.41 t .21 2.12 t	 .15 - .94	 i. .20 .63 t .05 .49 t .04 -
5 .34 i .o4 3.42 t .19 6.0 t .62 1.45 t	 .08 -- .75 i .04 .6o t .lo - -
Postflight data
Period:
1 0.38 ± 0.01 2.80 t 0.21 4.52 ± o.4o 0.87 t 0.30 - o.90 t 0.o6 0.33+- 0.08 0.42 ± 0.01 10.05 i.0.97
2 .36 ± .03 3.03 i .29 4.24 1 .67 .94 i	 .10 .05 ± .82 t .lT .15 t .03 .41 t .03 10.12 3 1.24
3 .39 i .08 3.46 1 .22 4.32 t .10 1.43 t	 .16 - .88 t .14 .55 t .12 .54 1 .lo 11.26 t .57
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Variable
Semple schedule
F-28 F-21 F-11 F 1 P-1A Preflight M 11 MD 17 ND 20 m 26 E*1. R+6 R+11.- 1N16.mean t SE
Phosphoseeine	 . . . 21.32 20.17 2T.20 17.50 14.92 20.22 ± 2.OT 29-OT 25.10 19.63 24.41 38.49 3T. 43 24.14 24.46
Phosphoethanolamine . . . . 9.52 8.68 7.38 8.90 8.32 8.56 ± 0.35 11.22 11.75 8.78 .9.78 16.19 21.o6 :13.35 14.04
Taurinee .	 .	 .	 .	 .	 .	 .	 . 168.52 T9.04 224.29 167.80 248.63 177.66 ? 29.26 218.93 214.80 142.13 172.20 472.09 20T.41 161.88 195.28
Ampartic acid.
	 .. 10.31 T.77 8.13 7.81 27.46 12.30 ± 3.82 11.24 5.17 6.39 9.55 12.95 10.58 io.o5 16.94
Threcnine . .	 . . . 23.14 24.12 26.12 20.31 12.53 21.25 ! 2.37 22.96 18.6o 18.15 21.68 32.84 42.78 24.48 23.54
Serine	 .	 ...	 .	 .	 . . 54.08 51.25 52.20 43.21 47.48 49.64 ± 1.93 .53.06 49.28 41.22 47.71 63.84 66.27 51.65 50.18
Glutamine/aspanWne . 104.94 110.27 108.40 85.76 84.n 98.70 ± 5.69 117.08 103.03 87.73 103.76 169.25 143.98 120.49 122.73
Glutic acid .. .u 5.T3 3 .81 5.00 4.59 3.21 4.4T t 0.44 8.72 5.32 4.65 5.09 8.00 T.35 6.48 14.03
Glycine .	 . . • 132.91 112.45 135.37 103.38 111.13 119.05 ! 6.36 126.18 135.50 119.67 118.22 199.50 148.33 142.09 118.42
Alsnine ..	 .	 .	 .	 .	 .	 .	 . 38.52 41.84 47.01 33.10 35-T6 39.25 t 2.42 43.51 40.33 37:82 38.70 53.10 55.87 42.17 45.63
ayeinoadipic acid	 . . 12.94 8.86 14.97 13.14 12.14 12.41 t 1.00 25.15 13.13 19.84 17.81 33.93 19.21 19.69 30.64
o-amiw n-butyric acid. 2.13 2.04 1.95 1.40 1.10 1.72 i 0.20 2.54 1.36 1.04 1.73 5.25 0.83 1.15 4.86
Valine	 .	 .	 .	 . .	 . 4.23 4.32 3.09 2.OT 3.64 3.4T t 0.41 11.50 3.00 3.49 3:37 5.42 15.3T 2.42 3.79
-Half cystine	 . . . 9.86 T.46 11.91 9.54 15.11 10.T8.± 1.29 40.21 23.24 21.18 26.27 28.23 11.68 19.22 18.70
Cystathionine . . . . . . 24.89 24.46 29.08 26.16 6.25 22.17 t 4.06 24.25 9.93 19.21 12.40 33.11 32.79 38.75 22.25
Nethionine	 . . 14.OT 5.00 5.97 5.02 7.12 7.44 t 1.7o 13.41 24.71 lo-96 15.63 16.65 18.26 15.05 1o.69
Iscleucine	 . .	 .	 . .
	 .	 . 3.52 3.86 3.25 1.T6 7.1T 3.91 t 0.89 8.87 6.10 T.37 6.40 10.76 9.20 T.T4 6.45
leucine . .	 .	 .	 . . 9.19 8.68 8.50 8.19 - 8.2T 8.5T t 0.18 13.35 11.54 11.01 9.6o 16.54 19.86 10.5T 10.5T
Tyrosine	 . . .	 . . 23.8T 22.83 22.37 22.01 13.93 21.00 t 1.80 28.33 22.08 25.46 23.43 3T.89 33.61 21.92 19.63
Phenylaianine . . 	 . . . .. 11.65 10.51 7-79 7.91 5.61 8.69E 1.07 12.97 10.22 21.95 17-45 30.03 16.9T 0.53 8.42
6-alaaine .	 .	 .	 . . .	 .. 2T.59 6.39 5.59 T-02 1.61 9.64± 4.58 6.27 6.89 31.41 10.40 24.42 7.25 4.49 8.T5
6-aminolsobutyric
acid	 .	 .	 .	 .	 .	 .	 . 6.07 4.13 3.4T 2.81 3.81 4.06 t 0.55 3.05 2.66 2.90 2.91 5.6T 6.48 4.9T 6.99
Rydro3 lysine.. . . . . 5.14 LDa O-TT o.61 1.83 1.67 t 0.92 0.95 1.91 2.04 4.04 5.61 4.15 3.10 1.42
'Ornithine	 . . . 7.73 0.98 1.07 0.67 .2.01 2.49 t 1.33 1.18 2.08 1.45 1.50 1.69 2.6o 2.18 1.40
Lysine	 .	 ..	 . . 27.54 2.28 75.77 93.23 7.72 41.3± 18.34 . 37.06 23.74 42.70 - 5T.52 74.o4 41.21 29.04
1-wthylhistidine . . . 82.12 43.52 62.58 41.64 258.38 97.65 t 40.85 .167.43 194.23- 137.74 - 154.13 311.9T 191.06 446.74
Bistidine .	 .	 .	 . 113.T9 84.12 44.91 77.79 n6.41 87.40 t 13.13 110.97 128.29 106.67 - 1T8.02 175.02 142.17 69.79
3-thylhietidine . . .me 82.12 43.52 62.58 41.64 82.77 62.53 ±8.92 76.2T 107.08 95.57 - 121.22 161.92 123.63 102.78
Anterine	 .!.	 .	 .	 . 43.08 8.30 LD LD 29.59 16.19 t 8.63 LD 93.64 l.oT 0.83 11.44 80.03 53.09 37.80
Cdestinine	 . . . . 3257.96 2324.23 1153.72 2859-OT 3233.11 2565.62 t 391.33 1716.33 3330.02 1275.16 1947.52 3172.62 5958.32 3868.87 3448.10
Carnoslne LD LD I11 LD 56.95 11.39 ! 11.39 67.47 111.65 94.26 79.70 149.84 110.54 108.90 65.60
N' Arsinine 2.72 LD LD LD LD 0.54 '- 0.54 LD LD 3.24 2.15 2.40 4.64 4.73 2.70
Ul 'tD means less than detectable at sample level.
Variable
Sample schedule
F-28 F-21 F-11 F-1 F-IA Preflight to u t^ 17 X41 20 !ID 26 INl IN6. INll M16S man	 SE
Phosphoserine ... 	 .	 .	 . 22.09 12.84 16.33 21.37 17.64 18.051 1.70 17.96 33.01 15.13 14.74 16.20 15.56 19.10 -13.72
Phoaphoethanolamine.. . . 7.50 7.49 5.93 7.97 11.48 8.OT	 0.92 8.46 16.99 9.25 10.00 31.72 9.94 4.10 6.71
Taurine ..	 .	 .	 .	 .	 . 434.42 145.12 316.43 -	 73.38 462.20 246.31 t 83.37 383.90 258.41 112.81 146.52 557.89 312.09 -122.99 95.70
Aspartic ecid . . . . . . 9.11 5.04 3.65 4.54 6.26 5.72	 0.95 10.00 14.53 5.44 4.77 10.93 5.02 15.90 T.62
Threonine . 19.34 21.42 14.80 13.80 26ao 19.09 ! 2.25 24.66 40.25 16.47 15.10 13.88 25.34 17.61 11.51
Serine
	
. .	 .	 . . 33.49 4o.27 2T.01 28.51 46.59 . 35.17 t 3.68 33.46 75.44 30.29 27.72 23.61 24.61 35.06 22.79
Glucamine/esparagine 	 . 67.10 102.og 64.05 T1.88 11T.4o 84.5o t lo.66 89.28 137.68. 68.33 59.78 42.24 81.60 83.56 58.14
Glutamic. acid .	 . . 8.08 5.02 2.68 3.78 5.11 4.93 .+- 0.90 3.45 8.54 5.46 4.15 3.78 2.54 4.99 4.02
Glycine	 ..	 ..	 .	 .	 ...	 . 42.70 56.02. 41.90 41.05 61.19 48.57 -' 4 .18 44.22 97.17 41.45 39.92 2T.21 40.33 39.09 29.17
Alanine .. .	 . . 28.26 36.82 26.83 29.19 37.82 31.78 ± 2.30 29.69 60.72 29.35 24.17 21.15 29.86 28.52 19.23
o-andaoadipic acid	 . . 9.54 10.35 4.27 6.94 11.78 8.58 s 1.33 12.56 18.5o 8.54 10.34 3.26 6.86 13.78 T.39
a-amino-nbutyric
acid	 .	 .	 .	 .	 .	 .	 .	 . 2.53 1.55 1.25 1.36 2.06 1.75 ± 0.24 1.32 2.22 1.51 1.31 0.70 o.16 o.65 0.72
Valine	 . . . .	 .	 . .	 . 5.8T 5.83. 1.96 2.50 4.67 4.17 t 0.82 3.62 5.96 2.53 2.20 11.24 9.87 3.48 1.90
Hair cystine	 .	 .	 ....	 .	 . 7.74 9.63 11.12 15.20 36.52 16.04 t 5.26 13.50 56.67 26.07 27.91 7.68 6.44 1T.17 15.65
Cystathionine	 . . . . 26.68. 26.18 19.38. 24.63 11.73 21.72 i 2.81 7.71 16.93 23.01 7.96 8.64 19.49 35.02 10.99
Miethionine	 .	 . . . 6.26 7.44 5.27 5.98 8.72 6.74 ± o.61 9.41 20.78 10.36 10.22 6.99 10.17 12.87 5.71
Isoleucine	 .	 .	 .	 .	 . . 4.26 5.28 3.80 4.98 5.46 4.76 t o.31 3.T1 9.25 4.87 4.59 6.38 5.55 3.88 1.89
Leucine .. .	 .	 . 9.01 9.41 5.92 7.44 10.51 8.46 t o.8o 8.30 16.o4. 8.11 7.52 10.25 12.91 7.91 5.45
Tyrosine	 . . . . . 26.39 26.66 16.36 17.87 25.78 22.61 t 2.26 22.37 40.29 19.39 18.98 16.92 13.80 12.6T 31.63
Phenyl-1-nine . ... . . 14.13 31.25 8.11 9.6o 14.86 11.59 t 1.29 16.92 33.53 16.40 16.09 14.67 6.65 7.04 9.73
8-alanine . . .	 . . 0.85 4.56 0.58 3.98 1.05 2.20 t o.85 14.11 7.78 4.4o o.46 13.79 0.29 0.42 8.02
8-am3no1sabutyric
acid	 .	 .	 .	 .	 .	 .	 . 0.69. 5.54 3.61 9.64 5.96 5.09 t 1.47 3.98 T-78 3.37 3.33 9.84 3.53 3.48 4.68
Hydroxylysine . .. 4.91 0.71 LD LD 2.61 1.65 t 0.94 2.69 9.01 1.28 11.69 - 0.61 2.33 2.06 4.81
Ornithine.. 3.96 3.07 1.44 2.12 8.28 3.77 t 1.20 4.72. T.63 2.58 5.59 0.57 1.91 1.86 2.33
Lysine	 .. .	 . .	 . 58.41 136.ol 68.38 55.49 Lgo.94 101.85 t 26.70 184.20 191.76 105.12 89.72 29.1T 172.16 107.08 51.15
1-sethylhistidine . . . 120.62 164_36 43.09 47.77 99.34 95.04 t 22.82 57.15 105 . 93 93.65 59.53 63.21 121.19 62.70 44.97
Histidine . . 93.94 89.14 2T.23 23.84 165.24 79.88 t 25.96 131.16 200.47 70.94 65.91 37.57 83.26 81.56 65.19
3-methylhistidine . . . 66.77 53.17 37.76 35.00 155.27 69.59 t 22.17 124.05 221.41 92.27 85.55 66.00 314.62 121.15 110.40
Anserine	 .	 .	 .	 .	 . . 20.44 8.12 LD LD 18.27 9.3T t 4.35 LD 1.65. 0.40 0.16 LD 1.72 28.52 1.11
Creatinine	 .	 . .	 .	 . .	 .	 . 2710.70 2372.21 '1539.66 2550.18 3324.78 2499.51 t 288.60 1862.51 2921.71 1248.94. 2250.32' 2047.29 3729.08 3208.59 3835.30
Carnosine .	 .	 . .	 . .	 . LD LD LD. LD 91.82 18.36 t 18.36 157.87 142.16 34.50 60.59 42.09 58.31 . 40.47 11.49
Arginine	 . . . 3-T6 LD LD LD 5.84. 1.92 t 1.22 LD 10.64 3.70 1.99 2.03 2.76 2.55 3.50
[Each value represents milligrams collected per 24 hr]
u	
S^
Variable
Sample schedule
F-28 F-21 F-11 F-1 'F-1A. Preflight MID 11 m 17 MID 20 MD 26 RF1 R+6 R+11 Rt16mean ± SE
Phosphoserine . .. 8.24 10.58 23.12 1o.68 31.84 16.89 i 4.56 20.66 32.17 17.79 27.08 23.04 24.85 18.64 29.89
Phosphoetbanolamine- . . . 4.07 9.30 11.13 4.16 17.25 9.18 1 2.45 9.52 16.62 13.47 15.21 12.13 . 15.90 11.39 16.18
Taurine .	 .	 .	 .	 .	 .	 .	 . 50.2T 64.52 75.76 45.08 308.31 108.79 '- 50.17 154.55 139.96 119.61 116.28 199.53 57.53 39.98 201.76
Aspartic acid.. .. 1.83 5.00 4.93 3.24 6.96 4.39 '-0.87 5.22 5.93 10.07 4.56 10.88 4.26 7.17 8.79
Thremine . ...
	
.	 . .. 5.71 19.28 19.70 10.90 25.96 .16.31 ± 3.57 17.06 19.30 20,74 11.79 16.57 27.34. 10.73 20.45
Serine	 .	 ....	 .	 .	 .	 . 10.78 40.33 41.09 23.57 58.47 34.85 1 8.16 37.73 48.91 45.08 36.16 21.30 39.65 31.54 51.81
Clutamine/asparagine	 . 43.37 98.08 73.22 46.72 126.23 77.52 1 15.70 86.01 101.56 99.12 69.98 75.27 96.51 70.90. 96.60
Olutsadc acid	 .. 1.00 3.48 4.07 2.14 6.9T 3:53 t 1.01 2.96 6.29 6.24 5.48 2.62 3.06 5.21. 7.03
Glyc1ne. . . .	 . 28.26 93.40 95.03 71.83 167.39 91.18 1 22.54 100.33 131.43 116.45 93.44 82.51 95.55 77.87 157.63
Alain . . . . . . . . 9.13 30.68 35.70 25.66. 50.08 30.25 1 6.67 36.18 48.15 43.63 32.32 27.72 33.48 25.39 .50.58
a-aminoadlpic acid	 . .2.72 5.41 6.51 2.46 22.77 7.97 ! 3.78 11.66 15.73 12.40 12.40. 12.94 10.69 10.80 12.T1
m-aatno-n-butyric
acid.	 .	 .	 .	 ..	 . 0.65 1.59 1.42 0.30 1.19 1.03 t 0.22 1.27 2.47 2.39 2.18 0.38 0.29 LD LD
Valine	 .	 .	 .	 .	 ..	 .	 .	 .. 1.81 3.87 1.97 1.50 5.78 2.99 ' 0.81 9.48 3.96 3.25 3.10 15.24 12.48 LD 1.12
Half cystine	 . . . . 3.79 5.33 9.15 4.66 26.39 9.86 1 4.23 13.54 28.62 20.02 18.53 4.62 5.50 LD LD
4yatatbimine . . . . . 8.60 19.79 26.55 3.53 12.16 14.13 1 4.08 24.07 40.49 36.86 31.48 23.88 31.02 44.48 53.T9
Methionine	 .	 .	 . . . . 1.81 4.80 T.6T 8.47 11.21 6.79 1 1.61 12.14 22.22 12..32 15.59 12.97 15.54 13.69 18.91
Yaoleucine	 .	 ....	 . 1.31 4.06 5.T5 3.26 8.90 4.66 1 1.28 9.16 15.87. 10.34 7.50 8.24 12.10 3.94. 19.49
Leaeine .	 ..	 . .	 ..	 . 3.52 8.99 10.16 -'	 6.05 15.03 8.75 1 1.95 13.11 16.10 11.38 13.03 12.81 16.25 10.09 20.95
Tyrosine	 .	 .	 .	 .	 .	 ...	 - 11.31 19.93. 17.52 10.91 26.37 17.21 1 2.88 16.68 21.20 19.34 16.00 15.24 1T.99 13.05 21.10
PhoWlalanine . .. . ... 5.35 7.72 7.T7 4.35 ,10.95 7.23 1 1.14 7.66 11.71 11.08 9.02' 7-.38 8.71 6.98. 9.43
0-alanine . . . . 2.57 0.93 0.60 0.71 3.81 1.72 i 0.63 5.92 0.28 5.53 o.64 o.84 LD LD 0.91
g-anlnoisobutyric.
acid	 ...	 .	 . 7.44 31.00 16.15 8.01 22.87 17.09 1 4.49 13.96 14.47 15.01 15.47 9.44 21.11 12.31 17.20
Wrote-,sine . . . . . . 0.11 LD LD LD 0.08 0.04 1 0.02 LD LD 2.17 1.92 1.11 1.31 0.35 OAT
Oenithine .	 . . . . 0.39 LD 0.07 LD 2.97 0.69 1 0.58 0.32 LD 0.70 0.83 0.56 1.o6 0.78 0.87
L"im	 . . _ .	 ... 14.39 132.72 , 70.00 103.56 49.00 73.93 ! 20.64 19.60 152.84 4.29 72.12 33.26 45.40 30.37 30.89
1-wthylhistidine . 46.12 47.62 62.67 99.56 145.02 80.20 1 18.85 49.39 143.91 178.47 198.43 101.56 138.94 63.65 1o6.61
Histidlne	 .	 . .	 . 22.87 47.10 34.33 60.96 213.5T 75.77 ± 35.03 93.00 76.20 114.39 86.52 83.57 125.44 78.o4 108.75
3-mthylblstidine . . . . 17.02 24.98 32.8T T3.14 159.19 61.441 26.28 82.58 . 209.33 126.71 1o4.89 78.6o 146.o7 107.25 136.91
Anserine	 .	 ... .	 .	 . .	 . LD LD LD LD 29.98 6.00 t 6.00 LD LD LD 31.25 0.65 LD 32.04 64.32
Crmtindhe	 . . . 508.36 1185.13 923.79 226.53 3120.8o 1192.92 1 509.50 1544.27 2949.49 2174.17 1927.09 2884.94 3356.30 2569.64 2402.51
arsosine . . . . . . . . LD LD LD LD 31.96 6.39 1 6.39 6o.io 159.72 61.42 76.57 48.65 39.07 6.56 81.66
Arginine	 _ .	 . .	 .	 . LD LD LD 6.70. LD 1.34 1.1.34 LD LD LD LD LD LD LD LD
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TABLE 1-X.- BODY FLUID VOLUMES
(a) Total body water rs
F X^1
i
T A"-^
Volume/kg
Schedule Volume,liters body weight,
ml/kg
Commander
Preflight mean ± SD 41.6 ± 0.4 670 ± 2
Recovery day 40.8 677
13 days postflight 41.2 678
Science pilot
Preflight mean ± SD 48.8 ± 0.6 626 ± 13
Recovery day 48.0 649
13 days postflight 49.1 655
Pilot
Preflight mean ± SD 52.2 ± 0.2 643 ± 4
Recovery day 50.0 658
13 days postflight 50.0 647
1
,,A
i
n
Volume/kg
Schedule Volume,liters body weight,
ml/kg
Commander
Preflight 16.1 257
Recovery day 15.8 262
13 days postflight 16.0 263
Science pilot
Preflight 15.5 197
Recovery day 15.2 204
13 days postflight 15.3 204
Pilot
Preflight 15.5 190
Recovery day 15.7 206
13 days postflight 15.7 203
TABLE 1-X.- BODY FLUID VOLUMES - Concluded
(b) Extracellular fluid
p
TABLE 1-XI,- TOTAL BODY EXCHANGEABLE POTASSIUM (meq K)
Schedule
Flight crewmen
CDR SPT PLT
Preflight mean ± SD 3266 ± 50 3971 ± 58 3846 + 52
Recovery day 2998 3678 3528
13 days postflight 3186 3704 3777
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four-hour urine volume analyses.	 Numbers within bars are
standard error of the mean.
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Figure 1-2.- Urinary ADH analyses (milliunits per total volume (mU/TV)).	 Num-
bers within bars are standard error of the mean.
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Figure 1-6.- Plasma creatinine analyses. Brackets represent mean ± standard error.
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I	 Figure 1-7.— Urinary cortisol analyses. Numbers within bars are
standard error of the mean.
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Figure 1-8, Urinary epinephrine analyses.
	 Numbers within bars are standard
error of the mean.
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2. MODULATING THE PITUITARY-ADRENAL RESPONSE TO STRESS
By Joan Vernikos-Danellis, Ph. D.
INTRODUCTION	 rr j
It is now generally accepted that the hypothalamic pituitary-adrenal re-
sponse to stress is controlled by at least three mechanisms: corticosteroid
negative feed back, central facilitatory, and central inhibitory, each of which
	 -- -
can be demonstrated in the absence of steroids. All three mechanisms presum-
ably exert their control by way of hypothalamic-hypophyseal neurohumoral path-
ways and are mediated by the adrenocorticotropic hormone (ACTH) releasing fact-
	 j
for (CRF). Thus, it might be expected that the preexisting state of the in-
dividual, or "baseline," determines to a great extent the magnitude and the
temporal characteristics of the response to a provocative stimulus or stress.
This is true, for instance, of the hyperresponsiveness to reentry that has been
observed in crewmembers following each space mission (ref. 2-1). It is true
of animals following chronic exposure to cold (ref. 2-2), confinement (ref.
2-3), or water deprivation -(ref. 2-4). It is also true of humans after 14
days of bed rest and
	 possibly after relative confinement.' Therefore, a
search has been made for a means-of modulating the magnitude of this response
to stress, a search based primarily on knowledge of the mechanisms regulating
pituitary-adrenal activity.
Serotonin is believed to be a transmitter or regulator of neuronal func-
tion, - and several reports have indicated a possible relationship between the
pituitary-adrenal secretion of steroids and brain serotonin in the rat (refs.
2-5 and 2-6). This relationship was investigated further by evaluating the
	
3
effects of altering brain 5-hydroxytryptamine (HT) levels on the daily fluc-
tuation oflasma corticosterone and on the response of the
	
jP p pitui ary-adrenal
system to a stressful or noxious stimulus in the rat. The approach was either
to inhibit brain 5-HT synthesis with para-chlorophenylalanine (PCPA) or to
raise its level with precursors such as tryptophan or 5-hydroxytryptophan (5-3
HTP)
i
METHODS AND RESULTS
Male Sprague-Da^,rley rats (150 to 200 grams) were kept in an enviror..ment of
12 hours of light and 12 hours of aark (lights on at 0700) and given food and
1'J. Vernikos-Danellis and M. E. Dallman, unpublished observations, 191'1+.
2-1
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y
and water ad libitum.
	
The animals were injected intraperitoneally (I.P.) with
pyrogen-free saline or PCPA in saline at a dose of 300 mg/kg/day.
Daily injections of PCPA for 2 or 4 days raised the morning low and pre-
vented the evening rise in plasma corticosterone levels. 	 This difference in w
levels was observed only in those animals killed within 24 hours after the
last injection (fig. 2-1).	 Figure 2-2 shows that pretreatment with PCPA en-
hanced and sustained the response to the stress of ether for 1 minute or of
electrical shock for 4.5 minutes. 	 Pretreatment with PCPA also resulted in a
50-percent increase in anterior pituitary ACTH concentration (9.34 ± 1.89 ml/ +
mg of pituitary tissue in PCPA-treated animals). 	 Thus, inhibition of brain 5-
HT synthesis enhanced the stress response in addition to altering the diurnal
pattern of the pituitary-adrenal system.
The alternate approach in studying the role of brain 5-HT in the regula-
tion of pituitary-adrenal function was to attempt to increase brain 5-HT by
the use of precursors.
	 L-tryptophan (408 mg/kg), 'or 5-HTP alone (212 mg/kg),
or 5-HTP (50 mg/kg) with the peripheral dicarboxylase inhibitor, L-a-hydra-
zinomethyldihydroxyphenylalanine (MK 486, 20 mg/kg), were injected I.P. into
groups of rats.
	
The animals were then studied 2 hours later, when brain 5-HT
had been reported to be at maximal levels after injection of precursors in a
similar study (ref. 2-7) and when plasma corticosterone levels had usually re-
turned to normal in control animals after the stress of an injection. 	 The an-
imals were decapitated and bled 2.5 or 15 minutes after the stress of ether.
Figure 2-3 shows that, in ad.rer}alectomized rats, tryptophan completely abol-
ished the stress-induced secretion of ACTH. 	 The stress response was reduced
significantly (P < 0.05) by 5-HTP alone or in combination with MK 486. 	 Hence,
these precursors of 5-HT tended to decrease or inhibit the pituitary-adrenal
response to stress.	 This inhibition was more evident in the absence of the
adrenals.
Preliminary reports on human studies also appear to support this 5-HT/
pituitary-adrenal relationship. The urinary 17-hydroxycorticosteroid (OHCS)
response to oral ingestion of MK 486 and 5-HTP was determined in four normal
male human volunteers. Figure 2-4 shows the results of this test in one of the
four subjects where 24-hour urinary 17-OHCS excretion was measured daily for
12 days. After 2 days of control collections, the subjects were given placebo
capsules containing lactose for 2 days. This was followed by 2 days of MK 486
(50 milligrams, four times a day) with placebo (for 5-HTP), to control for pos-
sible MK 486 effects on the steroid excretion; an additional 4 days of MK 486
(50 milligrams, four times a day) with increasing doses of 5-HTP (100, 200,
300, and 400 mg/day, respectively); and finally 2 days of placebo only,. me 486
raised 17-OHCS excretion and the combination of MK 486 and 5-HTP produced nau-
sea and vomiting. However, when treatment was discontinued, a prompt drop in
17-OHCS excretion, and a return to baseline levels resulted. Although it is
evident that the MK 486/5-HTP combination is not acceptable for human use, at
least in the dosage used, the results provide encouraging evidence that 5-HT
precursors could be used to suppress pituitary-adrenal secretion in humans.
It is now reasonably accepted that the pituitary-adrenal system functions
as a closed-loop system. In this system, the positive vector, or "driving
2
-2
th
r.
force," corresponds to environmental stimuli activated by way of hypothalamic
neurohumoral pathways (ref. 2-8), and the negative vector corresponds to the
level of corticosteroids, which act'by feedback inhibition on the pituitary-
adrenal system (ref. 2-9). The author's findings of enhancement of the stress	 9
response by inhibition of serotonin synthesis and indications of a reduction of 	 a
the stress response by serotonin precursors suggested that serotonin may medi-
ate or modulate the negative feedback mechanism regulating pituitary-adrenal
function (fig. 2-5). If this hypothesis were correct, then the inhibitory ac-
tion of corticosteroids on pituitary ACTH secretion would be expected to be
less effective in animals whose brain serotonin had been depleted. Figure 2-6
►
 «<
`	 illustrates the results of an experiment to test this possibility and compares
the corticosterone stress-response-inhibiting properties oftwo doses of pred-
nisolone in control rats and in animals whose brain serotonin content was
markedly reduced by pretreatment with PCPA. Both doses of the steroid effec-
tively inhibited the response to the stress of ether and laparotomy in the con-
trol animals. In 5-HT-depleted animals, neither dose was capable of blocking
the stress response, further indicating that serotonin is indeed involved in
the negative feedback to the pituitary-adrenal system.
a
{	 CONCLUDING REMARKS
a
These results have led to the suggestion that in some disease states such
as Cushing's disease, in which there is a similar inability of corticosteroids
to suppress the pituitary-adrenal system, there is a defect in serotonergic 	 ^.
neuronal processes that impairs pituitary-adrenal feedback mechanisms. A sim-
ilar but reversible serotonergic defect may be involved in the hyperresponsive-
ness to provocative stimuli during various chronic exposures wherein pretreat-
ment with serotonin precursors or appropriate dietary manipulation may be ef-
fective in modulating the stress response.
i
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INTRODUCTION
'j
	
	
Every physiological system and every psychological function in the human
body fluctuates temporally with a circadian period. No phase of medicine
from laboratory testing of new drugs and procedures, to clinical and public
health programs, to the study of humans in the space environment or in indus-
trial work-shift operations -- is likely to remain untouched by the recent
s findings in the study of biologic rhythms. The object of this presentation is
to provide evidence that the most important factor in the maintenance of opti-
mal health and performance is the stability of the relationship of one body
rhythm to another.
This evidence was obtained during a collaborative study conducted by inves-
tigators at the University of California at Davis and by those at the NASA
Lyndon B. Johnson Space Center. The object of the study was to evaluate the
effect of social interaction on performance, well-being, and physiological
rhythm synchrony.
MATERIALS AND METHODS
Three groups of healthy males, ages 21 to 25, were confined in rooms (3.4
by 5.2 meters (11 by 17 feet)) for a total period of 105 days. Two of the
groups were in rooms in which the environment could be regulated. The third
group served as the control group and was exposed to ambient experimental con-
ditions. The confined subjects were exposed for periods of several days either
to 16 hours of light (L) and 8 hours of dark (D), also referred to as L:D, or
to continuous light (24L:OD), also.referred to as L:L, at a light intensity of
161 ]m/m2 (15 foot-candles). The confined subjects were deprived of all time
cues, and meals were ad libitum. The subjects were observed throughout the
study by a video camera and were scored for activity. Communications were lim-
ited to meal and sample-collection information, and meals and samples were
passed through a two-way hatch. Rectal temperature and heart rate (HR) were
sampled every 30 minutes by telemetry throughout the study.
The design of the experiment is shown_ in figure 3-1. The subjects in the
north and south rooms were exposed to identical environmental conditions for
the first 63 days of the experiment.
F
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Figure 3-2 shows the summation dials of body temperature (BT) of the three
subjects that served as controls in the east room. 	 The occurrence of the peak
in BT was remarkably stable, as indicated by the direction of the vector that
points to 2000 hours.
	
The same stability was true for the HR rhythms of the
subjects, as shown in figure 3-3.
In contrast, the group in the south room (fig. 3-4) showed a phase shift
[	 and an increase in period length of about 12 minutes every 24 hours during
their 21-day exposure to constant light at 161 lm/m 2 (15 foot-candles).	 After ..^
a return to the 16L:8D cycle, the HR rhythm promptly recovered.
A similar desynchronization of the HR rhythm, with the environment in theY	 Y	 ^ ^
constant-light, 161-]m/m2 (15 foot-candles) condition, was observed for the sub-
jects in the north room, although their period length increased by 60 minutes g
'	 every 24 hours (fig. 3-5).	 Thus, by the end of 21 days, this group had "lost"
an entire day.
	 Despite the identical conditions for the two rooms, the rate of
desynchronization with the environment was strikingly different although the
subjects within each group were remarkably synchronized.
	
This difference sug-
gests that social synchronizers may play a very important role in the regula-
tion of human biologic rhythms.
	 During this free-running section of the exper-
iment, the investigators noted that internal synchrony was maintained.
	 That is,
although the individual was out of synchrony with sidereal time and the rhythms
were free running, the relationship of one physiological rhythm to another re-
mained stable.	 However, when the subjects were again exposed to the 16L:8D
regime, the rate of recovery of each body rhythm differed from that of the
others, resulting in marked internal desynchronization.
	 For example, underit
	 conditions during the control period, cortisol leads HR by 8 to 10
hours and HR leads BT by 2 to 4 hours. 	 During constant light, when the rhythmsk	
were free running, these lead times were maintained.
	 However, during the recov-
ery in 16L:8D, the BT peak returned to its original 2000 hours occurrence with-
in 8 days, whereas it took the HR 4 days to fully recover and the plasma corti-
sol peak 30 days to recover.
	 Thus, considerable internal desynchronization
existed in these subjects for at least this 30-day recovery period.
The intricate relationship of several physiological rhythms under "normal"
conditions is shown in figure 3-6. A delicate balance is somehow maintained so
that the peak activity of each rhythm occurs at the appropriate time for its
specific regulatory function in the body.
Figure 3-7 depicts the relationship of thesynchrony of BT and HR to per-
formance when either the synchrony with the environment (free running) or the
C	 internal synchrony is disturbed by an alteration of the light cycle. Perform-
_
i
r
ante did not appreciably change wh
 en the rhythms were free running. However,
a severe increase in the number of errors made by the subjects on their per-
formance tasks was noted when the subjects were returned to the controlled
environment (16L:8D) and when maximum internal desynchronization was present.
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Evidence from studies involving experimental animals indirectly suggests
that the period of internal desynchronization may be characterized not only by
a decrease in performance, but also by a decrease in the ability to cope behav-
iorally.in response to stressful conditions and by an increase in sensitivity
to infection and in the reaction to the toxicity of various drugs.
Several additional means of producing internal rhythm desynchronization
have been suggested over the years. These include bed rest of more than 20
days (refs. 3-1 and 3-2), weightlessness (ref. 3-3), the jet lag of east-west
or west-east travel (refs. ' 3-4 and 3-5), and work-shift cycles such as those
found in industry or hospitals (refs. 3 -6 and 3-7). Such internal desynchro-
nization could be produced by therapeutic procedures, surgery, infection, or
other forms of stress, although this hypothesis has not been proved. The impli-
cations of the disruption of this internal temporal organization to human men-
tal and physical health and the impact of such disruption on performance are
self-evident. Through studies of biological rhythms, many aspects of human
variability in symptoms of illness, in response to medical treatment, in learn-
ing, and in job performance are being quantitated so that peaks in strength and
productivity can be anticipated and predicted.
As a result, timing will become an important factor in preventive health
programs and medicine. For example, since the effects of drugs depend in part
upon the time of administration, timing may be used as a critical aspect of
treatment. Evidence now also suggests that the results of X-ray treatment,
surgery, and even psychotherapy are influenced by timing. Research of biolog-
ical rhythms will probably have an impact on problems of work performance,
including accidents and absenteeism; in the future, anew concept of scheduling
as a function of health may influence the determination of work shifts for ,
transportation and communications personnel and members of various professions.
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4. THE IMPORTANCE OF THE RENIN-ANGIOTENSIN SYSTEM IN NORMAL
CARDIOVASCULAR HOMEOSTASIS
By Edgar Haber, M.D.*
INTRODUCTION
The role of the renin-angiotensin system.. the maintenance of normal
blood pressure has been a subject of considerable dispute and conflicting ex-
perimental data. In the normal, conscious animal on a normal salt intake, an
giotensin II is not required for the maintenance of blood pressure. This con-
.	 cept has recently been supported through studies using two specific peptide
inhibitors working at different points on the pathway from renin release to
vasoconstriction. Several derivatives of angiotensin II are now available that
compete directly with this hormone at its effector site in vascular smooth mus-
cle (refs. 4-1 and 4-2). Several investigators have now shown that these com-
pounds, which effectively block the vasoconstrictor action of angiotensin II,
have no effect on blood pressure (ref. 4-3, 4-4, and 4-5).
A second series of peptide inhibitors competes effectively with angio-
tensin I for converting enzyme. The most potent of these peptides, which has
the sequency Pyr-Trp-Pro-Arg-Pro-Gly-Ile-Pro-Pro, is well tolerated in large
doses by normal animals. At doses of 0.25 mg/kg, the pressor response to
angiotensin I is completely inhibited, whereas that to angiotensin II is un-
affected (ref. 4-6). This compound has now been examined in the investigators'
laboratory under a variety of physiologic circumstances to define the contribu-
tory role of angiotensin II to blood pressure maintenance.
METHODS
Studies were carried out o^^ adult mongrel dogs (20 to 30 kilograms) which
were housed in air-conditioned rooms. Each dog was fed a fixed diet that had
bc,.n adjusted during the training period to maintain constant weight. Salt in-
take varied with the experimental circumstance, and water intake was carefully
measured but permitted ad libitum. Before any study, each dog was trained to
*This report is based on collaborative investigations performed in the
Departments of Medicine and Physiology of the Harvard Medical School by A. I.
Samuels, E. D. Miller, C. S. Fray, E. Haber, and A. C. Barger.
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lie motionless on its side on a padded table in a quiet air-conditioned labo-
ratory.	 Only the investigators were permitted to enter the laboratory during
the training and study sessions.
Blood pressure was measured:by catheterization of the abdominal aorta with
a polyvinyl chloride tubing by the method of Herd and Barger (ref. 4-7). 	 The l
proximal end of each catheter was exteriorized through a hollow needle and tied
1	 in a plastic loop implanted in the skin.	 The catheters were protected by a
cotton ,jacket. 	 Systemic blood pressure was monitored through the output of a
P23Db Statham pressure transdio er and recorded on a Grass polygraph. 	 Heart
rate was determined from the blood pressure record or from the electrocardio-
gram.
	
Blood pressure and heart rate were remarkably steady in these well-
-	 trained animals. 	 Mean blood pressure in the control studies rarely fluctuated
more than ±3 or 4 mmHg, although blood pressure did rise or fall beyond this
limit momentarily when the animal occasionally yawned or stretched. 	 Heart rate
was also constant within ±2 to 3 beats per minute.
Renin activity was determined in duplicate by radioimmunossay (ref. 4-8).
The values were expressed as nanograms per milliliter per hour of angiotensin I
generated.
RESULTS
The intravenous administration of 5 milligrams of the converting enzyme
inhibitor blocks the usual pressor response induced by the intravenous injec-
tion of 1 microgram of angiotensin I. 	 The pressor response of angiotensin II
was unchanged. In normal dogs on normal salt intake, the injection of 5 milli-
grams of converting enzyme inhibitor did not alter arterial pressure or system-
?	 is plasma renin activity.	 However, in dogs on a low salt diet with slight sys-
temic hypotension and significant elevation of plasma renin activity, blood
pressure fell approximately 10 mmHg when converting enzyme inhibitor was given
(fig. 4-1), and the plasma renin activity increased severalfold.
	 In adrenalec-
tomized dogs adequately treated with cortisone acetate (25 mg/day), but main-
tained in a hypovolemic state on a low dosage of deoxycorticosterone acetate
and with sodium .restriction (10 3 ;q/day), blood pressure fell strikingly with- µ
in 3 minutes of the injection of converting enzyme inhibitor (fig. 4-2).	 Plas-
ma. renin activity rose more than fivefold basal levels.
	
When a constant infu-
sioTh
 of angiotensin II was given to maintain blood pressure after converting
enzyme inhibitor administration., plasma renin activity did not rise (fig. 4-3).
However, when blood pressure was maintained at the same levels with an alpha-
adrenergic agent, phenylephrine, which by itself has no effect onrenin activ-
ity,-a considerable but somewhat lesser increase in renin activity following
converting enzyme inhibitor administration was noted (fig. 4-4).
k
L
k.	
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JDISCUSSION
Earlier experiments indicating that the renin-angiotensin system has a
small role in the maintenance of normal blood pressure have been confirmed by
the observation that no hemodynamic effect in response to converting enzyme in
hibitor is observed in the normal salt-replete animal. Conversely, when severe
sodium depletion has occurred, striking hypotension is a consequence of con-
verting enzyme inhibitor administration. Under these circumstances, it seems
that angiotensin II is essential for the maintenance of blood pressure and that
other compensatory mechanisms are insufficient. There is no evidence of sympa-
thetic blockade in these animals, and, indeed, tachycardia occurs in associa-
tion with hypotension. However, sufficient vasoconstriction cannot be effected
in order to maintain blood pressure. A second observation of considerable in-
terest concerns feedback control of renin secretion. Renal arterial pressure
is known to be a major determinant of renin secretion (ref. 4-9). It is not
surprising then that a marked increase in renin activity occurs in response to
hypotension induced by converting enzyme inhibitor (fig. 4-2). However, the
maintenance of normal blood pressure after converting enzyme inhibitor admin-
istration by phenyi ephrine results in far higher renin activities than when
blood pressure is maintained at the same level by angiotensin II (fig. 4-3 and
4-4). This result suggests a direct feedback on renin secretion by angiotensin
II that is independent of renal arterial pressure. When converting enzyme is
inhibited and angiotensin II is absent, renin activity is much higher than un-
der similar circumstances in which angiotensin II levels are maintained by ex-
ogenous infusion.
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SUMMARY
1. The renin-angiotensin system plays a major role in the maintenance of
circulatory homeostasis when extracellular fluid volume is depleted.
2. Angiotensin II concentration, in addition to renal perfusion pressure,
is an important factor in the regulation of renin release.
3
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5. STRESS-INDUCED CHANGES IN CORTICOSTEROID METABOLISM:
r
1 7 I
A PROGRESS REPORT.
By Martha M. Tacker, Ph. D.*
At the 1972 Endocrine Conference, the author presented a proposal to an-
alyze in detail the effects of stress on corticosteroid metabolism (ref. 5-1).
This proposal was prompted by the recurring difficulty in correlating and ex-
plaining corticosteroid concentrations measured in various NASA-supported
studies. Because plasma and urine corticosteroid concentrations are influ-
enced by several factors in addition to adrenal cortex secretion (fig. 5-1),
the effect of stress on all of these factors must be determined before a mean-
ingful interpretation of plasma and urine concentrations can be made. Further-
more, such evaluation must precede determination of the most appropriate and
optimal index of the adrenocortical response to stress.
Funds to support this study were received in the summer of 1972 and the
effort to date has been directed toward developing the methodology necessary
for these studies. Following the suggestion of last year's conference mem-
bers, methods for the determination of the plasma concentrations of free and
transcortin-bound cortisol were established (ref. 5-2). Plasma is equili-
brated with a tracer amount of 3H-cortisol at 310 K (37° C) and an aliquot
(1 or 2 milliliters) is placed inside a length (approximately 25 centimeters)
of dialysis tubing that has been soaked in distilled water for 24 hours. The
tubing is draped inside a glass centrifuge tube and the two ends are secured
over the top of the centrifuge tube with a rubber band; the glass tube is then
set in a covered water bath 310 K (37° C) for 5 minutes to saturate the air
with water vapor and is then sealed with Parafilm. Centrifugation for 45 min-
utes produces an ultrafiltrate of plasma, the volume of which is approximately
10 percent of the original plasma volume. The volume of ultrafiltrate does
not unacceptably alter the free-to-bound cortisol equilibrium (ref. 5-3)•
A comparison of the concentration of radioactivity in the ultrafiltrate
with that, in the original plasma reveals the relative amount of unbound cort-
isol in the plasma at normal body temperature 310 K (37° C). Multiplication
of the amount of total (free plus bound) plasma cortisol (jig/100 ml) by
this percentage gives the concentrations of cortisol in both the free and
bound fractions of the plasma. The addition of increasing amounts of cortisol
to the plasma increases the amounts of free cortisol after a, concentration of
20 ug/100 ml is reached (fig. 5-2).
'The technical assistance of Douglas Robbins is gratefully acknowledged.
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The other area of methodology being set up is the measurement of individ-
ual corticosteroids. Methods commonly used to measure corticosteroids have
varying degrees of specificity, and all require a preliminary chromatographic
separation to measure each corticosteroid specifically. The scheme considered
optimal (fig. 5-3) consists of separation of plasma corticosteroids with
Sephadex LH-20 column chromatography (ref. 5-4), followed by radioimmunoassay
of the individual steroids (cortisol, corticosterone, cortisone, ll-deoxycort-
isol, and ll-deoxycorticosterone) (ref. 5-5)•
The addition of tracer amounts of each steroid to the plasma sample per-
mits correction for methodological losses. A methylene chloride or ethanol
'	 extract of the plasma is passed through a 20-centimeter column of Sephadex
LH-20 using methylene chloride/methanol (99/1) as the eluting solvent. Sep-
aration of the five steroids of interest (fig. 5-4) is very reproducible; re-
coveries of cortisol and corticosterone are about 75 percent, and blank con-
tribution to the radioimmuncas says is negligible.
The potential problem of the poor separation of corticosterone and
ll-deoxycortisol can be approached in two ways. First, a longer column would
separate the two steroids, but would also require custom glasswork. More im-
portantly, a longer column would increase the volume of solvent necessary to
elute the steroids, especially cortisol. The second approach, which is cur-
rently being used with success, is the analysis of aliquots of the appropriate
fraction with specific antibodies. Recovery can be determined by using trit-
ium for one steroid and carbon-14 for the other and by using dual counting
technics.
Radioimmunoassay methods have been chosen for analysis of the amounts of
each steroid. Standard curves for the radioimmunoassay of cortisol are quite
reproducible (fig. 5-5), and the recovery of increasing amounts of cortisol
added to plasma and assayed directly (without the chromatographic separation)
is reproducible and virtually complete (fig. 5-6).
The antibody against cortisol also binds corticosterone almost as well
as it does cortisol. Because these two corticosteroids are separated by the
column chromatography, the cortisol antibody can then be used to measure cort-
icosterone using 3H-corticosterone in place of 3H-cortisol. This antibody
shows slightly less binding of ll-deoxycortisol (which is poorly separated
from corticosterone); and, because the same solutions and procedures can be
used to measure cortisol and corticosterone, the cortisol antibody is more
convenient to use than the antibody directed against corticosterone itself.
Recovery of standard corticosterone passed through the column and measured by
radioimmunoassay in two studies was quite good, yielding averages of 0.42 nan-
ogram and 0.46 nanogram compared to an expected average of 0.40 nanogram.
Deoxycortisol can be assayed with a specific antibody that does not
cross-react with corticosterone. Antibodies are available to assay cortisone
and deoxycorticosterone, but have not been received.
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A preliminary exercise study was made in which blood was drawn from a
subject before, during, and after an exercise test. This test consisted of
four consecutive 4-minute periods of increasing workload on an exercise bicycle.
Plasma corticosteroids measured with the corticosteroid binding globulin assay
showed a decrease during exercise from relatively high preexercise levels fol-
lowed by a transient increase immediately post exercise (fig. 5-'7).
r
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6. RECENT STUDIES OF PHYSIOLOGICAL FACTORS INVOLVED IN THE REGULATION
OF SEROTONIN CONTENT AND TURNOVER IN THE BRAIN
By William W. Morgan, Ph. D.
DISCUu'ION AND RESULTS
In recent years, considerable effort has been expended in an attempt to
elucidate the physiological role(s) of serotonin ( 5-HT) in the brain. No clear
functional role for the brain serotonergic system has yet been conclusively
demonstrated. However, a considerable amount of evidence has been accumulated
to indicate roles for brain 5-HT in a number of physiological processes. For
example, 5-HT pathways in the hypothalamus may be involved in temperature reg-
ulation, particularly in the production of increased body heat in response to
cold exposure (ref. 6-1). Serotonergic pathways may also play a regulatory
role in _reuroendocrine secretion. Intraventricularly administered 5-HT has
been shown to decrease the blood level of luteinizing hormone (refs. 6-2 and
6-3). Serotonin containing neurons may also be involved in the regulation of
adrenocorticotropic hormone (ACTH) release (ref. 6-4). The brain serotonergic
system is known to be activated by stress (ref. 6-5); thus brain serotonergic
pathways may play an important role in the adaptation to stress, probably in
part by affecting the release of ACTH. Available evidence suggests that 5-HT
containing neurons may function to decrease neural excitability. An inverse
correlation between brain 5-HT content and the susceptibility to audiogenically
induced seizures has been demonstrated (ref. 6-6). Also, low 5-HT in the brain
has been correlated with an increased seizure susceptibility (ref. 6-7). One
of the more documented roles of brain 5-HT is in the regulation of slow-wave
sleep (refs. 6-8 and 6-9). Changes in brain 5-HT levels have also been corre-
lated with some types of behavior. A decrease in brain 5-HT induced either by
chemicals or by lesions results in an increase in response to electrical shock
(ref. 6-10) and to an increase in approach behavior (ref. 6-11). An increase
in the activity of brain serotonergic pathways is believed to result in a de-
crease in "fearfulness" and anxiety (ref. 6-12).
Because of the evidence linking brain serotonergic system to sleep regu
lation, to emotional behavior, and to the adaptation to stress (partially
through actions of neuroendocrine regulation), it is likely that this putative
neurotransmitter system will be markedly altered in humans during prolonged
space flight and will play important roles in the adaptation of humans to
stress associated with spaceflight. It is thus important to gain an under-
standing of the physiological mechanisms that regulate the activity of the
brain serotonergic system and to further investigate the role of brain sero-
.tonergic pathways in the stress response and in reuroendocrine regulation.
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Daily changes in 5-HT content have been demonstrated in the brains of
many different organisms, and a considerable amount of evidence suggests that
the circadian change in 5-HT content may be a reflection of a daily change in
the activity of the serotonergic system. 	 Indeed, there is some evidence in B
humans that the changes in the incidence of some types of epileptic seizures a
C	
(ref. 6-13) and the severity of cases of mental depression (ref. 6-14) may be
correlated with daily fluctuations in the activity of the brain serotonergic
Al
	
system.	 It is conceivable that changes in serotonergic nerve activity or in
the levels of 5-HT in the brain may affect the ability of an organism to re-
spond to stress. 	 However, considerable disagreement has arisen in the last
few years concerning the time of day when the serotonergic system is most ac-
I	 tive.	 One of the research goals of the Department of Anatomy Laboratory at
4	 the University of Texas at San Antonio has been to study this question. 	 The
importance of plasma tryptophan in regulating the activity of the serotonergic
system has also been studied.
The presence of diurnal rhythmic changes in 5-HT in the brains of rodents
has been well documented (refs. 6-15 to 6-27).	 In most of these studies, the
highest level of 5-HT over a 24-hour period occurred during the light phase of
a regulated lighting regime with 12 to 14 hours of light. 	 Friedman and Walker
(ref. 6-17) observed that 5-HT levels in the midbrain and caudate nucleus of
the rat were elevated during the light phase when the rats were relatively in-
active or asleep.
	 They hypothesized that the elevation of 5-HT was function-
ally related to the cyclic inactive or sleep state observed in rodents. 	 In
support of this hypothesis,.a considerable volume of evidence from other stud-
ies, particularly those of Jouvet (refs. 6-8 and 6-9), also suggests a func-
tional role for 5-HT in sleep regulation. 	 Asano (ref. 6-24) reported that the y
development of the adult pattern for tbB daily rhythms in brain 5-HT correlated
closely in time with the development of the sleep-and-wakefulness pattern.
Schreiber and Schlesinger (refs. 6-26 and 6-28) positively correlated the daily
(	 elevation of 5-HT content in areas of the mouse brain with a daily decrease in
the seizure susceptibility of mice prone to audiogenic seizures.
	 In their
studies, Schreiber and Schlesinger found that 5-HT content was high during the
light phase when the mice showed a decrease in seizure susceptibility. 	 The
assumption made by most of the previously mentioned investigators is that an
I	 increase in 5-HT content reflects an increase in the activity of the seroto-
nergic system.
	 However, as Neff and Tozer (ref. 6-29) have pointed out, the
1	 content of tentative transmitter substances such as 5-HT may provide a rather
.	 poor indicator of the activity of the neurons in which the transmitters are
located.	 More information is needed to relate the brain serotonergic system
not only to the phases of a regulated lighting cycle but also to other cyclic
phenomena, such as motor activity and seizure susceptibility.
Another way	 f examining the activity of serotonergic neurons is to meas-Y	 g
ure the brain,content of the primary metabolite of 5-HT, 5-hydroxyindoleacetic
acid ( 5-HIAA) (ref. 6-29).	 Changes in the brain content of 5-HIAA have been
correlated with changes in the turnover of brain 5-HT (refs. 6-5 and 6-30).
Thus, experiments were undertaken to determine if the content of brain 5-HIAA
changed in a predictable fashion at different times of the day. 	 If the _levels
of 5-HIAA in the brain were found to change with the time of day, the next
step would be to determine the pattern of these changes in relation to the
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lighting regime, and further to determine how this pattern of changes in
5-HIAA content compared to similar diurnal changes in 5-HT content.
In three separate studies,.36 adult male mice were housed in groups of 6
in an animal room maintained at a nearly constant temperature (295 K (22° C)).
Balb/C mice were studied in the first experiment and AJAX mice were studied in
the second and third experiments.	 The mice were exposed for at least 3 weeks
to a daily cycle of 12 hours of light and 12 hours of dark (12:12 LA), with
t the lights on from 0900 to 2100 (central daylight time).
	 The animals were
provided with food (Wayne Lab Blox) and water ad libitum.4
H On the day of each experiment, the animals were sacrificed in groups of
h six at 4-hour intervals over a 24-hour period..
	 The cerebral cortex was dis-
i sected and 5-HT was extracted and quantitated using the method of Maickel
et al. (ref. 6-31); 5-HIAA was also extracted and quantitated from the same
homogenate by the method of Curzon and Green (ref. 6-32).
In two of these experiments, circadian changes in 5-HT content were ob-
served (fig. 6-1). In the third experiment, 5-HT content was not measured.
The highest daily level of brain 5-HT was observed at different hours in the
two experiments. Generally, however, 5-HT appeared to be high late in the
dark phase and/or during the early hours of the light phase (fig. 6-1). The
level of 5-HT declined as the light phase continued, and the lowest levels of
5-HT occurred during the early to middle dark phase. This pattern for the
changes in 5-HT content in the mouse cerebral cortex with time of day agrees
with that reported for 5-HT in the whole mouse brain (refs. 6-15 and 6-25) or
in regions of mouse brain (ref. 6-26). The variability of the peak in sero-
tonin content observed in this study is probably due partly because data were
collected at intervals of 4 hours and because the rhythm in 5-HT content is
not very precisely regulated by the lighting regime. Strain differences are
probably of minor significance in producing the variability in the hour of
peak 5-HT because the hour of peak 5-HT in the Balb/C strain (experiment 1)
compares favorably with that reported for whole brain in AJAX mice in a previ-
ous publication (ref. 6-25).
Significant circadian changes in 5-HIAA content in the cerebral cortex
were observed in each of the three experiments. Levels of 5-HIAA were high
just before the onset of the dark phase (fig. 6-2, experiment 1) or during
the early hours of the dark phase (fig. 6-2, experiments 2 and 3). The re-
sults of experiment 2 suggest that the daily 5-HIAA rhythm may be bimodal,
with the second elevation occurring late in the dark phase. This second ele-
vation of 5-HIAA during the late dark phase is probably of only short duration
since it was not observed in a repeat study (experiment 3) of the rhythm in
5-HIAA content in the brains of AJAX mice.
t
A comparison of the rhythms in 5-HT content and 5-HIAA content in experi-
ments 1 and 2 indicates that the patterns of the daily changes in the content
of 5-HT do not correlate well with the pattern of changes in the content of
its major metabolite, 5 -HIAA. Other investigators have correlated changes in
the brain content of 5-HIAA with the rate of turnover or metabolism of sero
tonin (refs. 6-12 and 6-30). It is thus likely that the daily changes in
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I5-HIAA content observed in the current studies reflect circadian changes in
the rate of turnover or metabolism of 5-HT in the cerebral cortex of the mouse.
If this is true, these data further suggest that the daily changes in the con-
tent of 5-HT do not correlate well with circadian changes in the turnover or
metabolism of 5-HT. The data suggest that serotonin is being metabolized more
rapidly just before the onset or during the early hours of the dark phase.
These results support Hery et al. (ref. 6-33) who reported an increase in the
rate of formation of radioactively labeled 5-HIAA from tritiated serotonin
with the onset of the dark phase. They concluded.that 5-HT was synthesized
more rapidly during the light phase, accounting for the increase in 5-HT con-
tent, but was utilized more rapidly during the dark phase.
Sheard and Aghajanian (ref. 6-34) observed an elevation of brain 5-HIAA
after electrical stimulation of the area of the raphe nuclei, the region of
the brain containing the bulk of the cell bodies of the brain serotonergic
system (ref. 6-35). These results suggest that an increase in the production
of 5-HIAA or an increase in the turnover of serotonin may reflect an increase
in impulse activity of serotonergic neurons. It is tempting to speculate that
the elevation of 5-HIAA observed in these present studies also reflects an
increase in the activity of serotonergic neurons before or during the early
hours of the dark phase. However, it is yet unclear whether the turnover of
serotonin reflects the activity of the functional pool of serotonin or the
activity of both the functional and the netwbolie pool of serotonin (ref. 6-11).
Thus, it cannot be presently assumed that the elevations of 5-HIAA observed at
certain time points in the current studies are a positive reflection of changes
in the impulse activity of serotonergic neurons. However, the data indicate
a need to evaluate more carefully the suggested functional correlations that
other investigators have made between diurnal changes in serotonin content and
similar diurnal changes in other parameters, such as sleep and motor activity
or audiogenic seizure sensitivity.
Because only the content of 5-HIAA was measured, it is possible that the
elevations of 5-HIAA content observed during the dark phase do not reflect an
increase in the metabolism of serotonin but are the result of a decrease in
the rate at which 5-HIAA is being actively transported out of the brain. Data
available from a recent experiment suggest indirectly that the higher levels
of 5-HIAA observed during the early dark phase may indeed be due to a decrease
in 5-HIAA elimination from the brain during this time period. Figure 6-3 is
a summary of the results of a preliminary experiment in which the turnover of
5-HT in the cerebral cortex of AJAX mice was determined during three separate
time intervals over a 24-hour day. The turnover of 5-HT was determined by
measuring the accumulation of 5-.HIAA in the cerebral cortex after the active
transport of this metabolite from the brain was inhibited by the injection of
probenecid (200 mg/kg). The primary metabolite of 5-HT is 5-HIAA, and like
5-HT its passive diffusion from the brain is prevented by the blood-brain bar-
rier (ref. 6-36). This acidic metabolite of 5-HT is normally eliminated from
the brain by an acid transport system (ref. 6-37). Neff and Tozer (ref. 6-29)
have shown that probenecid, a drug known to block acid transport in the kidney
and liver, also blocks 5-HIAA transport in the brain. These investigators
have also shown that the rate of accumulation of 5-HIAA in the brain after
probenecid treatment is equal to the rate of turnover of 5-HT as calculated by
other means (ref. 6-29). 'In the present experiment, the experimental animals
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received probenecid intraperitoneally 2 hours before sacrifice. At the same
time that the experimental animals received probenecid, a group of control
animals was sacrificed. Since probenecid inhibits the transport of 5-HIAA out
of the brain, the mean level of 5-HIAA in the brains of the control animals
represents the content of 5-HIAA in the brains of the experimental animals at
the time they were injected with probenecid. At 1000, 5-HIA.A content had in-
creased 75 percent over that observed in control mice sacrificed 2 hours ear-
lier (fig. 6-3). At 1800, the probenecid-injected animals had accumulated
45 percent more 5-HIAA th an the control animals. At 0+00, the 5-HIAA content
of the probenecid-injected animals was only 5 percent greater than that ob-
served in the control animals sacrificed 2 hours earlier. In this particular
experiment, the increase in 5-HIAA content in the control animals at 0+00 was
not statistically significant. The decrease in the total level of 5-HIAA
accumulated in the cerebral cortex of the probenecid-treated animals at 0+00
was statistically significant (p < 0.01) compared to the levels found in the
probenecid-injected animals at 1000 and 1800. As was anticipated from earlier
studies, the content of 5-HIAA in the cerebral cortex of the control animals
sacrificed at 0200 was greater than that observed in the control animals at
0800 and 1600.
The data from this experiment suggest that 5-HT turnover is greater dur-
ing the light phase than during the dark phase. If 5-HT turnover is corre-
lated with the impulse activity of the serotonergic neurons, the results sug-
gest that the serotonergic system is more active during the light phase when
5-HT levels are higher. This conclusion is contrary to that made on the basis
of the data obtained from studies of diurnal changes in the content of 5-HIAA
in the cerebral cortex. The results of the probenecid study suggest that the
elevations of 5-HIAA observed during the dark phase are the result of a de-
crease in the rate of elimination of 5-HIAA from the brain rather than an in-
crease in serotonergic activity.
However, several criticisms can be made of the pharmacological measure-
ment of 5-HT turnover using probenecid. Probenecid not only inhibits the acid
transport of 5-HIAA but also elevates the level of free tryptophan in the
blood and the content of tryptophan in the brain (ref. 6738). As will be dis-
cussed later in this report, there is evidence that the rate of turnover of
5-HT is influenced by the level of tryptophan in the brain (ref. 6-39), indi-
cating that probenecid itself may affect 5-HT turnover by'elevating the level
of tryptophan in the brain. Also, any alteration of the steady state levels
of 5-HT or its metabolites, such as that induced by probenecid may affect neu-
ronal activity and thus may indirectly affect 5-HT turnover (ref. 6-4o). It
has been known for some time that there is a circadian variation in the rate
of drug metabolism by the liver. Generally, drug metabolism is greater dur-
ing the dark phase (ref.. 6-41). Thus, the decrease in 5-HIAA accumulation
observed in the probenecid-treated mouse brain during the dark phase may re-
flect a decrease in the amount of probenecid that reaches the brain because
of the more rapid metabolism of this drug during the dark phase.
Probably the most direct and ultimately the most reliable method for de-
termining the rate of 5-HT turnover, thus arriving at some indication of sero-
tonergic neuronal activity, is the use of .radioisotopic procedures. Bapna
et al. (ref. 6-42) have recently described a radioisotopic method for
. .1
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measuring 5-HT turnover in small regions of brain by measuring the rate of
synthesis of radioactively labeled 5-HT from radioactive tryptophan injected
into the lateral ventricle of the brain. 	 This method combines the advantages
of specificity (only serotonergic neurons that contain the specific enzyme
tryptophan hydroxylase will synthesize radioactive 5-HT) with high sensitiv-
ity, because the labeled precursor is brought into immediate proximity to the
+ brain.	 This method has been criticized because the concentration of trypto-
phan used in the procedure may itself alter 5-HT turnover in the brain
(ref. 6-43); however, no direct evidence for such an effect of this procedure
on 5-HT turnover has been experimentally shown.	 Because of the advantages of '	 '•
the Bapna method for measuring 5-HT turnover, experiments were undertaken to
determine whether the intraventricular administration of tryptophan in quan-
tities less than those used by Bapna would alter 5-HT turnover.
The right lateral ventricles of Sprague-Dawley rats were cannulated
chronically using the procedure of Bapna et al.	 (ref. 6-42).
	
One week later,
the experimental animals received 5 micrograms of L-tryptophan dissolved in
20 microliters of Ringer's solution (pH7), and control animals received only
Ringer's solution. 	 Tryptophan, 5-HT, and 5-HIAA were extracted and quanti-
tated as described by Hery et al.	 (ref. 6-33).	 After 15 minutes, 5-HIAA con-
tent was significantly elevated in both the cerebral cortex (p < 0.01) and
( brainstem (p < 0,05) of the tryptophan-treated animals (table 6-I).	 Levels
z I of 5-HIAA in the cerebral cortex remained elevated throughout later time in-
tervals and were significantly above control values after 30 minutes
(p < 0.05) and 120 minutes , (p < 0.05).	 The elevation of 5-HIAA in these brain
` areas probably reflects an increase in 5-HT turnover in the tryptophan-treated
animals (refs. 6-12 and 6-30).
k; Tryptophan content was significantly elevated only in the cerebral cortex
(p < 0.05) of the-tryptophan-treated animals, and then for only 15 minutes
t i after tryptophan administration (table 6-I).	 Apparently, most of the intra-
` ventricularly injected tryptophan either is not taken up or is rapidly clearedfrom the brain.	 Unlike 5-HIAA and tryptophan, 5-HT content was not signifi-
cantly different in the brainstem or cerebral cortex of tryptophan-treated
animals compared to control animals.
The experiment was repeated. 	 However, in this study.,. 50 microcuries of
I tritiated ( 3H) tryptophan (6 micrograms) was administered intraventricularly.
After preliminary analysis, the results appeared to be inconsistent with those
of the previous experiment.	 No significant elevations in 5-HT, tryptophan, or
5-HIAA were observed in either the right or left half of the cerebral cortex
ij of tryptophan-treated rats compared to control rats after 15, 30, or 60 min-
utes (table 6-II).;	 The level of tryptophan in the brainstem was significantly
elevated 15 minutes after tryptophan administration (table 6-II).	 Evidence
that the labeled tryptophan had been properly injected into the ventricular
system was provided by the high specific activities of 5-HT	 tryptophan, and
5-HIAA in bCth the cerebral cortex and 'brainstem when aliquots of these
substances were courted in a liquid sciptillation counter (table 6-III).
i
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However, when regression andcorrelation analysis (ref. 6-44) were per-
formed on the data from the two experiments, some striking and reproducible,
1	 correlations between tryptophan and 5-HIAA content were observed, but only in
f	 tryptophan-treated animals. In both experiments, highly significant correlations between tryptophan and 5-HIAA content were observed in the cerebral
cortex of animals given intraventricular injections of tryptophan (p < 0.01)
(table 6-IV). No significant correlation between these two parameters was ob -
served in the same brain area of control animals (table 6-IV).
Unlike the cerebral cortex, no correlation between tryptophan and 5-HIAA
1	 was observed in the "brainstem of tryptophan-treated animals (table 6-TV).
However, in the initial study, a small but significant correlation between
{ tryptophan and 5-HIAA was observed in the brainstem of the control animals. 	 ~
yi. 3
i
The data from these two studies indicate that the intraventricular admin-
istration of 5 to 6 micrograms of tryptophan is not sufficient to greatly in-
crease 5-HT turnover. Therefore, 'brain 5-HIAA is not always significantly
elevated when. groups of tryptophan-treated animals arecompared to control
animals (table 6-II). However, when tryptophan and 5-HIAA are compared in in-
dividual tryptophan-treated animals by using correlation analysis, a signifi-
cant effect of the administered tryptophan on the relationship between these
two parameters is demonstrated. The significant correlation between trypto-
phan and 5-HIAA in the cerebral cortex of individual tryptophan-treated rats
(table 6-IV) probably reflects a small increase in the size of the tryptophan
pool in the cerebral cortex of these animals, with a subsequent increase in
5-HT turnover, reflected by 5-HIAA content. Because the turnover of brain
5-HT is normally regulated by a number of factors other than brain tryptophan,
tryptophan and 5-HIAA are not closely correlated in the brains of control rats
(table 6-IV). The potential influence of brain_ tryptophan on brain 5-HT turn-
over is suggested by the significant correlation observed between these param-
eters in the brainstcm in the initial study. The lack of correlation of
tryptophan and 5-HIAA in the, 'brainstem of tryptophan-treated rats suggests
that the intraventricular levels of tryptophan were not elevated in areas 're-
moved from the site of injection (the lateral ventricles) to produce a con
_sistent and significant effect on 5-HT turnover. The cerebral cortex contains
a predominance of serotonergic nerve endings, whereas almost all of the cell
bodies for serotonergic neurons are located in the brainstem. 'Thus, the Sig-
nificant effect of intraventricularly inj ected tryptophan on the correlation
between tryptophan and 5-HIAA in the cortex but not the brailstem may indicate
that serotonergic nerve endings are more sensitive to changes in tryptophan
than are cell bodies.
The results of these two experiments indicate that the intraventricular
L	 administration. of tryptophan in quantities less than those used by Bapna et
al. (ref. 6-42) is :capable, in itself, of altering the turnover of 5-HT.
Thus, this method should be used very carefully when studying changes in the
1 rate of turnover of 5-HT during different times of the day and under different
}	 lighting conditions. A procedure similar, to that of Bapna was used by Hery
et al. (ref. 6-33). _Thus, it may be necessary to reconsider their conclusions
concerning the levels of activity of the serotonergic system during the light
and the dark phase of a 12:12_LD 24-hour day._;
 Work is continuing on a chronic
cannula system for the external jugular vein by which high specific activity
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tryptophan could be injected into the blood vascular system. 	 The ultimate
use for this system will be to measure short-term changes in 5-HT turnover in
the brain.
a
Y
Considerable evidence has been accumulated in the last 2 years indicating
that the circulating level of plasma tryptophan may have an important role in
..'^.	 f regulating brain S-HT content.	 Fernstrom and Wurtman (ref. 6-39) found that
the intraperitoneal injection of L-tryptophan was followed by a significant i
elevation in brain 5-HT content. 	 The dosage of tryptophan given in their ex-
periment'caused a smaller increase-in blood tryptophan than was normally seen
when blood tryptophan, which shows p, circadian variation in content, reached
f its peak contentduring the night. = In a second study (ref. 6-45), the same
investigators found that a carbohydrate diet caused an elevation in whole
blood tryptophan content with an ensuing increase in brain 5-HT content. 	 In
this case, they suggested that the elevation of tryptophan content was the re-
sult of an increase in insulin release stimulated by the carbohydrate diet.
These investigators have therefore hypothesized that plasma tryptophan content
has an important physiological role in the regulation of brain 5-HT content.
Furthermore, they felt that the daily rhythm in brain 5-HT content may be the
result of similar daily changes in plasma tryptophan.
	
Numerous studies have x'_
confirmed the presence of daily rhythmic changes in the concentration of plas-
ma tryptophan in both-rodents ,_and humans (refs. 6-46 to 6-48).	 Perez-Cruet
et al.	 (ref. 6-30) have proposed that the diurnal changes in brain 5-HT'con-
tent maybe secondary to diurnal cycles in feeding activity and to the influ-
ence of food intake on circulating levels of plasma tryptophan.
An experiment was undertaken to test the role of food intake and of
plasma tryptophan content onthe daily rhythms of 5-HT content in the whole
brain of the AJAX mouse.
	
In this experiment, 72 adult male AJAX mice were di-
£; vided into two equal groups, and exposed to the 12;12 LD lighting regime. 	 The
control animals had free access to food (Wayne Lab Blox) and water.
	
The ex-
µf perimental animals were given water ad libitum but were given food daily for
;.; only 4 hours, between 1000 and 1400.
	 After 5 weeks under these experimental
`f conditions, the' mice were weighed and then sacrificed by decapitation in st grows of 12 (6 controls and 6 e	 )p	 xperimentals' at 4-hour intervals over a
^a -24-hour period.'	 Blood was collected from the cervical vessels in'heparinized{" 9-milliliter test tubes.
	 The brain was removed and divided longitudinally in-
to symmetrical right and left halves.
	 The content of 5-HT was determined in
ol 	 i one-half of the brain as described earlier.- Tryptophan content in the other
half of the brain was determined by the method of Denckla and Dewey
( (ref... 6-49).	 The blood was centrifuged and tryptophan content was determined 3
in the plasma fraction.
	 The statistical significance of the differencesin
plasma tryptophan, brain tryptophan, or brain 5-HT,, : with changes in the time
of day in both control and experimental animals, was determined by the analy-
sis of variance.
	 Effects:of the feeding regime on the phasing (clock hour of
peaks and troughs) of the daily rhythms in each of the above parameters were
s
F determined by comparing graphsof the rhythm for each parameter in control i
E versus experimental animals.
The results in table 6-V indicate that the adult male AJAX control mice
Y
consumed, on the average, more than 80 percent of their food during the dark
a
f
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phase of a 12:12 LD regime. Despite the restricted feeding time for the ex-
perimental animals, the body weights of these animals were equal to those of
the control animals at the time of sacrifice (table 6-VI).
' The diurnal rhythm in plasma total tryptophan content was markedly al-
tered by the feeding regime (fig. 6-4).
	 In both control and feeding-regime
animals, the highest level of plasma total tryptophan was observed when the
animals were consuming most of their daily intake of food.
By contrast, the circadian rhythms in brain tryptophan content and in
brain 5-HT content were not appreciably altered in the experimental or feeding-
100 regime animals when compared to those of control animals (figs. 6-5 and
6-6).	 These data suggest that the daily rhythms in brain 5-HT and tryptophan
exist independently of the level of tryptophan in the plasma.	 Thus, more evi-
dence was provided that further supported the hypothesis that daily rhythms in
1 5-HT and,-5-HIAA content area reflection of daily changes in the activity of ;.
the'serotonergic system and not merely a metabolic phenomenon caused by .a cir-
cadian rhythm in blood tryptophan. 	 The comparison of the circadian rhythms in
brain 5-HT and brain tryptophan (figs. 6-5 and 6-6) suggests an important cor-
relation between these two parameters and may indicate that changes in the
level of brain tryptophan have an important role in the daily changes in brain r«
serotonergic activity.
Recently, Fernstrom and Wurtman (ref. 6-50) have indicated that the ratio
of plasma tryptophan to other neutral amino acids in the blood that share a
common transport mechanism with tryptophan for uptake into the brain is of
M _
more importance in regulating the turnover of 5-HT than is the level of plasma
tryptophan alone.	 Also, more than 80 percent of the tryptophan in the plasma
is bound to albumin and is not immediately available for transport into the
brain (ref. 6-51).	 Tagliamonte et al. (ref. 6-52) have shown that the levels
' of "free" tryptophan do not always parallel the levels of plasma total'tryp-
tophan.	 Thus, it is possible that either the ratio of plasma tryptophan to
other neutral ;amino acids or the level of free tryptophan in the blood may
have a central role in regulating circadian variations in the activity of the
brain serotonergic system.
	
To test this hypothesis, an experiment was per-
formed in the laboratory.
In this experiment, 72 Sprague-Dawley rats were divided into two„groups.
One-half of the rats, designated as controls,' were given food 'and water`ad t
libitum, and the other half, designated as experimental rats, were given food
only between 1000 and 1+00 daily. 	 All of the animals were <exposed .to a'14:10
` ID lighting regime.
	 The animals were maintained under these experimental con-
ditions for 6 weeks.	 Groups of six control and six experimental rats were
sacrificed at '4-hour intervals over a 24-hour period.	 Cerebral cortex and
brainstem 5-HT, tryptophan, and 5-HIAA were extracted and analyzed as de-
scribed by Hery et al. (ref. 6-33).	 Plasma total tryptophan was analyzed as
described previously, and tyrdsine and phenylalanine were analyzed; by the
methods of Waalkes and Udenfriend (ref. 6-53)-and McCaman and Robins A3
(ref.  6-54), respectively.	 One milliliter of plasma was placed in a cellu-
lose dialysis sack and 0.08 milliliter of dialyzate containing free tryptophan
was collected following the procedure of'Tagliamonte et al. ('ref. 6-52). tr
In this experiment, consistently significant circadian rhythms in 5-HT
content were not observed. In the cerebral cortex, a significant daily rhythm
in 5-HT was observed in the experimental, or feeding-regime, animals but not
in the control animals (fig. 6-7). In the brainstem, however, the 5-HT rhythm
was statistically significant in the control animals but not in the experi-
mental animals (fig. 6-7). The inconsistency of these results probably re-
flects the daily disturbance of all the animals used in the study,
 when food
was given to and then withdrawn from the experimental animals. In previous
studies by other investigators as well as in the author's studies in which
consistent circadian rhythms in brain 5-HT content were demonstrated, the ani-
1
mals were left undisturbed for as long as ;a week at a time. !	 ­.A
Significant circadian changes in 5-HIAA content were observed in the
cerebral cortex of control and experimental animals and in the brainstem of
experimental animals (fig. 6-8). 	 A comparison of"the patterns of the daily
` changes in 5-HIAA-content in experimental and control rats suggests that, in
these animals, the feeding regime did alter the 5-HIAA rhythm to some extent.
In the cerebral cortex, a second peak in 5-HIAA content was observed in thei
experimental animals at 1200 during the 4-hour ,period in which food was avail-
able.	 In the brainstem, the rhythm 5-HIAA content-was significant in the ex-
perimental animals but not in the control animals, primarily because of a
marked decrease in,5-HIAA at 1600, 2 hours after -the -daily time at which the
--
food was removed.
Rosecrans and Schechter (ref. 6-12) felt that the ratio of 5-HIAA to 5-HT
provided a better indication of serotonergic neuron activity than did measures
of 5-HT or 5-HIAA alone.	 When the present data were expressed in this way, t"
the ratio of 5 -HIAA to 5-HT in the brainstem was considerably higher during
the dark phase than during the light phase (fig. 6-9).	 These data provide
further evidence that the serotonergic system may be more active during the
r dark phase when the animals are active.; Although not shown in this illus-
tration, in the cerebral cortex of the experimental animals, the peak of
5-HIAA at 1200 was even more exaggerated when expressed as a ratio of-5-HIAA
to 5-HT.
Significant circadian changesin tryptophan content were also observed in
both brain areas of both control and experimental rats (fig. 6-10).	 In gener-
al, the magnitude of the change _in brain tryptophan content,, as well as the
i level of statistical significance, was somewhat reduced in the experimental,
' or feeding-regime, animals.
	
In particular, brain tryptophan content was re-
duced in the experimental animals at 0800, ,just 2 hours before the start of
the daily 4-hour feeding period.
` r Statistically significant circadian rhythyms in both plasma total trypto-
phan and plasma free tryptophan were observed in'both control and experimental
rats (fig. 6-11).
	 These data represent the first experimental evidence for
-, the existence of a circadian change in free plasma tryptophan.	 Generally, the
circadian rhythm in plasma free tryptophan either parallels or leads by 4 hours
the rhythm in plasma total tryptophan. 	 As in the earlier study on mice, plas-
matrypotophan in the control rats was at its peak value during the dark phase
when the animals consumed the majority of their daily food intake. 	 In the {
x
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experimental rats, a peak in plasma tryptophan was also observed at 1200, dur-
i
ing the time the animals-were eating. 	 Evidence that the circadian rhythm in
plasma tryptophan is not merely secondary to the intake of food is provided by
the presence of a second peak in plasma tryptophan in the experimental animals
during the dark phase.
	 This peak coincides with the peak in plasma tryptophan
observed in the control animals.
t
I To obtain a clearer evaluation of correlations between the various param-
eters studied in this experiment, a correlational analysis and a regression
analysis were performed on the data (table 6-VII) (ref. 6- 44).	 The null is
hypothesis that the correlation coefficient (r) or the slope of the regression x	 _
line is equal to zero was tested by a "t" test (ref, 6-44).	 Highly signifi-
cant as well as consistent correlations between brain tryptophan and 5-HIAA
content were observed in the cerebral cortex (p < 0 ..005) and the brainstem
(p <-0.001) of both control and experimental animals.
	 However, no consistently
significant correlations were observed between plasma free or total tryptophan
-' and brain 5-HT, 5-HIAA, or tryptophan. 	 Plasma free tryptophan and brain
5-HIAA were slightly but significantly (p < 0.05) correlated in the cerebral
cortex of control rats (table 6-VII), and free tryptophan was also correlated
with 5-HT in the brainstem of these same animals (p < 0.01).
	 No correlations
were observed between the ratio of plasma tryptophan to plasma tyrosine plus e
phenylalanine and brain 5-HT, 5-HIAA, or tryptophan ( gable 6-VII).	 •> ._.
These data; obtained from correlational analysis suggest that brain tryp-
` tophan content may be intimately related, perhaps in a causative manner, to
the daily changes in the content of brain 5-HT and 5-HIAA. 	 This interpreta-
tion is consistent with the coincidence in the phasing of the daily rhythms in rt
brain tryptophan and 5-HT observed in the mouse feeding-regime-experiment de-
scribed earlier.	 The daily changes in 5-HIAA may reflect circadian fluctua-
tions in the turnover of 5-HT, and thus circadian changes in brain tryptophan '=
content may have a role in regulating a daily rhythm 5-HT turnover.
	 A signif-
icant correlation between two parameters does not always reflect a cause and
effect relationship;- however, tryptophan and 5-HIAA are already known to be
related as the precursor and principal metabolite of 5-HT.
The lack of significant correlations between plasma free or total trypto-
phan and brain 5-HT, 5-HIAA, or tryptophan indicates that these parameters are
'	
not 'linearly related to 5-HT rhythms in the brain and suggests that plasma
tryptophan does not have an immediate or predominant role in the regulation of
circadian rhythms of brain tryptophan or 5-HT or in the turnover of 5-HT.
However, some role for plasma; tryptophan in relation to the circadian rhythm"
'	 in 5-HT turnover in the cerebral cortex is suggested by the consistent coinci-
dence of the peaks of the circadian rhythms of plasma tryptophan (fig. 6-11)
and cerebral cortex 5-HIAA (fig. 6- 8).	 However, the peak of the circadian
rhythm in brainstem-5-HIAA is not consistently coincident with the plasma
tryptophan.	 These particular data may again reflect a greater sensitivity of
nerve endings to changes in tryptophan content. 	 The lack of significant
correlation between plasma free tryptophan or the ratio of plasma tryptophan to
plasma phenylalanine plus tyrosine and brain tryptophan,;5-HT, or 5-HIAA'sug-
gests that plasma tryptophan also does not have a major or predominant role in
the production of diurnal changes in brain tryptophan-content or the turnover
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of 5-HT.	 These data do not rule out a delayed effect of changes in plasma
l
€
tryptophan on brain tryptophan or 5-HT turnover.
During the past year, another research approach has also been used in the
author's 'laboratory to investigate the relationship between changes in the
' turnover of brain 5-HT and changes in other parameters, such as brain trypto-
phan, plasma total and/or free tryptophan, or the ratio of plasma tryptophan
to other neutral amino acids. 	 Perez-Cruet et al. 	 (ref. 6-30) have.shown that
~
24 hours of starvation causes a significant increase in- 5-HT turnover in ruts.
However, the causes for the increase in 5-HT turnover were not investigated
i
by these researchers.
	 They did suggest that these changes might be due to i
changes in the ratio of plasma tryptophan to other plasma neutral amino acids.'`
Experiments were undertaken to determine whether brain 5-HT turnover in
^ male golden hamsters was affected by 24 or 48 hours of starvation.	 Possible
relationships between changes ,in'the levels of tryptophan and other amino
acids in the plasma and the effects.of food deprivation on hamster, brain tryp-
tophan, _5-HT, and 5-HIAA content were also investigated.
Groups of six control, six starved, and six starved and then fed (refed)
hamsters were sacrificed at 0, 1, 2,, and 3 hours beginning 24 or 48 hours
after food deprivation. 	 Because no statistically significant differences in
G
- brain tryptophan,-5-HT, or 5-HIAA were observed at 0 versus 1, 2, or 3 hours
ry -- - within- an
	 of the three ey	 xpermental<groups, the data collected. after :differ- }
ent hours were combined to compare brain tryptophan, 5-HT, and ;5-HIA-A in con-
trol versus starved or refed animals.
Food deprivation of 48 to 51 hours resulted in a consistent and signifi-
cant increase in 5-HT turnover as evidenced by an increase in 5-HIAA content
(tables 6-VIII and 6-IX) and by an increase in the rate of accumulation of
5
-HT after monoamine oxidase inhibition (fig. 6-12).
	 The elevation of 5-HT
' turnover was not reduced by the feeding of the 48-hour starved hamsters for - r
3 hours (tables 6-VIII and 6-IX).
The increase in 5-HT turnover in 48- to 51-?hour starved hamsters was not
consistently correlated with the levels of brain tryptophan, and in separate
! experiments, brain tryptophan was found to be elevated (table 6-VIII) or un-
changed (table 6-IX) after 48 to 51 hours of starvation. 	 Moreover, brain
tryptophan remained elevated (table 6-VIII) or decreased below control levels
(table 6-ix) in 48-hour starved animals that had refed for up to 3 hours.
} The elevation of -5-HT 'turnover in 48- to 51-hour starved hamsters was not
related to an increase in plasma total tryptophan (ref. 6-39) or to an in-
I crease in the ratio of plasma tryptophan to tyrosine (ref. 6-50). 	 The data
show that plasma tryptophan (fig. 6-13) and the ratio of plasma total tryp-
tophan to tyrosine (table 6-X) decreased rather then increased in these animals.
In 24-hour starved hamsters, the levels of 5-HIAA, which probably reflect
5-HT turnover, were not significantly elevated. 	 However, in the initial
study (table-;XI), 5-HIAA content was si-4-hour starvation 	 gnificantly increased
after 27 hours of food deprivation.	 Lack of food was probably not the only
I
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cause for the increasein 5-HIAA at 27 hours, because the 24-hourmstarved-then-
3-hour-refed hamsters also showed a significant elevation in brain 5-HIAA(table 6-xi).
Brain tryptophan in the 24-hour-starved hamsters was already elevated at
24 hours and remained elevated at 27 hours.
	 The increased level of brain
tryptophan in these hamsters coincided with the' elevation of 5-HIAA at 27
hours.	 After 3 hours of feeding, brain tryptophan in the starved animals had
decreased below levels found in the control animals. This decrease in brain'
tryptophan was not positively_ correlated with the elevation of 5-HIAA observed
in the brains of these same animals during the same time period.
As in the earlier studies_ summarized in this report, the elevations of
5-HIAA content in the brains of the 27-hour-starved hamsters and the refed
hamsters (24 hours starved plus 3 hours; refed) were not well correlated with
the change in the ratio of plasma tryptophan to tyrosine (table 6-XII).
	 If ^.
the increase in 5-HIAA content or 5-HT turnover were due to a change in the
ratio of plasma tryptophan to tyrosine, the ratio would be expected to in-
crease coincidently with the elevation of 5-HIAA. 	 However, the value of this
in the 24- to 27-hour-starved hamsters was not significantly different_ratio
from that found in control animals (table 6-XII), and the same ratio in refed
hamsters was significantly lower than that observed in control hamsters
(table 6-XiI).
The 24-hour-starvation study was repeated.
	 In this study also, 5-HIAA s
content was found to be elevated.in`the starved and the refed hamsters; how-
_::"--..• ever, in this experiment, the elevations were not statistically significant
(table 6-XI).	 In this repeat study, the ratio of plasma tryptophan to tyrosine
+ phenylalanine was significantly lower in both starved and refed hamsters
(table 6-XII).
The underlying mechanisms responsible for the elevation of 5-HT turnover
in 48-hour-starved hamsters are not clear.	 However, the elevation of 5-HIAA
and 5-HT turnover observed'in these,: animals is,not due to changes in brain s
J tryptophan, plasma tryptophan, or the ratio of plasma tryptophan to other
neutral amino acids.	
It-coul d
 
 be argued that not enough ofthe neutral amino
n theseac ds tudies 	 obtain a'proper ratio. 	 However,
Fernstrom and Wurtman (ref. 6-55) have reported that only tryptophan and
tyrosine must be measured to show a correlation of this ratio with brain 5-HT -
synthesis.	 The 'elevation of 5-HT turnover in 48-hour-starved hamsters may be
due to an increase in the level of free tryptophan in tie ` plasma (ref. 6--52).,'
But after the refeeding of 24-hour-food-deprived hamsters, a very rapid increase
in plasma free tryptophan was observed without,any,subsequent increase in'5-HIAA k
content (fig. 6-14).	 Admittedly, if the increase in S-HT turnover was very
short term, it might have been missed in this experiment.
The increase in 5-HT turnover observed in these starvation studies proba-
bly does not reflect-a component of the brain serotonergic system that is`in-
volved in the regulation of food intake and metabolism (ref. 6-30).-	 This does-
not imply that serotonergic pathways in certain' discrete areas of the hamster
brain are not involved in the regulation of food intake, but rather that the
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present data do not seem to demonstrate these particular pathways.
	 The ele-
vation of 5-HT turnover observed in the hamster brain after 48 hours of star- j
vation may be due to stress induced by this periodof starvation.
	 The eleva-
tion of 5-HIAA observed in one of two studies after 27 hours of food depriva-
tion may indicate the lower limit of time required for starvation to induce an
' appreciable increase in 5-HT turnover, or may indicate that 24-to-27-hour-•
starved hamsters are more 'sensitive than control' animals to the stress of
j noise or handling.
SUMMARY
The presence of high levels of 5-HIAA, the principal metabolite of 5-HT,
during the dark phase of a 12:12 LD lighting regime, suggests that the turn-
over of 5-HT may be higher during the dark phase than during the light phase.
m. A significant increase in the ratio of 5-HIAA/5-HT during the dark phase in
both the brainstem and cerebral cortex of rats exposed to 14:10 LD lighting
regime provides further evidence that 5-HT turnover in the brain is greater
1	 during the dark phase. 	 The increase in 5-HT turnover observed curing the dark
t phase `may `reflect an increase in serotonergic activity at this time.	 However,
,.	 preliminary evidence suggests that the dark-phase elevation of,' 5-HIAA may be
_-- -	 due to a decrease in the rate of elimination of 5-HIAA from the brain, rather
than to a change in_serotonergic activity.
Direct experimental evidence was obtained to show that the intraventric- ;.
ular administration of 5 to 6 micrograms of tryptophan, a quantity consider-
ably less than that frequently administered as a radioactive isotope to meas- N.
ure 5-HT turnover, is capable itself of slightly increasing 5-HT turnover.	 In
the mouse, the daily rhythms in plasma total tryptophan were not well corre-
lated with daily rhythms in brain tryptophan and 5-HT.
	 However, a coincidence
`	 of the peaks of the daily rhythms in brain tryptophan and 5-HT suggests a
possible interrelationship.
Highly significant correlations between brain tryptophan and 5-HIAA con-
tent were observed in the cerebral cortex and the brainstem of rats sacrificed
- at periods over `a 24-hour day.' Similar correlations between brainstem 5-HT
and tryptophan were also observed in the brainstem of these animals.
	
However,
no consistently significant correlations were observed between either brain
5-HIAA'or 5-HT and plasma-free or total tryptophan, or between brain 5-HIAA or
5-HT and the ratio of tryptophan to neutral plasma, amino acids. 	 These data
again indicate that brain tryptophan may have an important role in the regu-
lation of circadian changes in 5-HT turnover, whereas plasma tryptophan seems'
to be of less importance._ Some role for plasma tryptophan in the regulation
of circadian variations in 5-HT ,turnover is suggested by the coincidence; of
peaks observed in the circadian rhythms of plasma tryptophan and cerebral cor-
tex and brainstem 5-HIAA.
A consistently significant increase in 5-11T turnover was observed in the ;,=
whole brain of 48-hour-starved hamsters.	 Elevation of 5-HT turnover or 5-HIAA
content was noted in the hamster brain after 27 hours of starvation.
	 However,
6-14
}
4 r-

aREFERENCES
'	 6-1. Myers, R. D.; and Beleslin, D. B.:	 Changes in Serotonin Release in
'• Hypothalamus During Cooling or Warming of the Monkey.	 Am. J. Physiol.,
vol. 220, no. 6, June 1971, PP• 1746-1754.
6-2,. Kamberi, Ibrahim A.;,Mical, Renon S.; and Porter, John C.: 	 Effect of
Anterior Pituitary Perfusion and Intraventricular Injection of
Catecholamines and Indoleamines on LH Release. 	 Endocrinology, vol. 8791 +
no. 1, July 1970,  PP • 1-12.
6-3. Schneider, H: P	 G.; and McCann, S. M.:	 Possible Role of Dopamine as
Transmitter to Promote Discharge of LH-releasing Factor.	 Endocri-
nology vol. 85, no. 1, July 1969, pp. 121-132.
6-4. Vernikos-Danellis, J.; and Berger, P. A.	 Brain Serotonin and the
Pituitary-adrenal System.	 In J. Barchas.and E. Usdin (eds.) Sero-
tonin and Behavior, Academic Press (New York), 1973, pp . 173-177•.
6-5. Bliss, E. L.:	 Effects of Behavioral Manipulations Upon Brain Serotonin
_ .._ and Dopamine.`	 In J. Barchas and E. Usdin (eds.) Serotonin and
Behavior, Academic Press (New York), 1973, pp. 315-324.
£ 6-6. Schlesinger, Kurt; Boggan, William; and Freedman, Daniel X.: 	 Genetics
of Audiogenic Seizures:	 I.	 Relation to Brain Serotonin and
Norepinephrine in Mice.. Life Sci., vol. k, no. 24, Dec. 1965,
pP • 231+5-2351.
F 6-7. Boggan, W. 0.; and-Seiden, L. S.:	 5-hydroxytryptophan Reversal of a
Reserpine Enhancement of Audiogenic Seizure Susceptibility in Mice.
Physiol. Behay., vol. 10, Jan. 1973, pp. 9-12.
6-8. ` Jouvet, M.:	 Insomnia and Decrease of the Cerebral 5-hydroxytryptamine
After Destruction of the Raphe System in the Cat. 	 In S. Garattini
and P. A. Shore, (eds.) Advances in Pharmacology, Academic Press(New York), 1968, pp. 265-279,
a
6-9. Jouvet, Michel:-	 Biogenic Amines and.the State of Sleep. 	 Science,
:. vol. 163, no. 3862,,. Jan. 1969, Pp. 32-41.
6-10. Harvey, John A.; and Lints, Carlton E.: 	 Lesions in the Medial Fore-
brain Bundle:	 Relationship Between Pain Sensitivity and Telence-
phalic Content of Serotonin.' J. Comp.;Physiol. Psychol. vol. 74
no-. 1, 1971, pp. 28-36. r
6-11. Aprison, M. H.; and Hingtgen, J. N.: 	 Serotonin and Behavior:	 A Brief
Summary.	 Fed. Proc., vol. 31, Jan.-Feb. 1972, pp. 121-129.
:t
6-16
Jk
E
J
a
}...	 _
6-12. Rosecrans, J. A.;..a,nd Schechter, M. D.:	 Brain 5-hydroxytryptamine
Correlates of Behavior in Rats:	 Strain and Sex' Variability.
Ph	 '	 Vol. 8.
	
03-510.ysiol. Behay.	 ^ Mar. 1972 Y	 ^	 ^ PP•	 5
6-13. Halberg„ F.:	 Some_ Physiological and Clinical Aspects of 24-hour
Periodicity.	 J. Lancet, Vol. 73, 1953, pp. 20-32-'
±-^ ► 6-14. Curzon, G.:	 Tryptophan Pyrrolase — A Biochemical Factor in Depressive
^. Illness9	 _Brit. J. Psychiat., vol. 116., no.. 571-2, May 1970,
PP • 1367-137. +
+ 6-15. Albrecht, P.; Visscher., M. B.;,Bittner, J. J.; and Halberg, F.: 	 Deily a
Changes in 5-hydroxytryptanine Concentration in Mouse Brain. 	 Proc.
Soc. Exp. Biol. Med., vol.-92, 1956 9
 Pp. 703-706.
. i 6-16. Dixit, Balwant N.; and Buckley, Joseph P.: 	 Circadian Changes in Brain
5-hydroxytryptamine and Plasma Corti.costerone in the Rat.
	 Life Sci.,
-Vol. 6, no. 7 9 1967 9 pp- 755-758•
6-17. Friedman, Alexander H.; and Walker, Charles A.: 	 Circadian Rhythms in
'- Rat Mid-Brain and Caudate Nucleus Biogenic Amine Levels.
	 J. Physiol.,
Vol. 197, no. 1, July 1968 9 PP • 77-85•
` 6-18. Friedman, Alexander H.; and Walker, Charles A.:_ Rat Brain Amines,
Blood Histamine and Glucose Levels in Relationship to Circadian
Changes in Sleep Induced by Pentobarbitone Sodium. 	 J. Physiol.-,a	 ....
Vol. 202, no. 1. May 1969, PP . 133-146.
' 6-19. Scheving, L. E.; Harrison, W. H.; Gordon, P.; and Pauly, J. E.: 	 Daily
Fluctuation (Circadian and Ultradian) in Biogenic Amines of the Rat
Brain..	 Am. J. Physiol, Vol. 214, no. 1, Jan. 1968, pp. 166
-173•
6-20. Quay, W. B.: 'Regional and Circadian Differences in Cerebral Cortical
Serotonin -Concentrations.
	 Life Sci., Vol. 4. no. 3. Feb. 1965,
PP• . 379-384.
F
6-21. Quay, W. B.:	 Differences in Circadian Rhythms in 5-hydroxytryptamine
According to Brain Region.	 Am. J. Physiol., Vol, 215, no. 6, Dec.
1968 9 PP• 14+8-1452.
6-22. Okada, Fumihiko:	 The Maturation of the Circadian Rhythm of Brain
' Serotonin in the Rat. ,Life--Sc -i. , vol.; 10, pt.
	 I, no. 2, Jan. 1971, r:
pp. 77-86.
. 6-23. Scapagnini, U.-; Moberg, G. P.; Van Loon, G. R.; De Groot, J.; and
Ganong, W. F.:	 Relation of Brain 5-hydroxytryptamine-Content to the
Diurnal Variation in Plasma -Corticosterone_in the Rat.	 Neuroendo-
crinology, vol. 7, 1971 9 pp. 90-96•
6-24. Asano, Yutaka:
	 The Maturation of the Circadian Rhythm of Brain
Norepinephrine and Serotonin in the Rat.
	 Life Sci., Vol. 10, pt. I, •,
no. 15, Aug. 1971, pp.;, 883-894.
6-17 _`
if
6-25. Morgan, W.'W.; and Ynd&, C. A.: Daily Rhythms in Tryptophan and Sero- 	 a
tonin Content in Mouse Brain: The Apparent Independence of These
Parameters From Daisy Changes in Food Intake and From Plasma Trypto
phan Content. Life Sci., vol. 12, Mar. 1973, pp. 395-408.
_ 6-26. Schreiber, Robert A.; and Schlesinger, Kurt: Circadian Rhythms and
Seizure Susceptibility: Relation to 5-hydroxytryptamine and 	 ,a
Norepinephrine in Brain.	 Physiol. Behay., vol. 6, no. 6, June 1971,
pp . 635-64o.
6-27. Morgan, W. W.; Yndo, C. A.; and McFadin, L. S.:	 Daily Rhythmic Changes
in the Content of :Serotonin and 5-hydroxyindoleacetic Acid in the
Cerebral Cortex of Mice.	 Life Sci., vol. 14, Jan. 1974, pp. 329-338.
6-28. ',Schreiber, R. A.; and Schlesinger, K.:	 Circadian Rhythms and Seizure
Susceptibility:	 Effects of Manipulations of Light Cycles on Suscep-
tibility to Audiogenic Seizures and on Levels of 5-hydroxytryptamine
and Norepinephrine in Brain.	 Physiol. Behay., vol. 8, Apr. 1972,
pp. 699-703•
6-29. Neff, Norton H.; and Tozer, T. N.: 	 In Vivo Measurement of Brain Sero-
tonin Turnover. 	 Advanc. Pharma., vol. 6, pt. A, 1968, pp. 97-109.
6-30. Perez-Cruet, J.; Tagliamonte, A.; Tagliamonte, P.; and Gessa, G. L.;
Changes in Brain Serotonin Metabolism Associated with Fasting and -.
N Satiation.
	 Life Sci.	 vol. 11	 1972,
a!	 6-31. Maickel, Roger P.; Cox, Raymond. H., Jr.; Saillant, Jean; and Miller,
Francis P.:	 A Method for the Determination of-Serotonin and
.' Norepinephrine in Discrete 'Areas of Rat Brain.
	
Int. J. Neurophar-
mac., vol.
	
7, no. 3, May-June'1968, pp. 275-281.
6-32. Curzon, G.; and Green, A. R.:	 Rapid Method for the Determination of
5-hydroxytryptamine and 5-hydroxyindoleacetic Acid in Small Regions
of Rat Brain.	 Brit, J. Pharma., vol. 39, July 1970, pp. 653-655.
6-33. Hery, Francis; Rouer, E.; and Glowinsky, J.:	 Daily Variations of
Serotonin Metabolism in the Rat Brain. 	 Brain Res., vol. 43, 1972, z	 j
pp. ,445-465. €
6
-34. Sheard	 Michael H.; and Aghajanian, George K.:	 Stimulation of the
Midbrain Raphe:
	
-Effect on Serotonin Metabolism. 	 J. Pharmacol. Exp.
Ther., vol.163, no. 2, 1968, pp-.,--425-43C).
6-35• Fuxe, ! Kjell	 Evidence for the Existence of Monoamine Neurons in the
Central Nervous System.	 IV.	 The Distribution of Monoamine Terminals
in the Central Nervous System.	 Acts, Physiol. Scand. 64, suppl. vol.
7 247, 1965, pp. 39-85. x
1  a
6-18
Tf
6-36. Roos, Bj8rn-Erik: On the Occurrence and Distribution of 5-hydroxyin-
doleacetic Acid in Brain. Life Sci., vol. 1, no. 1, Jan. 1962,
pp. 25-27.
6-37. Neff, N. H.; Tozer, T. N.; and Brodie, B. B.: Indole Metabolism.
Part 2. Specialized Transport Syst7em to Transfer 5-HIAA Directly
from Brain to Blood. Pharmacologist, vol. 62, 1964, p. 194.
6-38. Tagliamonte, A.; Biggio, G.; and Gessa, G. L.: Possible Role of "Free"
Plasma Tryptophan in Controlling Brain Tryptophan Concentrations.
Rivista di Farmacologia et Terapia, vol. 11, 1971, pp. 251-255.
6-39. Fernstrom, John D.; and Wurtman, R. J.: Brain Serotonin Content:
Physiological Dependence on Plasma Tryptophan Levels. Science, vol.
173, no. 3992, July 1971, pp. 149-152.
6-40. Wurtman, R. J.; Anton-Tay, F.; and Anton, S.: On the Use of Synthesis
Inhibitors to Estimate Brain Norepinephrine Synthesis in Gonadecto-
Life Sci., vol. 8, pt. I, no. 17, 1969, pp. 1015-1022.mized Rats.
6-41. Heikkinen, E.; Karppanen, H.; Vapaatalo, H.; and Pelkonen, 0.: Lack of
Effect of Pinealectomy on the Diurnal Rhythm in Drug Metabolism.
Acta Pharmacol. Toxicol., vol. 32, -'1973, pp. 157-160.
6-42. Bapna, J.; Neff, N..H.; and Costa E.: A Method for Studying Norepine-
phrine and Serotonin Metabolism in Small Regidns;of Rat Brain:
Effect of Ovariectomy gn Amine Metabolism in Anterior and Posterior
Hypothalamus. Endocrinology, vol. 89, no. 6, Dec. 1971, PP. 1345-1349.
6-43. Hyyppg , M. T.; Cardinali, D. P.; Baumgarten, H. G.; and Wurtman, R. J.:
3Rapid Accumulation 6f H _ serotonin in Brains of Rats Receiving
Intraperitoneal H^-tryptophan: Effects of 5, 6-di-hydroxytryptaxaine
or Female Sex Hormones. J. Neural Transm., vol. 34, 1973, pp. 111-124.
6-44. Sokal, Robert R.; and Rohlf, F. James: Biometry; The Principles and
Practice of Statistics in Biological Research. W. H. Freeman and
Company, San Francisco, 1969.
6-45. Fernstrom, John D.; and Wurtman, : Richard J.: Brain Serotonin Content:
Increase Following Ingestion 
of 
-Carbohydrate Diet. Science, vol. 174,
no. 4013, 1971, pp. 1023-1025.
6-46. Rapoport, Morton I.; Feigin, Ralph D.^ Bruton, Joseph; and Beisel,
William R.: Circddian Rhythm for Tryptophan Pyrrolase Activity and
its Circulating Substrate. Science, vol. 153, no. 3744, Sept. 1966,
pp. 1642-1644.
T
6-19
ia
6-47. Wurtman, Richard J.; Rose, Christopher M.; Chou, Chuan; and Larin,
Frances F..:	 Daily Rhythms in the Concentrations of Various Amino
- Acids in Human Plasma.	 New Engl. J. Med., vol. 279, no. 4, July
1968, pp. 171-175.
6-48. Fernstrom, John D.; Larin, Frances; and Wurtman, Richard J.: 	 Daily
Variations in the Concentrations of Individual Amino Acids in Rat
3
Plasma.	 Life Sci., vol. 10, pt. I, no. 14, July 1971, pp. 813-819•
+	 l
6-49. Denckla, W. D.; and Dewey, Henry K.: 	 The Determination of Tryptophan
in Plasma, Liver, and Urine. 	 J. Lab. Clin. Med., vol. 69, no. 1, }`
Jan. 1967, pp. 160-1.69.
6-50. Fernstrom, John D.	 and Wurtman, Richard J.:	 Brain Serotonin Content:
Physiological Regulation by Plasma Neutral Amino Acids. 	 Science, vol.
178, no. 4059, Oct. 1972, pp. 414-416.
! 6-51. McMenamy, Rapier H.; and Oncley, J. L.: 	 The Specific Binding of
L-tryptophan to Serum Albumin.	 J. Biol. Chem., vol-233, no. 6,
Dec. 1958, pp. 1436-1447.
6-52. Tagliamonte, A.; Biggio, G.; Vargiu, L.; and Gessa, G. L.: 	 Free Tryp-
to han in Serum Controls Brain Tryptophan Level and Serotonin..S n-P y `.
thesis.	 Life Sci., vol. 12, Mar. 1973, pp. 277-287.
6-53. Waalkes, T. P.; and Udenfriend, S. A.: 	 Fluorometric Method for Estima-
tion of Tyrosine in Plasma and Tissue. 	 J. Lab. & Clin. Med., vol. 50,
1957,'Pp• 733-736. a
6-54. McCaman, M. W. ;'and Robins, E.:	 Fluorometric Method for Determination
of Phenylalanine'in Serum.	 J. Lab. Clin. Med., vol. 59, May 1962,
pp. 885-890:.
6-55. Fernstrom, J. D.; Larin, F.; and Wurtman, R. J.: 	 Correlations Between
Brain Tryptophan and Plasma Neutral Amino Acid Levels Following ,Food
I
f
j
Consumption in Rats. 	 Life Sci., vol. 13, 1973, pp. 517-524•
,a
I	 II t
4
6-20
a
J
Af
TABLE 6-I.- COMPARISON OF 5-HT, TRYPTOPHANI, AND 5-HIAA CONTENT IN EXPERIMENTAL
ANIMALS INJECTED INTRAVENTRICULARLY WITH 5 u g OF TRYPTOPHAN VERSUS CONTROL
ANIMALS INJECTED WITH SALINE
	
A
i
E
5
K
t
Time Treatment 5-HT,
+
Tryptophan, 5-HIAA,
±after group ug/g SE ug/g ± SE Ng/g	 SE
infection, min (a) (c) "(c) - (c)
_.Cerebral cortex
15 C 0.186 ± 0.030 (5) 2.70 ±_0.25,(6) 0.342 ± 0.009 (61
E .230 ± .029 (7) x3.62 ±	 .31 (6) e . 398 ±	 .012 (6)
30 C _ 0.246 ± 0.034 (7) 3.30 ± 0.21 (7) 0.334 + 0.017 (7)
E' .263 ± .022 (7) 3.45 +	 .21,(5) 3.386 ±	 .015 (6)
60 C 0.233 ± 0.024 (7) 3.56 ±_Q.19 (6) 0.367 ± 0.016 (7)
E .265 ± .035 (7) 3.54 ±	 .09 (5) .379 ±	 .013 (7)
120 C 0.276 ± 0.028 (6) 2.98 ± o.2o (4) 0.319 + o.ol6 (6)
E .220 + .029 (6) 2.91 ±	 .24 (6) x.382 ±	 .020 (5)
180 C 0.277 + 0.,023 (6) 2.92 ± 0.25 (5) 0.341 ± 0.012 (6)
E .232_± .019 (6) 3.00 ±	 .06 (6) .334 +	 .007 (6)
Brainstem
15 C 0.717 ± 0.023 (7) 4.08 ± 0.23 (7) 0.766 ± 0.032 (6)
- E .766 ± .o62 (6) 400 ±	 .18 (6) d. 923 ±	 .033 (5)-
30 C 0.719 ± 0.080 (7) 3.97 ± 0.21 (7) 0.849 ± 0.057 (6)
E .729 ± .064 (7) 4.26 ±	 .27 (7) •945 ±	 •o45'(7)
60 C o.654 ± 0.039 (7) 4.23 ± 0.23 (7) 0.880 ± 0.031 (6)
E :,7o6 ± .074 (7) 4.37 ±	 .20 (7) .918 ±	 .054 (7)
120 C 0.602 ± 0.077 (5) 3.78 ± 0.25 (5) 0.894 ± 0.033 (5)'
E	 '' -714 .036 (6) 3.73 ±	 .27 (6) .922 ±	 .065 (6)
180 C o.68o ± 0.079 (6)` 3.89 ± 0.20 (6) 0.929 + o.o64 (6)
E .707 ± .030 (6); 3.65 ±	 .13 (6) ;822 ±	 .038 (6)
If^
F
^k
i
f
i
Time
Treatment
5-HT, Tryptophan, 5-HIAA,
after ug/g ± SE ug/8 ± SE ug/g ± SE
injection, min group (a) (a) (a)
Right cerebral cortex
15 C 0.363 ± 0.021 (8) 4.41 ± 0.21 (7) 0.332 t 0.030 (8)
E .392 ±	 .016 (11) 4-.46 ± .16 (9) .292 ± .017 (11)
30 C 0.392 + 0.027 (8) 4.55 ± 0.20 (7) 0.324 ± O.Oo9 (8)
E .386 ±	 .016 (8) 4.55 ± .o6 (8) .332 ± -.o16 (8)
60 C 0.404 ± 0.012 (8) 4.19 ± 0.13'(8) 0.309 # 0.019 (8)
E .4o9 +	 .005 (8) 4.41 ± .22 (8) .309± ._019 (8)
Left cerebral cortex
15 C 0.323'± 0.031 (3) 4.43 ± 0.12 (8) 0.379'± 0.016 (8)
E .328 ±	 ,023 (11) 4.31 ± .09 (9) .342 ± .022 (10)
30 C 0.307 ± 0.040 (7) 4.4`4 ± 0.17 (8) 0.357 ± 0.014 (6)
E .336 ±	 .033 (8) 4.69,± .19 (7) .378 ±- .024 (8)
60 C 0,313 ± 0.041 (8) 4.48 + 0.10 (7) 0.353 ± 0.019 (8)..
E
.297 ±	 .037 (7) 4.67 ± .25 (8) •356 ± .020 (7)`
Brainstem
15 C 0.106 ± 0.122 (5) 3.96 ± 0.13 (8) 0.619 ± 0.020 (8)
E .958 ±	 .113 (8) b4.62 ± .16 (11) .669 ± .021 (10)
30 C 0.786 ± 0.087 (6) !4.48 ± 0.21`(8) 6.704± 0.019 (8)
E .785 ±	 .082 (7) 4.42 + ..09 .(8) .674 ± .024 (7)
60 C. 0.836 ± 0.063 (8) 4.32 t- 6.14 (8) 0.641 ± 0.017 (8)
E .877 ±	 .074 (7) _•_4.38 ± .17 (8) .683'± .035 (8)
ti
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TABLE 6-II.- COMPARISON OF 5-HT, TRYPTOPHAN, AND 5-HIAA CONTENT IN EXPERIMENTAL
i, ANIMALS INJECTED INTRAVENTRICULARLY WITH 6 ug (50 MICROCURIES) OF 3H TRYPTOPHAN
VERSUS CONTROL ANIMALS INJECTED WITH SALINE
i,
Fr-
h
4
G
a
G
i
N
r.	 tx
t,
Time
after , Blood serum, 5-HT, Tryptophan, 5-HIAA
injection,
aDPMjml ± SE DPM/nmole ± SE DPM/nmole + SE DPM/nmole + SE
min
Right cerebral cortex
15 1291.8 ±118.2 x 10 3 412.8 ± 52.1 x 103 48.6 ± 9.8 x 103 _. 14.0 + 1.7 x 103
30	 -- 821.4 ± 60.0 296.6 ± 4o.2 11.4 ± 2.7 9.9 ± 1.8
60	
1
411.8 ±! 69.4 230.6 ± 34.0 5,7 ± ,8 -- lo. i ± 1.6
Left cerebral cortex
15 1291.8 ± 118..2 x 103 290.0 ± 27.0 x 103 35.1 ± 15.8 x 103 8. 1 + 1.3 x.103
30 821.4 + .6o.o 265.9 ± 31.9 7.0 ± 1. 7 7.0 ± 1.5
6o 411.8 ± 69.4 345. 1 ± 55.6 3.3 ± . 5 8.1 ± 1,5
Brainstem
15 1291.8 +'118.2 x 103 224.8 ± 47.7 x 103 30.6 ± 5.3 x 103 30.2 ± 5. 4 x 103
30 821.4 ± 60.0 294.9 ± 37.8 14.9 ± .9 33.4 ± 2.6
60 230.4 + 29.1 230.4 ± 29.1 8.3 ± .$ 24.5 ± 1.8
3
f^
7
1
7j
Cj a'DPM	 Disintegrations per minute.rn
ti
}
a
a„i
N1
k
y.
i
}
f
t
s^
	 f
E
E'
i
Correlation Percentage of 5-HIAA Statistical Statistical
Brain area Injection coefficient (r) due to significance significances(a) regression
(b)
of r of regression
Experiment 1
Cerebral cortex Tryptophan 0.488 (29) 24.0 p < 0.05 p < 0.01
Saline .145 (30) 2.0 NS NS
Brainstem Tryptophan 0.282 (31) 8.0 NS NS
Saline .381 (32) 15.0 p < .05 p < •02
Experiment 2
Right cerebral cortex Tryptophan 0.670 (24) 45.0 p < 0.001 p < 0..001
Saline .412 (22) 17.0 ?uS NS
Left cerebral cortex Tryptophan 0.686 (22) 47.0 p < 0.001 p < 0.001
Saline .091 (22) 1.0 NS NS
Brainstem. Tryptophan 0.263 (26) 7.0 NS NS
Saline .052 (24) .3 NS NS
NPhase of lighting Total nunber Percentage of Statistical
regime of determinations total consumption -,± SE
significance
(a)mean
Light 42 12 t 2 p < 0.001
Dark 42 88 t 2 P < 0.001
r{t	 j
d
Animal group Number of
animals Weight, _g ± SE
Statistical
a
significance
Control 30 21.7 ± 0.44 NS
Experimental 30 22.5;±	 .40 NS
r
I
Ek
S1
^
rg
^
p
Parameter Brain area Treatment
group
Correlation
coefficient (r)
Percent of change;
Y due to X_ - -
Significance
of r
Significance
 ,_Of
regression
Correlations between parameters in brain
Brain tryptophan
compared with
S-HIAA
Cerebral
cortex
C
E
0.496
.474
24.6
22.5
p < 0.005
p < -.005
p < 0.005
p <
	 .005
Brainstem C
E '
0;.532
. 564
28.3
31.8
p < 0.005
P <	 .005
p < 0.005
p <	 .005
Brain tryptophan
compared with
5-HT'
Cerebral
cortex
C
E
0.056
.014
0.3
0.0
NS
NS	 -
NS
NS
Brainstem C
E
0.557 -
.494
31.0
24.4
p < 0.01
p <	 01
p < 0.01
p <	 .01
Correlations between parameters in plasma and in brain
Plasma free tryptophan
compared with 5-HIAA
Cerebral
cortex
C
E
0.367
,044
13.5
.2
p < 0.05
NS
p < 0.05
NS
Brainstem C 0.119 1.4 NS NS
E .033 ,l NS NS
Plasma free tryptophan
compared with-5-HT
Cerebral
cortex
C
E
0.068
.200
0.5
4.0
NS
NS
NS
NS
Brainstem C
E
0.562
.252
31.5
6. 3
p < 0.01
NS
p < 0.01
NS
I{^
[, 4
k^E
^^ a
t
i
#n 	 n	 u	 ^r n
The ercent changey _ in Y due to X was d
sion --0 -and the correlation coefficient= 0 was tested by t test (ref. 6-44).i j	 perk t 	 	 that w red
etermined by squaring the: correlation coefficient (ref. 6-44).
e
y	 Z
r
Parameter Brain area- - Treatment--	 -group
Correlation
coefficient (r)
Percent of change
Y due to X
Significance
of r
Significance
of
regression
Plasma tryptophan/tyrosine + Cerebral C 0.223 5.0 NS	 -- NS
phenylalanine compared, cortex E .090 _.._..	 .8 NS NS
with 5-HIAA
Brainstem C 0.139 1.9 NS	
_
NS
E .166 2.8 NS NS
Plasma tryptophan/tyrosine + Cerebral C 0.086 0.7 NS NS	 -
phenylalanine compared- cortex E .139 1.9 NS NS
with 5-HT
Brainstem C 0.193 3.7 NS NS
E
.123 1.5 NS NS
Free tryptophan compared Cerebral C 0.008 0.0 NS NS
with brain tryptophan cortex E .029 .1 NS NS
'Brainstem -C 0.330 10.9 NS NS
E .157 2.5_ NS NS
Plasma tryptophan/tyrosine + Cerebral C 0.009 0.0 NS NS
phenylalanine compared cortex E .118 ' 1.4 NS NS
with brain tryptophan
Brainstem C' 0.192 3.7 NS NS
i
y
`s
t
M
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TABLE 6-VIII.— COMPARISON OF BRAIN TRYPTOPHAN, 5-HT, AND 5-HIA.A IN THE
'	 BRAINS OF CONTROL, STARVED, AND REFED HAMSTERSa
F
s^
a^
r;5
Brain Brain Brain
Treatment tryptophan, 5-HT, 5-HIAA
group ug/g + SE ug/8 ± SE ug/g + SE(b) (b) (b)
C6ntrol 3.18 ± 0.42 (24) 0.318 ± 0.01 (24) 0.226 ± 0.02 (24)
Starved 03. 96 ±	
-54A23) .309 ±-	 .02 (22) c.363* t	 .02 (23)'
Refed 04.07 +	 .15 (24)- .283 +	 .01 (23) 342,±	 .02 (24)
Treatment Body weight, Brain Brain Brain
g ± SE
tryptophan, ,
-5-HT, _ 5-HIAA
group
(b) ug
/g ± SE ug/g ± S-E ug/g + SE(b) (b) (b)
Control 116 ± 1 (24) 2.95 ± 0.05 ( 24) 0.526 + 0.02 (24) 0.242 ± 0.01 ( 24)
Starved 103 + 2 (24) 2.96 +	 .10 (24), .474 +	 .02 (24) d^292 ±	 .01 (23)
Refed X 103 t 1 (24) 02.61 ±	 .09 (24) .514 ±	 .02 (24) x .305 ±	 .01 (24)
sx
t
k,
G
F
#I
i
Bw ^ 	...... _ ............._..,^.-...,,..., m.......1 ,.,_.^..., ^_v„ 	 ^,.......,:,...._^.....t....E_...R. ^, a	 a........._,...., .. _..^.t,.__. 	 .^, .,.,. , .,.^_k ......	 -	 ^nd.,;a,. ,.. ,. 	 .j^.s,^.b:^.	 — e -^= l^m.^.i:..+.,. 	 _.^...._..^
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TABLE 6-X.- THE RATIO OF PLASMA TRYPTOPHAN TO TYROSINE IN CONTROL, STARVED,
t	 AND REFED HAMSTERS
f
I^
i
I ^^s
F
.S^
Treatment
group
Ratio of plasma tryptophan to tyrosine, after -
0 hr, 1 hr, 2 hr, 3 hr,
u'g/$ ± SE ug/g ± SE F►g/g ± SE ug/g ± SE
Control 2.o6 ± 0..17 a2.44 ± 0.10 1.70 t 0.09 1.84 ± 0.09
Re'
-
fed 1.83 ±'	 .18 b ' al.11 ±	 .07 ^'a1.22 ±	 .09 1.74 ±	 .17
Starved x1..57 +	 .11 b .99 ±	 .12 b .98 ±	 .03 b 'e .76 ±	 .12
I'	 9
i
{
!
aLevel of significance of that time period value from the values of
;:
other time periods in the same treatment group; p < 0.005.
bLevel of significance from control group; p < 0.001.
Level of significance from control group; p < 0.005.
' dLevel of significance of that time period value from the values of
other time periods in the same treatment group; p < 0.001. `=
1. eLevel of significance of the starved value from the refed value;
p < 0.001. V
f
I
^.
i
a
OTT
I
"+	 E 6-31 ^.
Time after Brain Brain BrainTreatment
re feeding, tryptophan, 5-HT, 5-HIAA,group hr Pg/g ± BE pg/ g ± BE ug/g ± BE(a) (a) (a)
Initial study
Control 0 4.34 0.14 (8) 0.640 ± 0.032 (8) 0.284 ± 0.013 (7)
3 4.18*± o6 (8) .635 ±	 .029 (t) -257 ±	 .013 (7)
Starved 0 b,c 5.34 ± 0.22 (8) 0-551 ± 0.023 (8) 0.274 ± 0.007 (8)
3 d,e4.78 ±	 .37 (81 ) .589 ±	 ol6 (7) f c., ^. 368 ±	 .028 (8)
Refed 0 b,c 5.18 ± 0.28 (6) 0.640 ± 0.024 (7) 0.295 ± 0.037 (8)
3 d,c 3.90 ±	 .37 (7) .601 ±	 .030 (8) f,c 353 ±	 -031 (8)
Repeat study
Control 0 3.43 ± 0.15 (8) 0.466 ± 0.015 (8) 0.239 ± 0.007 (8)
3 3.46 ±	 .07 (7) .532 ±	 .033 (7) .234 ±	 .020 (7)
Starved 0 3.67 ± 0.20 (8) 0.498 ± 0.030 (8) 0.265 ± 0-017 (8)
3 3.68 ±	 .25 (8) .518 ±	 o4o (8) .248 ±	 oil (8)
Refed 0- 3.69 ± 0.30 (8) 0.513 ± 0.030 (8) 0.270 ± 0.011 (8)
3 3.49 ±	 .13 (8),' -, .530 ±	 .024 (8) .253 ±	 .013 (7)
TABLE 6-xi.- COMPARISON OF BRAIN TRYPTOPHAN, 5-HT, AND 5-HIAA IN CONTROL,
STARVED, AND REFED HAMSTERS
Ratio of plasma trypt9phan to
-,
tyrosine plus phenylalanine, afterTreatment
0 hr, pg/g	 SE	
-T 3 hr, pg/g	 SEgroup
Initial study
Control 0.811 ± 0.042. 0.886 ± 0.037
Starved .832 ±
	
1093 .944 ±	 046
Refed a.419 ±	 .035 a .609 ±	 026
Repeat study
Control 0.646	 0.010 0.672	 0.014
'Starved a,b 529	 -024 .780	 065
Refed 8.332	 -007 453	 008
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i Figure 6-1.- Comparison of daily rhythmic changes in the content of serotonin
! in the cerebral cortex of Balb/C mice (experiment 1) and AJAX mice (experi-
ment 2).	 Brackets represent mean ± standard error (SE); black bars represent
dark phase of lighting regime,
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Figure 6-2.- Comparison of daily rhythmic changes in the content of 5-HIAA in
the cerebral - cortex of Balb /C mice ( experiment 1) and AJAX mice ( experiments
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Figure 6-5, Effect of a controlled feeding regime on the diurnal variation of
`-	 }-- tryptophan content in the mouse brain. 	 Brackets represent mean ± SE; black
bars represent dark phase of lighting regime.
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Figure 6-6.- Effect of a controlled feeding regime on the diurnal variation of
serotonin content in the mouse brain.
	 Brackets represent mean ± SE; black
bars represent dark phase of lighting regime.
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Figure 6-9.- Circadian changes in the ratio of 5-HTAA to 5-HT in the brainstem
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7. THE ROLE OF BRAIN BIOGENIC AMINES IN THE CONTROL
OF PITUITARY-ADRENOCORTICAL ACTIVITY
By Roger P. Maickel, Ph. D. {
INTRODUCTION	 J,
Pretreatment of rats with the monoamine oxidase (MAO) inhibitor pargyline
prevents the metabolic destruction of 5-hydroxytryptamine (5-HT) and
norepinephrine released in the brain by a subsequent dose of reserpine, and
high levels of the amines remain in the brain.
	
Under these conditions, the
hypersecretion of adrenocorticotropic hormone (ACTH) usually evoked by
reserpine does not occur.
	
The elevated levels of brain 5-HT and norepinephrine
produced by MAO inhibition do not cause ACTH hypersecretion nor do they prevent
the ACTH hypersecretion caused by exposure to cold or by administration of l
z -sedative doses of chlorpromazine.
Previous reports have indicated that sedative doses of reserpine evoke
a hypersecretion of ACTH in rats, similar to that produced by exposure to low
environmental temperatures (refs. 7-1 and 7-2).	 The characteristic response
includes decreased adrenal ascorbic acid and increased, plasma corticosterone,
liver tryptophan pyrrolase (TPO), and adrenal gland weight. 	 Similar- effects
were produced in rats by sedative doses of the Rauwolfia alkaloids, raunescine
and rescinnamine, the reserpine analogue syrosingopine, or the. benzoquinolizine
Ro 4-1284 (2-hydroxy-2-ethyl- 3-isobutyl-9, 10-dimethoxy-1,2,-3,6,7-hexahydro-
?	 beazo(a)quinolizine). 	 In contrast, isoreserpine, the pharmacologically inac-
tive stereoisomer of reserpine, failed to evoke a pituitary-adrenal res onse.`z'P	 ^	 P	 Y-	 p
The ACTH hypersecretion evoked by -reserpine was shown to be independent
of the sedation caused by the drug (ref. 7-3)•	 For example, pretreatment of
animals with-desmethylimipramine antagonized the reserpine-induced sedationf	 _
without, preventing the decline An brain amines or the hypersecretion of ACTH.
This 'report explores the antagonism of reserpine-induced ACTH hypersecretion
by the MAO! inhibitor,pargyline (MO 911, N'-methyl-N-benzyl-2-propynylamine).-
Evidence is presented that this antagon' is, in is related to the level of brain
biogenic amines_ maintained during the course of action of the drug. 	 Pretreat
ment with MAO inhibitors does not affect `the ACTH hypersecretion evoked by ex-
to cold or chlorpromazine, lending further support to the hypothesis
that reserpine-induced ACTH hypersecretion is related to brain amine changes.
it
posure
7-1
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MATERIALS AND METHODSY
a
Experimental procedures were performed with unanesthetized adult male
-Sprague-Dawley rats that weighed 250 to 300 grams.
	 The animals were allowed 5
food and water ad libitum and maintained as previously described (ref. 7-1).
t Reserpine, as the lyophilized phosphate,salt, was dissolved in 0.5 milliliter
of water and injected into the tail vein. 	 Chlorpromazine,pargyline, and Ro 4-
1284 were dissolved in distilled water'and injected intraperitoneally.
	 Control
animals were injected with saline or distilled water..
	 Animals were stunned and
then immediately decapitated.
	 Blood was collected in beakers containing hepar-
in, transferred to tubes, and centrifuged immediately.
	 Plasma samples for cor-
ticosterone assay were stored at 263.15 K (-10° C).
	
For the assay of liver
TPO, adrenal ascorbic acid, and brain 5-HT, norepinephrine, and MAO, tissues
were removed and stored at 263.15 K (-10
	 C). 3
Chemical Methods
The level of adrenal ascorbic acid was determined by the Maickel method
(ref. 7-4); plasma corticosterone levels were determined by the Guillemin meth-
f^ od (ref. 7-5); the level of liver TPO was determined by the Knox method (7-6);
, 1 amounts of brain 5-HT and norepinephrine were determined by the method of a
Maickel et al (ref. 7-7); and the amount of brain MAO activity was established
w by the method of Weissbach et al.(ref. 7-8).
„ Parameters of Pituitary-Adrenal Stimulation
t The following indices of pituitary-adrenal stimulation were measured:	 a
fall in the level of adrenal ascorbic acid, a rise in the level of plasma _cor-
ticosterone, and an increased activity of liver TPO. 	 The limitations and ad-
vantages of each of these indices have been discussed in a previous paper
(ref. 7-1).	 In some experiments, the changes in plasma corticosterone`levels
were used as the sole index of pituitary-adrenal hyperactivity._
RESULTS ?3
Effects of Pargyline-on Brain Levels of 5-HT and Norepinephrine
on Pituitary-Adrenal System
The administration of a single dose of pargyline (25 mg/kg, intraperitone-
ally) or two doses 18 hours apart did not affect the levels of adrenal ascorbic
_	 c acid, plasma`corticosterone, or liver TPO (table 7-I).
	 Brain levels of 5-HT
and norepinephrine were markedly increased, and brain MAO activity was more
' than 95 percent inhibited.
	 The extent of MAO activity was determined by the
method of Weissbach et al. (ref 7-8).
i
7-2
$' H
- Effects of Pretreatment With Pargyline on
Reserpine-Induced ACTH Hypersecretion
In a previous report, the pretreatment of rats with pargyline was deter-
t mined to have prevented both the sedation and the ACTH hypersecretion induced
1}j by reserpine (ref. 7-3).
	
The results in table 7-II show that administration of
reserpine to rats pretreated with pargyline (25 _mg/kg, intraperitoneally) A
caused little change in brain 5-HT and_norepinephrine levels in 6 hours.	 The
f' animals did not show the sedation characteristic of reserpine, and there was no
evidence of ACTH hypersecretion.
x	 3^' When rats were pretreated with smaller doses of pargyline, the subsequent;
ai
administration of reserpine produced a variety of results (table 7-III). 	 In
` some animals (group 1), MAO inhibition was not sufficient to prevent the imme-
diate metabolism of the amines released by reserpine.	 These animals became
' deeply sedated in 3 hours.- At that time, brain levels of 5-HT and nor
epinephrine had fallen markedly, and there was a pronounced hypersecretion of
ACTH.	 In other animals (group 2), the MAO inhibitor was only partially effec-
tive in protecting the released amines; in such animals, the sedative action
,^` of reserpine was delayed.	 In the second group, sedation was apparent in 6
`? hours; however, the brain levels of 5-HT and norepinephrine had not fallen to
? minimal values, and no ACTH hypersecretion was observed. 	 Finally, a third
group of animals was observed in which the MAO inhibitor protected most of the
released amines from destruction; 6 hours after doses of reserpine, the ani-
mals showed only a slight sign of sedation. 	 In--this -third group of animals,
reserpine had no significant effect on pituitary-adrenocortical activity.
' Dose-Response Relationship of Pargyline Antagonism
of Reserpine-Induced ACTH Hypersecretion
Previous papers have shown that a number of compounds similar to reserpine
lower brain amine levels and cause ACTH hypersecretion in rats ('refs. 7-1 and
7-2).
	
One striking similarity in these data is that levels of amines in the
brain must be depleted below 50 percent of the normal level in order to observeP
hypersecretion of ACTH. When rats pretreated with varying doses of pargyline
were	 i	 es animals in which the level of brain aminesg ven r erpine,^
 onlg	 P	 y those 
fell below 50 percent of that in the control animals showed ACTH hypersecretion
(table 7-IV).	 If the dose of pargyline was sufficient, to protect the reser-
pine-released amines to the extent that the levels of 5-HT did not fall to val-
ues below 50 percent of normal, there was no measurable pituitary-adrenal stim-
ulation.
ir,
Lack of Effect of Pargyline Pretreatment on ACTH
Hypersecretion Induced by Other Stressful Stimuli
Previous reports from the Endocrine Laboratory of the Lyndon B. Johnson
Space Center have described the ACTH hypersecretion evoked by exposure to cold
or administration of chlorpromazine (refs. 7-1 and 7-9). 	 Pretreatment of rats
4 with pargyline had no effect on the ACTH hypersecretion induced by exposure to
7-3
G
J
W
ra
}	 cold or chlorpromazine (table 7-V).	 This absence of effect is in striking
contrast to the antagonism of reserpine action produced by pargyline and lends
further weight to the hypothesis that the action of reserpine on the pituitary-
adrenocortical system is mediated through an effect of the drug on brain
amines.
DISCUSSION
The studies presented in this paper further support the hypothesis that ^X
the ACTH hypersecretion caused by reserpine and drugs similar to reserpine is
related to the effects of the drugs on the storage of MAO in the brain., A pre-
vious paper (ref. 7-2) noted that these drugs, produce ACTH hypersecretion only
when givenin doses that lower the amine stores below 50 percent of normal, re-
' gardless of whether this:lowering effect was achieved by administration of a
single large dose or-repeated smaller doses. 	 In animals pretreated with pargy-
line (in doses that block brain MAO activity by 95 percent), administration of
reserpine does not lower the level of brain amines_. 	 Although reserpine impairs
the storage of 5-HT and notepinephrine, the liberated amines are protected fromw
the degradative action of MAO; because of their poor lipid solubility, the
amines can diffuse across the blood brain barrier into the bloodstream only
very slowly.	 Thus, high levels of free amines remain in the brain for a long
period of time. .:.
The relationship of pituitary-adrenal hyperactivity to depletionof brain
amines to values below 50 percent of normal, !first noted with reserpine alone, ^_	 ...
has also beenobserved in pargyline-treated animals. 	 The !possible significance
p immediate ly ;apparent.	 In the-rat, the whole brain..of this relationshi
	
s not 
is used for the determination of 5-HT and norepinephrine; the assay method mea-r
sures the amines as if they were uniformly distributed throughout the entire
brain.
	
Perhaps this level of amines in a brain homogenate is equivalent to a
complete depletion of the amines in one or more specific areas of the brain, or
perhaps this amine level is- related to an imbalance of amines and, consequently,
to neural function in some specific neuronal circuits.
The observation that pretreatment of rats with an MAO inhibitor does not
prevent the stimulatory effects of exposure to cold temperatures or chlorpro-
mazine on 'the pituitary-adrenal axis may also suggest that the hypersecretion
° of ACTH evoked by reserpine is caused by interference with storage processes
for brain biogenic amines,
i
i
F
r
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Group No. of
animals
Adrenal
ascorbic
acid,
Plasma
corticosterone,
lig/mi
Liver TPO,
Umole/g liver/hr
Brain amine
5-HT, Norepinephrine,
mg/100 9 pg/g pg/g
Control 20 447
	
41 0.15	 0.05 3.2	 0.36 0.45	 0.04 o.46 f 0.04
Pargyline- 13 451	 40 .16	 .05 -2.9 -M	 .38 c.69	 06 c.60	 04
(one dose)
Pargy1ine 15 453 t 46 .19	 o4 3.0	 .27 C.80	 .06 c 72	 -07
two doses 18
b
hours apart)
Group
No.
of
Plasma
corticosterone,
Brain amine
Sedation5-HT, Norepinephrine,
animals Ug/ml
u g /g ug/B'
Control 20 0.15 ± 0.05 0.45	 ±'0.04 0.46 ± 0.04 --
Pargyline 15 :19 ±	 .04 b.80 ± ,06 b.72 ± .07 No
Reserpine 11 b.44 ±•.04 b.08 ± .02 b.07 ± .03 Yes
Pargyline and 9 .12 t	 .03 b.76 ± .03 .55	 ±	 .05 No
reserpine
Group
No.
of
Sedation Plasma
corticosterone,
Brain amine
3 hours after 6 hours 'after -5-HT, Norepinephrine,animals ug/mlreserpine reserpine ug/g ug/g
Control 20, -- -- 0.15 + 0.05 o.-45 ±.0.04 0.46 ± 0.04
Pargyline 6 -- .16 + .03
b
.62 ± .03 b.57 ± .04
Reserpine 11 Deep Deep b.44 ! .04 b.08 t .02 b.07 ± .03
Bargyline and
C
reserpine
Group 1 10 Deep Deep b.39 + .03 b.20 ± .03 b.19 ± .04
Group, 2 10 Slight Deep .18 ± .05 .40 ± .03 b.34 ± .03
Group 3 11 None Slight .17 ± .05 .53 + .03 .45 ± .05
fF'
F
w
a t
$Animals were given a single intraperitoneal dose of pargyline (18-mg/kg) 18 hours before an intra
ventricular administration of reserpine (l, mg /kg), and all animals were killed 6 hours after injections
of reserpine were administered.
bValue is significantly different from control (p < 0.05)•
`
	
	 cGroups were selected by visual observation of degree of sedation at 3 hours after injection of
reserpine.
r,....._. . 	 s.
No.
of
animals
Pargyline,
mg,/kg
ReserpineD
mg/kg
Plasma
corticosterone,
Jig/ml
5-HT,
Lig/g
Norepinephrine,
Wg/g Sedation
20 -- 0.15 ± 0.05 o.45 ± 0.04 o.46 ± 0.04
6 10 -- .14 ± .03
b
58 ± .03
b
50 ± .02
6 10 1 b 37 ± .03 21 ± .02 b 16 ± .02 Yes
13 25 -- -13 ± .03 b. 69 ' + 	 04 b .60 ± .02
9 25 1 .15	 04 •57 b.494 	 .03 No
15 c25 .14 ±	 o4 b .80 ±	 06 b 72	 .07
9 C25 1 .12 ± .03 b 76 ± .03 b 55	 .05 No
ij
aReserpine was administered intraventricularly 18 hours after intraperitoneal injection of
pargyline; animals, were l killed ,6 hours after reserpine injections.
b:Value is significantly different from control (p < 0.05)•
CAdministered for 2 days.
Group
No.
of
animals
Plasma
corticosterone,
jig/ml
Control 20 0-15 ± 0.05
Control (chlorpromiazine)- 10 39 ±	 ,o4
Pargyline 15 .14	 o4
Pargyline (exposed to cold) 13 . 40	 .03
`
'
`
'
e'I.-(.
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8.	 STUDIES OF ACID-BASE HOMEOSTASIS DURING SIMULATED WEIGHTLESSNESS:
APPLICATION OF THE WATER IMMERSION MODEL TO MAN
By Murray Epstein, M.D.
;t
INTRODUCTION
Previous reports from the author's laboratory at the University of Miami
School of Medicine have proposed the use of a model of water immersion as an
investigative tool for studying the circulatorymechanisms of plasma volume
control and sodium homeostasis during weightlessness (refs. 8-1 to 8-3).
These studies have demonstrated that the redistribution of blood volume that
"headaccompanies	 out" water immersion (to the neck) results in a significant
i and,,reproducible natriuresis and a suppression of the renin-aldosterone system
k (refs.,8-1 and 8-3).
	 Since volume expansion is known to decrease bicarbonate
reabsorption in the proximal tubule (ref. 8-4), and since aldosterone deficiency
_ impairs distal hydrogen secretion (ref. 8-5), it was anticipated that water
^-- immersion would exert significanteffects on acid-base homeostasis.
	 This study
was undertaken to assess the effects of water immersion on acid-base homeostasis
under carefully controlled conditions.
DISCUSSION
Studies of renal acidification were carried out on seven healthy male
E
Y
subjects, each consuming a diet containing 150 meq sodium and 100 meq potassium.
Control andimmersion studies were carried out on each subject on the fourth
and sixth days, respectively, of dietary equilibration, by which time all
_ subjects had achieved sodium balance.
	 The experimental protocols on study days i
i were similar (except for the amount of water administered) and were carried out
as described in the following paragraphs.
Following 10 hours of overnight dehydration, the subject was awakened at
0700 and instructed to sit quietly for l hour.
	 Beginning at 0730, an oral water_
load totaling 800 milliliters was administered during control. 	 Since water -
immersion predictably induces a diuresis (ref. 8-2), the water load was omitted
during immersion in the present study to match the urine flow rates during
control and immersion, thereby obviating the effect of increased urine flow on
urinary pH (ref. 8-6).
	 At 0800, venous blood was drawn for the determination of
serum electrolytes, creatinine, plasma hematocrit, pH, and partial pressure of
-carbon dioxide (pC0`).
	 The venous sample was obtained in the following manner.2
Blood for electrolyte determinations was first drawn into a 20-milliliter
8-1
r
^I
syringe, the tourniquet was released immediately and without stasis, and a
J 2-milliliter heparinized syringe was transferred to the needle for aspiration of
the sample for pH and pCO2 determinations. After completely emptying his a
bladder, the subject again assumed a seated position for 6 hours (0800 to 1400).
During control, the subject sat quietly outside the immersion tank for the
6-hour period.	 During immersion, the subject sat in the study tank immersed in P'
water to the neck for 5 hours (0900 to 1400), preceded by 1 hour of quiet
11
	 'I	 sitting outside the tank (prestudy immersion hour).ff
_ I	
Each subject voided spontaneously at hourly intervals during the study.
During immersion, the subject stood briefly on a platform in the immersion tank
to void.	 All urine samples were collected under mineral oil.
' !	 To maintain an adequate urine flow during control, 150 milliliters of water
were administered orally every hour.. Sodium, potassium, and creatinine were
measured in aliquots of the hourly;urine collections. 	 Blood was collected at
the midpoint and end of each study.	 All subjects were weighed every morning
at 0700 after voiding, and before and after each study.
I
Immersion was carried out in a waterproof tank described in detail in
- -F-	 reference 8-2.	 A constant water temperature of 307.15 ± 0.5 K (34 t 0.5° C) was
maintained by two heat exchangers with a combined output of 4 kilowatts
3
(13 500 Btu/hr), controlled by an adjustable temperature-calibrated control
meter, with input derived from two thermistors immersed at different water
levels.
j
Blood and urine pH and pCO2 were measured within 5 minutes of collection
on a Radiometer Acid-Base cart ABC-1. 	 Ammonium was measured by the method of
Seligson (ref. 8-7); titratable acidity was measured by titrating the urine to
blood pH with 0.1 N sodium hydroxide using a`Radiometer Automatic Titrator,
Type TTTllb.	 Blood bicarbonate concentration was calculated from the
I
Henderson-Hasselbalch equation, assuming a pKa of 6.10 and a solubility
coefficient of 0.0301; urine values were calculated similarly, using a pK	 of.'
a a
(6.33 -'0.5'^	 (ref. 8-8) and a solubility coefficient of 0. 0309.	 Net acid
excretion was calculated as the sum of "ammonium (NH 4 ) and titratable acid (TA),
1
less bicarbonate (HCO3 	 excretions:
Net acid excretion = UNH V + UTAV - uHCO V
4	 3
The effects of 5 hours of water immersion on ao1?a um and potassium 3
excretion are shown in table 8-1.	 During quiet sitting (control), the rate of
^.	 sodium excretion (UNaV) was constant, ranging from 33 to 43; ueq/min.
Immersion resulted in a highly significant increase in'UNaV as compared to both
the control periods and the prestudy hour, beginning at hour 1 of immersion'
8-2
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(P < 0.005). As shown in table 8-II, the absolute quantity of the sodium
excreted during 5 hours of immersion was fourfold greater than that excreted
during the control, period (P < 0.001). Figure 8-1 illustrates the effect of
immersion on urine pH and on the rate of bicarbonate excretion (UHCO V)'3
During control, urine pH was constant, ranging from 5.21 to 5.52. Immersion
resulted in a highly significant increase in urine pH, beginning at hour l
(P,0011B h	 5	 Hhd'	 df	 31t 6,. y	 our	 ,mean urine p	 a	 increase	 rWill 5.	 o	 .77
(P < 0.001).	 During control, the urine of all subjects was bicarbonate free.
+
Immersion was associated with an increase in Ur1C0 V during hours 2, 4, and 5.
3
Concomitantly with these changes, net acid excretion was markedly suppressed.
I
Urine pCO	 was constant during control, ranging from 36 to 40 mm Hg
1 (fig. 8-2).	 Beginning with the initial hour of immersion, there was a
significant increase in urine pCO2 compared to the level at the prestudy hour.
I	
The peak level of pCO2 of 73 + 4 mm Hg was attained during the final hour of
study.
y' These changes in the absolute value of urine pCO2 cannot automatically be
interpreted to indicate increased generation of CO 	 from carbonic acid (H2CO3)
ti formed within the tubular lumen. 	 Since 'CO	 diffuses freely across cell
membranes, alterations in plasma pCO 2 will change the pCO2
 in urine without any a,
associated change in intraluminal HCOproduction.
	 To correct for this s2	 3
diffusion, pCO2 has been expressed as the difference between urine and plasma
CO2 tension (ref. 8- 9).	 As shown in figure 8-2, urine minus plasma pCO2 3
';. paralleled the changes in urine pCO2.	 Of note, the urine pCO 2 has already
increased by hour 2 of immersion at a time when blood pCO 2 had not changed
from the preimmersion value.- 1
Titratable acid excretion significantly decreased during the final 2 hours
3
of immersion (table 8-I).	 Urinary ammonium excretion also decreased during the
final'4 hours of immersion compared to control. 	 As a consequence of the
simultaneous decrease in TA and NH 4 --excretion and the concomitant
bicarbonaturia,`net acid excretion decreased during immersion from
^I 38 ± 3 peq/min e-during the prestudy hour to 1 + 7 ueq/min during hour 5'
(p < 0.005)
	
(fig.	 8-1).
' The possibility that otherL effects related to the experimental design
(other than redistribution of blood volume) might explain the alterations in
urinary pH and the increase in-UHCO`V must be considered first.	 Since an+
3
increase in urine volume will result in an increase in the urine pH of an acid
urine (ref. 8-6), it was important to ensure that changes in urine flow were
responsible for the pH changes.	 As shown in table 8-I,	 he modification of the
p water load during control and the omission of the water load during immersion
8-3
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were successful in the matching of the urine flow rates during control and
immersion.	 Urine flow during immersion was not significantly different from
•comtrol during each hour of study.
	 Similarly, urine osmolality during each
hour of immersion did not differ from the comparable control hour.
	 Although
' potassium has been demonstrated to exert a regulatory role over renal HCO 3
reabsorption independent of any effect attributable to volume (ref. 8-10), it
appears unlikely that changes in the state of body potassium stores during
immersion could have induced the observed changes in HCO
3 reabsorption.	 It is
well established that potassium depletion enhances HCOreabsorption at any 4,.3
level of sodium excretion.	 Thus, if the small (albeit significant) increase in
potassium excretion during immersion observed in the present studies played a a
Al
role in altering HCO 3
 handling, an increased proximal reabsorption of HCO3,
rather than the observed bicarbonaturia, would have been favored.
Finally, although plasma CO2
 tension is a determinant of HCOreabsorption3
(ref. 8-11), it is unlikely that the decrease in venous pCO 2 at the termination
of the present study could be invoked to explain the observed alterations.
' The encountered increases in urine pCO2 and UHCO V were in evidence as early as
2
s hour 2 of immersion, at a time when blood pCO2
 had not changed from the
preimmersion value (fig. 8-2). 	 The differences encountered must therefore
represent true changes induced by immersion to the level of the neck.
The mechanism whereby immersion alters renal acidification is not yet
clear.	 As noted earlier in this report, several possibilities must be
considered, including decreased HCOreabsorption in the proximal tubule, and3
impairment of distal tubular hydrogen-ion gradient generation.
	 Although
immersion is associated with a decrease in aldosterone excretion (refs. 8-1 and
8-3), it would appear unlikely that a decrease in aldosterone is the sole cause
of the encountered bicarbonaturia. 	 The increase in HCOexcretion in the3
present study was accompanied by a, significant increase in urinary pCO2 2 whichS
(	 presupposes a significant degree of 1ydrogen secretion in the distal tubular
fsegment.	 Furthermore, the bicarbonaturia occurred as early as the second hour
of immersion (fig. 8-1).	 Previous studies have suggested that even after
changes in aldosterone have occurred, these is a 1- to 2-hour lag before they
are reflected in changes in renal tubular reabsorptive and secretory processes
" (refs. 8-12 and 8-13).
	
These data suggest that the initial increase in
bicarbonate excretion occurred before any aldosterone-mediated; changes in
distal hydrogen secretion. The present results, considered_ as . a whole, suggest
'	 that suppression of distal hydrogen secretion mediated by suppression of
aldosterone cannot be the sole factor responsible for the prompt
` bicarbonaturia observed. 	 Rather, it is more likely that the bicarbonaturia was
primarily attributable to an increased proximal rejection of filtered HCO3
8-1+
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s
	
a
secondary to an increase in central blood volume.
	 However, only additional
studies carried out during HCO
	 infusion to assess alterations in net tubular3 A
reabsor tion of HCO
	 will. definitely resolve this point.p	 3	 	 p
Although the precise mechanisms for the encountered bicarbonaturia remain
1 o	 e elucidated,	 e demonstrated ability of water immersion to alter renal
acidification su 	 ests that this model may
1
gg 	  constitute a tool for further `
_
assessing the effects of increases in central blood volume on regulating renal;
HCO	 handling, in humans.	 Furthermore, the similarities in renal sodium and3
potassium handling between the present study and manned space flight suggest
that consideration be ;given to a systematic assessment of parameters of renal
acidification during future manned space flights.
	
Such studies may help to !
elucidate, further the mechanisms mediating the perturbations in sodium
_	 -homeostasis during weightlessness.
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Parameter/Group
(b) Prestudy
Results, after
1 hr .2 hr 3 hr 4 hr 5 hr
V, ml/min
Control 0.7 0'.1 0.9 Oo2 1.6 o.6 1.31± 0.2 1.8 o.4 1.5 o.4
Immersion .7 .1 1.2	 .4 2.3 .5 1.6 .2 1.4 .2 1.6 .3
UOSM', mOsm/kg H 2 0
Control . . . .	 . 794 62 694 loo .542^± 103 483 80 396 83 ^-----439 76
Immersion . . . . 80.8 56 558	 88 435 89 496 68 553 64 516^± 67
U	 V,, peq/minNa
Control 43 ± 11 36 8 38 11 33 8 35 9 34 6
Immersion 55 ± 12 c 88 18 c 121 24 c 147 26 c 161 21 c 191 19
UTA^' pecl/min
Control 19.0 ± 3.3 14.2 ± lo7 17.1 ± 4.1 17.5 .9 19.9 ± 1.1 22.3 ± 1.6
Immersion 15.0 ± 2.2^ ll.o ± 4.5 6.4 ± 2.9 6.9 2.9 d6.1 ± 2.6 c5.6 ± 2.1
V . -veT/minU NA4
Control . . . 33.1 3.7 26o7 ± 3.5 29.4 ± 2.5 27.4 ± .4 31.6 ± 3.2 28.8 4ol
Immersion . . . . 30.7 7.5 17.6 ± 2.3 d 15.4 ± 1.7 c'14.9 2.0 c14.3 ± 1.4 d 1 - 2.3 .5
ar
I
 i
i
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TABLE $-II.- CHANGES IN CUMULATIVE '(3RINARY SODIUM AND POTASSIUM EXCRETION
DURING 5-HOUR WATER IMMERSION
[Results are mean + ;SE_ for _seven subjects]
_ -.3
•t
r`
Group Sodium Excretion, Potassium excretion,i
meq/5 hr meq/5 hr
( a ) (b)
Control 10.5 ± 2.3 15.2_± 0.8
Immersion 42.0 ± 5.8 23.5 + 2.0
ap
< 0.001.
by < 0.01.
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9.	 PARATHYROID HORMONE, CALCITONIN, AND VITAMIN D 1974:
PRESENT STATUS OF PHYSIOLOGICAL STUDIES AND ANALYSIS
OF CALCIUM HOMEOSTASIS
By John T. Potts, Jr., M.D., and K. G. Swenson j
The ultimate purpose of the research efforts of the authors and NASA has
`	 been to define the role of parathyroid hormone, calcitonin, and vitamin D in
	 -
the control of calcium and bone metabolism.	 Particular emphasis was placed on r
the physiological adaptation to weightlessness and, as a potential model for
this purpose, on the immobilization characteristic of space flight or prolonged
bed rest.
Recent studies of prolonged bed rest have shown a negative calcium bal-
ance; and, in the 50- to 60-day Skylab missions, an increase in urinary calcium
- has been detected consistent with at least incipient negative calcium' balance. i§
1	 It is of practical importance to define the factors responsible for this dis-
order in calcium homeostasis in order to prevent or reverse this trend to
negative calcium balance so that longer duration space flights could be under- 7
' taken without the risk of serious bone mineral loss.
Very little information is now available concerning the nature of changes,
if any, in the relative rates of secretion or metabolism of parathyroid hormone
(PTH), calcitonin, or vitamin D under conditions of prolonged weightlessness or
immobilization.
	
The determination of the importance of alterations in the
normal endocrine homeostasis of PTH, calcitonin, and vitamin D in response to
f prolonged immobilization will require considerable basic research into the r
} physiology and the techniques of measuring these hormonal agents.	 This deter-
mination must take into co,,sideration present investigations into the biosyn-
thesis, control of secretion, and metabolism of these hormonal agents.
BONE MINERAL AND CALCIUM LOSS AND HORMONAL CHANGES DURING
PROLONGED IMMOBILIZATION
-	 The studies of Hulley et al. (ref. 9-1) have indicated that prolonged bed
rest leads to a negative balance as great as 200 to 300 milligrams per day
during the second month, as well as a substantial' reduction in bone mineral as
estimated by bone'densitometry. 	 Recently, attempts have been made to reverse -
bone mineral loss by the administration of calcitonin, the application of a
regimen of intermittent compression and.exercise, ` and/or the administration of
large amounts of supplemental calcium and phosphate.	 Preliminary findings,
9-1
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although not conclusive, are encouraging because they suggest that calcium and
I' phosphate supplementation and a combination of compression and exercise may
help retard bone mineral loss (ref. 9-2).	 However, extensive study will be
required to firmly establish the value of any countermeasures to retard n.ega-
tive calcium balance.
? Very little information is presently available concerning potential 'cir-
cadian rhythms or diurnal fluctuations in the rate of production, secretion, or
turnover of biologically active forms of PTH, calcitonin, or vitamin D.
	 One
report (ref. 9-3) has suggested the existence of a circadian rhythm in PTH
concentrations in normal humans. 	 In otherwise healthy, normal, male and female a
subjects, an approximate twofol_ increase in PTH concentration was detected in
short-term studies in association with sleep.
	 Such changes in immunoreactive
s^ PTH concentrations during sleep are difficult to interpret, however, because
much of the immunoreactive hormone in blood represents biologically inert frag-
-s . rents whose rate of metabolic turnover may change with the reduced renal blood 7
flow occurring during sleep and with the reduced fluid intake at night.
PARATHYROID HORMONE
Physiologists and clinicians concerned with improved understanding of the
homeostatic role of PTH in calcium and bone metabolism and with improved
methods of diagnosis and treatment in disease states associated with disorders
of the parathyroid function have been understandably excited by the ;many ad-
vances in fundamental research on PTH in the last decade.
	 The amino acid
sequence of the biologically active amino terminal portion of human PTH has
recently been determined; the complete amino acid sequence of the bovine and
porcine PTH was determined earlier. 	 Synthesis of biologically active subfrag-
ments of PTH has permitted a systematic, analysis of structure/activity rela-
tionships in PTH and has provided much material for detailed biochemical,
it physiological, and immunochemical studies.
Paradoxically, however, these fundamental advances have led not only to
f## improved understanding of parathyroid physiology but also to confusion and
uncertainty in parathyroid-related physiological and clinical research because
of a recognition of the hitherto unappreciated complexity in hormone biosynthe-
sis and metabolism.
Biosynthesis
!. Recent advances in the knowledge of the chemistry of PTH have greatly
t` aided studiek- of its biosynthesis (refs. 9-4 to 9-9).
	 The successful develop-
n
ment of an in vitro system for study of PTH biosynthesis, using slices of
bovine parathyroid glands, was reported by Corn et al. (ref. 9-10).
	
These
studies indicated the presence of a rapidly synthesized peptide that was larger
than PTH but was biologically active.
	 The peptide produced hypercalcemia in
rats and bone' resorption in vitro,- and was chemically similar to 'PTH in that
I the larger peptide reacted with antisera to PTH. 	 This peptide was referred to
! 9-2
p.
l^
r-  
k	 as "a nonparathyroid calcemic fraction (calcemc fraction A)" while awaiting
proof that it was a true biosynthetic precursor. 	 Subsequently, it was con-
clusively demonstrated that this larger peptide was indeed a precursor of PTH;
..	
Ii
}	 that is, a prohormone, or proparathyroid hormone (proPTH) (refs. 9-10 to 9-12).
Shortly after the existence of proPTH was conclusively established, Cohn
et al. (ref. 9-10) undertook large-scale^^	 	 purification of the prohormone and
isolated a sufficient quantity (approximately l milligram) to permit, in
collaboration with the authors and others, a determination of proPTH primary
#	 amino acid sequence (refs. 9-1.3 and 9-14).	 The additional hexapeptide sequence
=j	 at the amino terminus of the hormone is heavily basic; four of the six addi-
tional amino acids are positively charged (three lysine and one arginine) (fig: 	 °±
9--l).
	
It has not yet been established conclusively whether the 90 amino acid
prohormone is the direct product synthesized from the messenger ribonucleic
t	 acid (RNA) for PTH.	 Larger, as yet unidentified, precursor polypeptides of PTH
may exist.
In a recent study (ref. 9-15), the author and others greatly extended the
4	 sensitivity of the radioactive-microsequencing approaches. 	 The amino terminal
sequence of the human proPTH was determined after tissue slices were pulsed4	
with radioactive amino acids and structural analysis was performed by Edman
degradation. The sequence studies indicated that the aminoterminal prohormone
specific sequence of the human hormone is identical with that of the bovine 	 -,
molecule; that is 	 the amino terminal  sequence analysis indicated the structureq	 Y
Lys-Ser-Val-Lys-Lys-Arg, which was followed by the.amino terminal.sequence of
the human hormone Ser1-Val2^-Ser3 , already established (ref. 9-14).
Until recntly, very little was known `about ,cellular mechanisms involved in 	 s
,i	
the biosynthesis, transport, and storage of PTH or about the critical points of
intracellular control of hormone production.
	
Recent studies, however, are now
providing considerable information about the intracellular sites of proPTH
synthesis and conversion and the processes that lead to the storage and secre-
tion of PTH,i
Figure 9-2 summarizes and schematically depicts proposed rate-limiting
points in the parathyroid cell biosynthetic machinery. 	 These points are those
at which calcium or other agents may exert a regulatory influence on the syn-
thesis, transport, cleavage, or storage as well as secretion of PTH. 	 Little
information exists regarding the role of calcium at specific control points,
but some conclusions are possible.
No effect of Ca++ ion on the activity of the cleavage enzyme '(step 	 of
fig. 9-2) has been shown.	 Preliminary studies (ref. 9-16) suggest that, al-
`	 though low calcium stimulates and high calcium suppresses the overall synthesis'
I	
of proPTH, there is no evidence of a direct effect on transcription or trans-
lation'(steps 2 and 3 of fig. 9-2).	 There isevidence, however, of a consid-
erable intracellular turnover of PTH or proPTH (steps 6 and 7 of fig. 9-2) and
evidence that high Ca++ stimulates this process and low Ca++ inhibits intra-
cellular degradation.
9-3 ,
3A more definitive picture of the normal controlling processes within the
! parathyroid cell involved in regulation between the initial steps of proPTH
synthesis and the eventual release of PTH from storage granules will be off
f fundamental interest and will serve as a model for evaluating the defects in
cellular control that are involved in excessive PTH secretion. Hence, defects
a	 { such as the release of predominantly prohormone (lack of specific cleavage
' enzyme) or predominantly fragments (uncontrolled proteolytic degradation) might
be found in pseudohyperparathyroidism. 
In the development of a radioimmunoassay for proPTH, immunization with
synthetic peptides containing the prohormone specific hexapeptide sequence has +
resulted in the production of uniquely useful antibodies (ref. 9-17). 	 Assays`
based on this antiserum-readily detect intact prohormone and synthetic peptides
incorporating the prohormone sequence, but do not detect the hormone or hormon-
al fragments, such as the prohormone hexapeptide sequence alone or the amino
terminal peptides of the hormone itself (fig. 9-3).	 Prohormone appears to be
rapidly degraded in blood by proteolytic-activity, and no conclusions have yet
been reached on the secretion of' bovine `or human prohormone. 	 However, the
4 development of human prohormone-specific antisera (now that the structure of
the human precursor is known) and the continuing efforts to block prohormone
degradation in plasma seem promising.	 Therefore, crucial _issues in these areas
of biosynthesis investigation include the completion of analysis of the intra-
cellular processes and controlling features of hormone biosynthesis, storage,
and release; the detection of the secretion of prohormone or prohormone-related 5
(hexapeptide) peptides; and the development of routinely applicable immuno-
assays for measurement of these precursor molecules.	 Advances in these invest-
I igative areas should provide unique approaches for clinical and radioimmuno-
'^ assay ,studies aimed at improvi;zg^the detection of abnormalities in parathyroid
_	 _^• _^
function.
a
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Secretion and Metabolism
' Recent studies have led to an important new area ofinvestigation in the
metabolism and peripheral turnover of PTH. 	 It has become apparent, for the
first time, that the fate of PTH after release from the gland involves a much
more complex process than a simple uptake by receptors or an all-or-nothing =
removal from the circulation.
	 It is also apparent that an appreciation of the
physiological significance of this process of peripheral clearance or meta-
bolism of PTH requires the development of new techniques to assess the nature
of the cleavage, the site or sites of occurrence of the cleavage, and the
biological and chemical properties of the circulating fragments.
	 Efforts in
I 	 , this laboratory have been concentrated on the application of region-specific ='
antibodies to characterize the fragments detected in blood.
	 Since the minimum'
sequence of amino acids required for biological activity has been determined,
immunochemical testing.can be applied; to determine whether or not any fragment
in the circulation has the structural_ features required for biological
activity.
It has been possible to modify,antisera by absorption methods so that
recognition is limited exclusively to 'certain regions of the sequence, such as-
9 4
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the amino (N assay) or carboxyl teruunal end (C assay) of the hormonal molecule
(fig. 9-4) (refs. 9-18 and 9-19).	 Thus far, studies of endogenous hormone in
the circulation of humans and of normal cows, as well as hormone injected into
r	 k calves and dogs, have established through gel filtration analysis that the
large peak of immunoreactive material (which elutes at a position correspondingt
to a molecular weight of approximately 6000) is detected using antisera that 1
I	 ^j recognize antigenic determinants "carboxyl terminal to position 30" (MC frag-
ment).
	
Existing information_ about the structural requirements for biological
!	 1 activity makes it probable that any fragment that does not contain the amino-
terminal residues 2-27 in intact form will be bilogically inert.
	
Since this
.large fragment in the peripheral circulation lacks the critical amino terminal
sequence required for biologic activity, it must be biologically inactive.
A smaller fragment that was biologically active in an in vitro renal
adenyl cyclase assay has been found in concentrates of human plasma. 	 The larger
fragment (which appears to be equivalent to the large, middle plus carboxyl
terminal fragment (MC fragment) that we have identified) was found to be in-
active, corresponding to the predictions based on immunochemical analyses of
!	 I
the MC fragment
Recent investigations by' the authors involving several different approaches
' have helped to identify more precisely the site of cleavage. 	 Chemical evidence
was found to confirm that peripheral cleavage of the hormone could result in
the production of an active fragment (ref. 9-19).	 In preliminary animal studies,
3
{ 1251-labeled bovine PTH (BPTH), with radioactive iodine linkedto the tyrosine a
( residue at position 43, was infused into dogs.	 As serial blood samples are
analyzed, the peak corresponding'to the elution position of the MC fragment
` increases in concentration with time.
	
This large 6000-molecular-weight-frag-
ment was separated by gel filtration from other peaks of radioactivity. 	 The MC
fragment was subjected to sequential degradation, using the Edman procedure to
remove, step-wise,-amino acids from the aminoterminal end of the peptide. 	 The
use of this procedure has made it possible to determine the number of amino
acids present in the sequence of the MC fragment, beginning at the amino termi-
nus of the fragment and extending to the radioactive tyrosine at position 43
(fig.	 9-5).
I
I Thus, the determination of the probablesite or sites of cleavage in the
_	 hormone is possible. 	 These studies have shown the appearance of radioactive
tyrosine after 7 and 10 steps of degradation, indicating that the 6000-
} molecular-weight fragment isolated from the circulation of the dog probably =
consists of at least two fragments closely related in size. 	 One fragment
`I presumably consistsof sequence 34 to 84, and the other of sequence 38 to 84.
Both fragments must be biologically inactive since they lack the amino-terminal
25 amino acids_ required for activity.
	
In these studies, a variety of region or
Isequence-specific antisera have also been applied to the analysis of the rate
of disappearance and of formation, respectively, of intact hormone, and the
} analysis of the rate of formation of the MC fragment following, injection of
t	
i
1
unlabeled, biologically active hormone (fig. 9-6).
	 The results achieved by
,
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this approach are in close agreement with the stuides based on radiochemical
approaches.	 Similar estimates are found by each method for the rate of dis-
appearance of the intact hormone and for the formation of the MC fragment
(resulting from cleavage of the injected hormone) (fig. 9-7).
These studies (sequence analysis) confirm that the MC fragment is indeed a
cleavage product and that peripheral cleavage of intact hormone entering the
circulation is the origin of the MC fragment.
	 The similarity of results seen
t by the immunochemical approaches using nonradioactive, biologically active
1hormone have validated the use of radiolabeled peptide to investigate the
metabolism of endogenous hormone.	 Furthermore, these results indicated, by two
independent methods, that if fragmentation results from a single site-specific
v, cleavage, such as that which would occur by the action of an endopeptidase, the
smaller amino terminal fragment (presumably residues 1-33) resulting from
cleavage could be biologically active sine it would contain the structural
region necessary for activity..
	 This concept, however, is still speculative.
A
Many broad issues of great interest need to be resolved concerning the
peripheral cleavage of PTH. 	 The site, nature, and physiological significance
of the cleavage must be defined. 	 If all fragments generated are inactive, then
the cleavage process reflects simply metabolic degradation of the hormone.
However,; if one or more of the _fragments are biologically active and if' they
are cleaved in the vicinity of receptors in the target organs, such fragments,
even though they need not be present in the general circulation, could consti-
tute a major, if not the sole, mediator of PTH actions.
	 Because the activity
of the intact hormone even in the in vitro assays might reflect prior conver-
sion to active fragments, it must
	 considered that there is noconclusive
evidence that the intact hormone is the active molecular species in vivo.
Thus, the issue of hormonal metabolism is critical in present efforts to under-
stand the mode of action of the hormone (the homeostatic regulation of expres-
sion of hormonal effects such as the precise control of hormone secretion) and
j in efforts to develop radioimmunoassays that can measure the most appropriate
and reliable index of hormonal activity.
i	 a
r The parathyroid cell is the site of initial cleavage-prohormone to hormone a
conversion, and peripheral metabolism is the second site of cleavage conversion
of secreted hormone into one or more peptide subfragments.
	 When the issues
concerning the nature of these hormonal products released into the circulation
(fig. 9-8) can be resolved and eventually analyzed by appropriate; immunoassays,
a new era in the use of special laboratory aids for improved diagnosis of para-
thyroid disorders should be opened.	 In particular, the possibility exists for -
a more meaningful .analysis of the details of the normal secretory patterns of
biologically active PTH, including circadian rhythms, as a background for the
investigation of homeostatic perturbations induced by prolonged immobilization.
VITAMIN D METABOLISM_
The authors' efforts have continued to focus on the development of assay,_
methods and selected' animal studies to provide techniques suitable for clear
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2delineation in humans (in vivo) of essential features of the metabolism of
C vitamin D and to detect specific disorders in disease states.
y -	 Vitamin D is now known to be stored in the body after formation in the skin
or absorption from the diet and then converted to 25-OH-vitamin D (25-OH-D)
' by a specific hydroxylase in the liver.	 This ,compound must be further
hydroxylated in the kidney before it can act on its target tissues in vivo.
-	
-!
One renal metabolite (1,25-(OH) 2D) stimulates calcium transport by the intes-
( tine and mobilizes bone calcium in vitamin D-deficient rats and may be the
principal hormonal form of the vitamin.
	
The physiological roles of a second
dihydroxy metabolite (24,25- (OH) 2D) and a recently discovered trihydroxy metabo-
lite (1,2 1+,25-(OH)3D) are as yet unclear (ref. 9-20).
The metabolic activation of vitamin D appears to be a regulated process in
both the liver and the kidney.
	
In vitro and in vivo experiments in the rat had ^.
suggested product inhibition of the liver hydroxylase. 	 Using the competitive a
binding assay for vitamin D and OH-D, the authors have found wide variations
(tenfold or greater) in the serum OH-D levels in D-deficient-rats with little
or no change in serum calcium. 	 In contrast, small changes in'OH-D levels with
large changes in 'serum calcium were found. 	 Indeed, in these latter, clinically
deficient animals with hypocalcemia, stunted growth, and abnormal bones, the
OH-D 'levels were reduced by one-third to one-half, but were still detectable {
(>l ng/ml) for at least 4 to 5" weeks after the onset of clinical deficiency
(fig. 9-9)
In a group of normal human subjects, no apparent correlation was found
between serum 25-OH-D levels and the absorptive efficiency for calcium. 	 Some
of the subjects had very efficient absorption with low levels of 25-0H-D; in
others, the converse was found. 	 In serial studies over a 2-year period in a
few of these subjects, calcium absorption and 25-OH-D content in serum seemed
to vary independently, whereas serum calc:i.,nn,_phosphorus, and alkaline phospha-
tase remained unchanged.	 Thus, in humans and in rats, no direct correlatioi
` was found between serum 25-OH-D levels and the consequences of vitamin D meta-
bolism, which might have been expected if strict product; inhibition of the 25-
hydroxylase in the liver was operative over the normal range of vitamin D
' intake.	 Although blood 25-OH-D levels may be an important parameter for assess-
ing overall status of vitamin D intake and metabolism, the results clearly
emphasize the need to focus on concentrations of dihydroxy metabolites to
examine the precisely regulated homeostasis of vitamin D (ref. 9-21).
	 The
renal hydroxylase, in contrast to the hepatic hydroxylase, seems to be tightly
controlled by one or more metabolic variables related to or varying with cal-
cium or skeletal metabolism.
In contrast to the hepatic hydroxylase, the renal	 dro	 lase is subjectP 	 hy xy ^  
not to simple product inhibition but rather to complex metabolic regulation.
The nature of the metabolic control has not yet been clarified and is, in fact,
the subject of some dispute.
	
Omdahl and DeLuca (ref. 9-22) have shown that
formation of 1,25-(OH) 2D3
 was favored in<hypocalcemic states in animals with
intact parathyroid glands and by the administration of parathyroid hormone to
— tF	 w
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thyroparathyroidectomized animals. T]
(OH)2D3 was favored in thyroparathyro:
depleted prior to surgery and were the
- with subcellular fractions has confiri
of subcellular fractions of renal tis.
contradictory. Larkins, et al. (ref.
was suppressed in some animals follow:
I	 (OH)2D3 formation was favored. This
tion of the experiments of Omdahl and
of 1,25 di-OH-D production continues
y also reported that formation of 1,25
.ectomized animals who had been phosphate-
	
3
relatively,' hypophosphatemic. Most work
d this finding, but other investigations
.e and whole animal experiments were
-23) found that 1,25-(OH) 2D3 formation	 4
g administration of PTH and that 24,25-
nding is apparently a-direct contradic
,eLuca. The examination of the control
numerous laboratories. It seems impera-
humans.
To develop selective assays for 1,25-(OH) 2D-and.to farther examine the ti
general issue of -the plasma transport of vitamin D, the authors have analyzed
vitamin D transport proteins in several species.-	 In vitro studies have con-
clusively demonstrated a single transport protein for vitamin D and OH-D in rat
serum and have shown that it binds only vitamin D and D metabolites and not
other steroids or sterols. 	 The authors have now shown that 25-hydroxylated
forms of vitamin ;D are preferentially bound, whereas other changes in the basic
vitamin D molecule, either on the side chain or on the A ring, seem to reduce
the binding affinity (ref. 9-24) (fig. 9-10)4 	 In other species, the authors
have demonstrated two vitamin D transport proteins (one binding vitamin D alone a
and the other binding vitamin D and OI-I-D) but have not yet studied other
µ vitamin D analogues in these systems except in the case of the chick. 	 In this
case, D2 and OH-D2 are poorly bound by chick binding proteins (when compared to
D
3
 and OH-D3), which may explain the differential potency of D 2 and D3 in
curing rickets in the chick (ref. 9-25) (figs. 9-11 and 9-12). 	 (D2 and D3 are
equipotent on a weight basis in the line test using vitamin D-deficient rats,
whereas D2
 is only 1/100 as potent as D 3 in the line test using vitamin D-
deficient chicks.)
The authors have continued to investigate the method of delivery of 1,25-
(OH) 2D to receptor sites in bone and intestine from production sites in the
kidney.	 Thepresence of 1,25-(OH) 2D3 _n plasma is estimated to be at low
concentrations (pg/ml); that is, in very small amounts compared to the con-
centrations of circulating vitamin D and 25-OH-D (ng/ml).__Thus, plasma trans-'
1 port could ?-e accomplished by either a large excess of a single vitamin D/011-
' D/(OH)2D protein or, if the concentration of the binding protein is rate limit-
ing, by a preferential binding of 1,25=(OH)2D 3 over vitamin D and 25-OH-D.
i When isotopic 1,25-(OH)2D3 is added to rat plasma, most of the activity appears
to be associated' with the vitamin D/OH-D transport protein. 	 Isotopic 1,25-
1 (010 D3 could be displaced from plasma by nonisotopic 1, 25-(OH) 2D3 ; but, on a
?
'
weight 'basis`, 25-OH-D is bound 1.0 times as tightly as the dihydroxy compound.
i
i
9-8
z^
Y	 ,
44
Further studies are required to clarify the nature of 1,25-(OH) 2D3
 transport in
plasma, but these studies suggest that a single vitamin D/OH-D/1,25-(OH) 2D
binding protein may perform: this transport function in rats.
Transport of the dihydroxy metabolite is ,probably accomplished by a large
}	 ' excess concentration of the transport proteins.
	 The authors have found an
p undersaturation_of the plasma transport proteins in the rat. 	 Although normal
rats contain a total of approximately 50 ng/ml of vitamin D and 25-0H-D, the
total binding capacity measuy---d with an in vitro assay can be shown to be a
t	 - minimum of 1200 to 1500 ng/ml and as great as 2500 to 3000 Ug/ml in animals with
-combined calcium and vitamin D deprivation.
	 Hence, no separate binding protein
need be postulated for carraige of the dihydroxy metabolites in rat plasma.
The situation is somewhat different for human plasma.
	 When isotopic 1,25-
(OH)2D3 is added to human plasma, only a small amount of activity is associated
with the vitamin D/OH-D transport protein; the bulk of the activity is associ-
ated with another distinct fraction that is clearly not identical with other
vitamin D or 25-OH-D binding proteins noted previously.
	
If 14D-D3 and 3H-
x" 1,25-(OH)2D3.are added to human plasma, additional 25-OH-D displaces the 14 C-
D31 but not the 3H-1,25-(OH) 2D3 , from plasma binding, consistent with the
4 existence of a separate dihydroxy transport oi- binding protein (ref. 9-26).
Such a separate binding protein would be of great physiologic importance and
practical interest, since a'specific rapid assay for the dihydroxy metabolite -
might be readily developed with the 1,25-(OH) 2D binding protein.	 Dihydroxy
transport proteins continue to be studied to clarify the importance of plasma
transport in normal vitamin D metabolism and in disorders of calcium
or skeletal homeostasis, such as sarcoidosis, in which vitamin D responsiveness
is abnormal.
Studies are now underway to purify the suspected binding protein that
selectively binds'1 ,25- (OH)2D and other dihydroxy-metabolites of vitamin D in
( human plasma.	 This protein mig` gtes with the D/OH-D transport protein when
] human plasma is fractionated by gel filtration over 5ephadex G-200, but is
separable from this latter protein on acrylamide gel electrophoresis.
	 For assay
' pv.^pos,es, the separation of 1,25 di-OH-17 binding protein from the D/OH-D trans-
port protein would be very important because the latter inferferes with assay
of 1,25-(OH)2D. 	 Currently, attempts are underway to separate the proteins on
the basis of charge with either preparative acrylamide gel electrophoresis or ..
the use of chromatography,
Application of the 25-OH-D assays to physiological studies in humans hasd been difficult because Dand 25-OH-D3
 (resulting from photoactivation of3
f
precursor in the skin and the physiologic form in humans) and D2	 and 25-OH-D2
(from dietary sources) are not equally reactive in the assay system with the
rat binding protein, although they are equipotent biologically.' The authors
^ r
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discovered, however, that the vitamin D binding protein in chick sera is
relatively insensitive to D2 and 25-OH-D2 and may provide the basis for develop-
ment of selective assays for vitamin D2 and D3 separately. 	 This finding would
' provide,
 -for the first time, the opportunity to accurately assess the contrbu-
ton of dietary as compared to environmental factors in the provision of vita-
min D in normal humans.
The ultimate aim_of,these investigations is to provide a battery of highly
selective saturation analysis assays with which to assess the concentration of
D25 D39 25-(OH)D2 and 25-(OH)D3 , and the dihydroxylated metabolites of vitamin
D.	 By this means, one can adequately evaluate vitamin D metabolism patterns in
humans under normal physiological conditions as a prelude to screening for
` homeostatic perturbations either in various calcium deficiency states in humans -.
or under unusual physiological stress states, such as prolonged immobilization
' or weightlessness and space flight.
C.ALCITONIN
The development and application of sensitive and specific radioimmunoassays
for the calcitonins have been useful in defining the control of secretion ofr
this hormone (ref. 9-27).	 Bioassay techniques of much greater sensitivity than
bioassays for parathyroid hormone have been applicable to analysis of gland
content of hormone; and they have been applicable to analysis of secreted hor-
mone in certain species, with conbentration of blood or in thyroid effluent
r blood.	 However, the biological assays are at the borderline of necessary
r.
sensitivity and are technically difficult or cumbersome for-multiple'analyses. x
The first immunoassay developed was for porcine calcitonin (ref. 9-28).
_ This assay was sufficiently sensitive to detect peripheral concentrations of the
t peptide in both the rabbit and porcine species and in human medullary thyroid
tumors grown in vitro (ref. 9-29).	 Initial studies demonstrated that calcitonin
is continuously secreted at physiological concentrations of blood calcium.
Measurements made during calcium infusion in these animals demonstrated that_the
concentration of the hormone rises within minutes of induced hypercalcemia.
Bioassay studies of _thyroid effluent blood and immunoassay of mixed venous
blood have shown that the secretion of the hormone is under the directly
proportional control of blood calcium.
The importance of calcitonin in calcium and skeletal homeostasis in normal
'
humans has not been established. 	 The study of the secretion of calcitonin in
humans has been most extensively done in patients with medullary thyroid
carcinoma who have elevated concentrations of the peptide in peripheralblood.
Because of methodological problems, the reliable measurement ofcalcitonin in
^t humans other than those with calcitonin-secreting tumors of the thyroid has not
been possible (fig. 9-11).
	 Until calcitonin can be shown to be secreted in
humans, no hormonal or physiological role can be ascribed to the peptide.
Earlier reports based on bioassay measurements of human calcitonin in the blood -r
of normal subjects led to estimates varying from 200 to 1700 pg/ml (refs. 9-30 ={
`. 9-10
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and 9-31).	 Later, however, these reports were shown to be incorrect; spuri ous
factors and artifacts were shown to be present in the methods used (ref. 9-32).
The development (ref. 9-33) and subsequent application (refs. 9-34 and 9-35) of
immunoassays for human calcitonin also led, initially, to conflicting results,.
However, subsequent to the demonstration of artifacts in immunoassay methods
(ref. 9-36), the preliminary estimates that calcitonin is secreted normally in
humans at a concentration of 50 to 400 pg/ml have been revised sharply downward.
Studies with a sensitive immunoassay for human calcitonin (ref. 9-36) haveki shown the peptide to be undetectable (less than 100 pg/ml) not only in the
peripheral plasma of many normal subjects but also in thyroid venous blood
taken from patients (primarily with hypercalcemia) during selective venous
catheterization or at surgery (fig. 9-12).	 These findings suggest that the
concentration of calcitonin in the peripheral blood of humans, if present at
all, must be much lower than that found in other mammals.
	 Development of much
more sensitive assays will be required to determine whether calcitonin does
circulate but, perhaps analogous to adrenocorticotropic hormone, at very low
concentrations or whether the hormone simply is not secreted -under physiological
conditions in normal humans and is, therefore, vestigial in humans in contrast A
to other mammals.
Recently, however, calcitonin has been detected after calcium infusion by
radioimmunoassay in the peripheral blood of patients with diseases associated I
with chronic hypocalcemia (ref. 9-37).	 These findings increase the possibility
that calcitonin is secreted in normal human subjects and have spurred efforts
by the authors and by others, to develop more sensitive assays for calcitonin.
Affinity chromatography methods, in particular, show promise for meaningful
interpretations of calcitonin sec retion dynamics in humans.	 Questions of
adaptive responses to protect skeletal calcium stores during prolonged immobili-
zation can then be evaluated with appropriate assays of requisite sensitivity.
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Figure 9-2.- Possible points in biosynthetic machinery of parathyroid cell
where calcium may be proposed to exert regulatory, effects.
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Figure 9- 3'.- Specific radioimmunoassay for bovine prop arathyroi d hormone, show-
ing competitive displacement of a 125 1_labeled prohormone peptide comprising
the prohormone-specific hexapeptide and the first 12 residues of PTH (pro
1-12) by a number of prohormone and hormone peptides. Curves are plotted as
a function of molar concentration of peptide versus bound to free ratio (B/F)
of labeled pro 1-12 ,expressed on thebasis of percent of B/F value without
peptide present. Only prohormone peptides (not the prohormone hexapeptide,
bovine` PTH -( 1-84). or PTH fragments) competitively react in assay.
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Figure 9-4.- i''l:te antigenic recognition sites of two antisera (GP-133 and GP-1)
after each has been blocked by addition of excess concentrations of either
bovine 1-34 or 53-84 fragment. 	 The region of the molecule blocked by addi-
tion of the fragment is indicated by `the hatched area and the recognition
sites by the heavily shaded areas.
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Figure 9-6.- Gel filtration profiles of izmlunoreactive hormone BPTH in samples
z
taken 4 and 24 minutes after intravenous injection into adog. 	 Samples were
chromatographed on Bio-Gel P-100.,
	
Each fraction was assayed in four differ-
ent sequence-specific radioimmunoassay,systems.
	
The elution position ofvoid r
volume (Vo ), intact hormone, bovine hormonal fragment 1-34, and 131I are
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Figure 9-8.- Schematic summary of present knowledge and views concerning the
biosynthesis, secretions, and metabolism of parathyroid hormone and the ori-
gins of the heterogeneity (known or suspected) for immunoreactive parathyroid
hormone; in blood. In addition to the release of intact hormone from the
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parathyroid cell, there may be release of prohormone or the prohormone pep-
tide after cleavage from the precursor (?). Uptake of hormone after -secre-
tion occurs in peripheral organs (perhaps target organs) followed by a second
cleavage; the larger ,fragment (C) reenters the circulation but the fate of 	 u
i	 the smaller fragment (N)-, which may be biologically active (and may be re-
i leased adjacent to receptors), is at present uncertain (it may not reenter
the circulation in significant amounts, if at all).
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Figure 9-9.- Displacement of 3H-25-OH-vitamin D3
 from D-deficient rat plasma with vitamin D analogs.
Plasma obtained from D-deficient rats was cleared of nonspecific binding proteins and diluted with
tarbital acetate buffer,	 H $.6.	 Increasing amounts of the aLalo, p	 	 gue to be tested with a fixed amount
of 3H-25-OH-D 3 , all in 95 percent ethanol, were added to the diluted binding protein (B) or to buffer
only (D).	 An additional aliquot of the analogue with'the 3H-25-0H-D3 was added to a counting vial
' for determination of the counts/min added to each tube (T-total counts/min).
	 Separation of unbound
r' 3ti-25-OH-D3 in both B and D tubes was accomplished with Dextran-coated charcoal (0.25 percent Norit A
Charcoal_and,_0.025 percent Dextran T80).
	 Specific binding was determined by _subtracting counts/min
in the supernatant in the absence of binding protein (D) from the counts/min with the binding protein
G
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present (B) and the bound/free (B/F) ratio calculated: 'B/F = B--D/T--(B--D).
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Figure 9-10.-Displacement of 3H-25-OH-vitamin D3 from D-deficient chick plasma
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with vitamin D analogs.
	
The determination of B/F ratios for comparing bind-
" ing of D analogs was accomplished by the procedure outlined in fig. 9-9,
except that chick plasma was used as a source of the specific D binding pro-
tein.; r
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Figure 9-11.- Effect of charcoal adsorption on immunoassayable calcitonin concentration in plasma
sample',from` patient
-
with medull	 ary thyroid carcinoma and on apparent immunoassayable calcitonin con-_
centration in plasma sample from normal adult. 	 The solid line represents the standard curve of
tracer displacement, produced by human calcitonin assay standard. 	 Charcoal adsorption removes all
calcitonin activity from medullary thyroid carcinoma plasma sample and eradicates progressive dis-
placement.of tracer from antibody produced by increasing aliquots of this plasma sample before char-
coal adsorption.	 Charc`^al adsorption has no significant effect on displacement of tracer produced by
aliquots of plasma from Normal adult. 	 Because displacement of tracer by normal plasma is not eradi-
cated by charcoal adsorption, it must be concluded that the sample does not contain detectable au-
thentic human calcitonin,
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tients with hypercalcemia compared to hormone concentration in thyroid vein
•{	 samples from patients with hyperparathyroidism and idiopathic hypercalciuria
and in a thymic 'vein sample from a patient with idiopathic hypercalciuria. 	 The
hashed line represents upper limits of detection; open circle values are too
1	 ^	 close to detection limits for reliable estimation of concentration.
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10. ENDOCRINE CONSIDERATIONS IN THE
RED-CELL-MASS AND PLASMA-VOLUME CHANGES OF
THE SKYLAB 2 AND 3 CREWS 	 r
By Philip C. Johnson, M.D., Carolyn S. Leach, Ph. D.,
and Theda Driscoll	 `^
„ INTRODUCTION
3
Decreased red cell mass has been found regularly among crewmembers who
return from space flight.	 This observation was first documented in the crew
E of the 8-day Gemini V..mission and confirmed in the crewmembers of the 14-day
--'-	 '` Gemini VII mission.	 This finding was generally not pre-,licted before these
missions, since it was not found in ground-based studies designed to simulate
weightless flight (ref. 10-1). 	 Studies after four Apollo Moon-landing mis-
sions and the first two manned Skylab missions showed a mean decrease in red
cell mass of approximately 10 percent. 	 It has been tempting to explain the
decrease in red cell mass of Gemini and Apollo crewmen as being due to the
' effects of hyperoxia. 	 However, the Skylab missions, unlike the Apollo mis-
sions, did not have hyperoxic environments; yet, proportionately similar de- ".
creases in red cell mass were found. 	 Therefore, hyperoxia cannot be the only
cause of the decrease in red cell mass, and other possibilities must necessar-
r
ily be considered (refs. 10-2 and 10-3).'
:_	 w
Accompanying the decreases in red cell mass have been changes in plasma_
volume.	 Unlike the red-cell-mass deficit, plasma-volume changes were pre-
dicted even before the Mercury flights because plasma-volume decreases had
been found consistently in subjects studied during and at the termination of
prolonged bed rest (ref.-10-1).	 It is generally thought that plasma-volume
decreases result from a redistribution of the labile portion of the blood vol-
ume, which is no longer needed in a weightless environment as circulating
blood is freed from the effects of gravity.
Gemini IV crewmembers showed a decreased plasma volume on their return.
A
A mean decrease in plasma volume 'was measured after an additional Gemini,
seven Apollo, and two Skylab missions.	 One exception to`this rule was the
crew of Gemini VII (the longest space flight before the Skylab missions), who
3. showed an increase in plasma volume at recovery (ref., 10- 3).
} Because blood-volume changes are found regularly after each mission, one
might expect endocrine responses,to'the decrease in circulating blood volume
when the crewmembers return and experience the effects of gravity. 	 What is
dt{ unknown is whether these changes in blood volume elicit an endocrine response _
10-1
a
5
f #
j"
i
t
i
t
I
during weightlessness.
	 Changes in endocrine function have been shown to occur
during weightless flight,•and these endocrine changes may have increased, de-
y creased, moderated, or even caused the blood-volume changes. 	 The purpose of
this report is to point out how the unknown endocrine changes may have
affected the blood `volume of the crewmembers.
	
From this preliminary analysis,
plans can be made to study this relationship during future missions.
RESULTS AND DISCUSSION
Table 10-I shows the mean percent change in the plasma volume and red
cell mass of the returning crewmembers.
	 Except for the Gemini VII crew, all
values are negative and considerably different from the controls.
	 The in- -
^	 creased plasma volume of the control subjects is believed to be a reflection
of the increased environmental temperature that was present in the week before
each recovery.	 The control subjects were aboard sparsely air-conditioned car-
riers in the tropical waters before the recovery process.
	
The only cold en-
j	 vironment occurred during the days before the Skylab 3 recovery,
	 it is there-
fore not unexpected that the plasma volume of the control subjects for the
` - t	 Skylab 3 mission showed a decrease.
` Table 10-II shows the effect of increased hormone levels on plasma volume
and red cell mass, and indicates that each hormone has its own effect on cir-
^
culating blood volume.
	 Levels of antidiuretic hormone (ADH) have been mews=
ured in selected Apollo and Skylab missions (refs. 10-4 and 10- 5).
	Generally,
ADH activity is lower and osmolality is higher during the flights than in the
preflight specimens.- Any decrease in ADH should cause a decrease in plasma aP
volume.	 Dilute urine has never been excreted during space flight, even though
" adequate water is available forthe crewmembers.
	 Characteristically, in-
flight urine osmolality is greater than preflight.
	 The Russians use a provoc-
ative water-loading test postrecovery.
	 They have found a delayed water-diure-
sis that they interpret as evidence for a continuing negative water balance in
` the flight (ref. 10-6).
	 Our crews have consistently produced increased uri-
nary ADH levels post-recovery, helping to account for the Russian results
ref. 10-4
	 The ADH changes are not known to bej	 (	 ).	 	 produced during prolonged =	 ^
1	 bed rest, except during the first 2 days.
j
Human growth hormone (HGH) levels have been measured during the Skylab
" missions only (ref. 10-7).
	 The HGH levels were increased on the first flight
day and during the first few days after recovery.
	 While prolonged elevations
of HGH would be expected to change the blood volume, the short duration of the
'Skylab increases would not appreciably change the blood volume.
Parathormone and thyrocalcitonin levels have not been found to be in-
creased during or after space flight (refs. 10-4 and 10-7).
	 However, calcium
losses do occur, and both calcium and phosphorus tend to be higher in the
plasma and urine during the mission than they are premission (refs. 10- 5 and
f 10-7).	 An increase in serum phosphorus would increase 2,3-diphosphoglycerate
and might, in that way, inhibit bone marrow function. 	 This increase could
help explain the lowered red cell mass found postmission.
	 Elevated plasma
10-2
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calcium is often associated with anemia due to early loss of red cells from
the circulation. A calcium diuresis resulting from the release of osseous
calcium would decrease plasma volume.
Thyroid blood levels were increased in the returning Apollo crewmembers
(ref. 10-8). This increase has been observed in Skylab crewmembers when
thyroid-stimulating hormone levels were measured also (ref. 10-7). An in-
crease in thyroid function does not occur during bed rest. The changes in
thyroid function could have moderated both the plasma-volume and red-cell-mass
decreases, because thyrotoxicosis causes increases in both compartments
(ref. 10-9).
In diabetics, insulin helps correct the plasma-volume decreases produced
by glycosuria.
	 It would not cause changes in subjects without glycosuria.
	 A
relative glucose intolerance occurs during bed rest, but insulin levels are
unchanged (ref. 10-1Q).
	 This characteristic contrasts with space flight, dur-
ing which insulin levels are _decreased (ref. 10-7).
	 In the absence of glyco-
suria, decreased insulin levels would not be expected to change the plasma
^j volume or the red cell mass of crewmembers.
Plasma cortisol was elevated during the Skylab missions (ref. 10-7).
	 Free
r -cortisol excretion was elevated in the urine of the Skylab 2 and 3 crewmembers
(ref. 10-5).
	 But 17-hydroxysteroid excretion was decreased in the urine of
the Gemini VII and Skylab crewmembers during the missions (refs. 10-5 and
10-11).
	 Increased cortisol ,
 excretion was noted on stressful mission days dur-
ing the Apollo 17 mission (ref. 10-12).
	 Increased cortisol would tend to in-
I` crease the plasma volume and, to a lesser'extent, the red cell mass.
	 However,
a change in blood volume would not be expected if tissue levels of this hor-
mone were not actually increased, because the increased urinary cortisol and
decreased 17-hydroxysteroid excretion resulted in no net increase in plasma
:
i
cortisol activity.
There is considerable' evidence that aldosterone excretion is increased
during a prolonged mission.
	 Increases occurred during the Apollo 15 mission,
V a	 the second flight week of the Apollo 17 mission, and the Gemini VIZ mission
(refs. 10-11 to 10-13).
	 Increased aldosterone excretion by the crewmembers
has been found during the Skylab missions (ref. 10- 5).
	Surp.^°singly, plasma
aldosterone was elevated only during the first 28days of Skylab 3 (ref.
10-7).	 Both total-body exchangeable potassium and serum potassium tend to be
7 t	 decreased at the end,of a space flight (refs. 10-4 and 10-13).
	
Increased`
aldosterone activity should increase :plasma volume and may be responsible for
f
the increased plasma volume noted in the returning crewmembers of the Gemini
i [	 V_T mission (ref. 10-1).
	 Usually, plasma volume did not increase above pre-
flightlevels.
	 This fact suggests that the ,increased aldosterone excretion
^ I is secondary to a prior loss of plasma volume, because adequate or increased
	 =	
	 P
aldosterone excretion ordinarily would prevent a decrease in plasma volume
unless salt and water intake was inadequate, renal function was impaired, or
	 Ak cortisol excretion was reduced, none of which was likely in the Skylab crew-
members.	 The increased. aldosterone excretion might be a response to the space-
` flight-induced decrease in ADH.
	 Aldosterone increases are not found in bed-
# rest subjects until after the end of the bed-rest period (ref. 10-14).
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There is no evidence of a change in testosterone levels. However, 17-
ketosteroid excretion increased during the Skylab flights (ref. 10-7). Some
of the adrenal androgens have a profound effect on red cell mass and may have
increased the red cell mass; others have lesseffect. Fractionation of the
17-ketosteroids will help determine if the excreted steroids might have af-
fected the red cell mass.
Epinephrine and norepinephrine have been measured in the postflight ur-
ines of returning Apollo and Skylab crewmembers, and elevated levels have been
found (ref, 10-4). In-flight urine of the Skylab crews showed that both nor-
epinephrine and epinephrine decreased (ref. 10-7). An in-flight decrease in
catecholamine levels should have increased plasma volume.
5	 The changes in hormone levels noted during examination of plasma and
urine of Skylab and Apollo crewmembers may have affected both the plasma-volume
and red-cell-mass changes caused by weightless flight. With the exception of
the ADH changes, the endocrine changes would tend to increase plasma volume or
at least to impede a decrease in plasma volume. In the past, it has been noted
that the decreases in plasma volume during space flight have been smaller than
the decreases from similar periods of bed rest (ref. 10-1). The differences
in aldosterone excretion might account for the smaller decreases after space
flight. because this hormone is not excreted in increased amounts during bed
rest (ref. 10-14). However, differences in other hormones (for example, ADH)
might be involved also. This is true also of red-cell-mass decreases, which
may have been moderated by changes in endocrine function. The increase in
' both thyroid hormone and cortisol levels could stimulate the bone marrow to
increase the production of red cells. This effect would be counteracted by
the increased plasma=calcium and plasma-phosphorus levels.
r
	
	 Table 10-III summarizes the effects that endocrine changes may have had
on the circulating blood volume of the Gemini, Apollo, and Skylab crewmembers'.'
t CONCLUDING REMARKS
The answer to the question of whether the blood-volume changes produced
the endocrine changes or whether the endocrine changes followed d.s a response
to the in-flight blood-volume changes is still unknown. The fact that some of
the changes were in the wrong direction suggests that changes in endocrine
function were not the primary cause of the decreases in the plasma volume and
red cell mass.
I
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